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Streptococcus pyogenes (Group A Streptococcus, GAS) is a Gram-positive 
obligate human pathogen that causes a range of diseases at many different tissue sites. 
The ability of this organism to colonize and persist within these various niches of the 
body correlates with broad changes in gene expression.  Mga, the multiple gene regulator 
of GAS, is an important global transcriptional regulator of virulence genes that encode 
factors promoting adhesion, host cell invasion and immune evasion.  Mga directly 
activates these genes by binding to specific promoter sites that range from 45 to 60 
nucleotides in size based on DNAseI footprint analysis; however identified Mga binding 
sites share less than 50% DNA sequence similarity, making the identification of a 
consensus Mga binding site difficult. We have identified nucleotides necessary for Mga 
binding in the Mga-regulated Pemm promoter from the clinically relevant M1 
MGAS5005 strain of GAS.  Random and directed mutations were assessed for effects on 
transcription in vivo and DNA binding in vitro.  This screen identified predominately Gs 
and Cs, in two clusters at the 3’ and 5’ end that suggest that Mga binds DNA as a dimer 
and reduced the Pemm binding site to 35 bp.  However directed mutagenesis in other 
  
binding sites found that these interactions were not necessarily conserved.  These 
experiments also sought to establish a method to study genome-wide DNA binding and 
can successfully enrich for Mga-regulated genes.  Protein-protein interactions with RNA 
polymerase are another key component to activate transcription.  Functional in vitro 
transcription assays and in vitro co-purification assays were performed to determine if 
Mga interacts with either the α C terminal domain or domain 4 of σ.  While Mga does 
appear to make protein-protein contacts with the holoenzyme, they do not occur through 
either domain alone.  The dimerization of Mga through its EIIB domain was established 
by analytical ultracentrifugation.  In vitro transcription assays linked phosphorylation by 
the phosphoenolpyruvate transferase system to the down regulation of Mga activity.  By 
understanding how Mga interacts with essential elements of its promoters, this study 
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Recognizable descriptions of the diseases caused by the Group A Streptococcus 
(GAS, Streptococcus pyogenes) have existed since at least the 16th century.  In 1874, 
Billroth is credited with using the name streptococcus, from the Greek streptos, for 
twisted or chain, and kohkos, meaning berry or seed, to describe the globular chain 
forming bacteria that had been identified by many investigators [1].  At this time 
Streptococci were named according to the disease they were isolated from, e.g. 
Streptococcus scarlitinae or Streptococcus puerperalis.  In 1903, Schotmüller classified 
streptococci based on their hemolytic pattern on blood agar plates; α, β or γ [1].  In 1933, 
Rebecca Lancefield developed a method to classify the β-hemolytic streptococci 
serologically by the group-specific carbohydrate and later according to M-protein type 
[1].  The β-hemolytic strains that fell into the serotype A group of the Lancefield 
classifications system were also the majority of strains that were pathogenic in humans; 
thus they were renamed as Streptococcus pyogenes.  
Classification 
General characteristics and growth requirements 
Streptococcus pyogenes, or group A streptococcus (GAS), is a Gram-positive, 
non-motile bacteria, which forms chains of varying lengths.  GAS will appear on 5% 
blood agar plates as β-hemolytic colonies.  GAS is both catalase and oxidase negative. 
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GAS is a fastidious bacterium that relies on the fermentation of sugars for growth.   
In the laboratory GAS is grown in Todd-Hewitt, a nutrient rich media that includes 
neopeptone extracts, dextrose as a carbon source, and a complex mixture of nutrients 
from beef-heart infusion [2].  Yeast extract (0.2%) is added to the Todd-Hewitt (THY) to 
further enhance growth [3]. Cultures are grown statically at 37°C with 5% CO2 or under 
ambient conditions.   
Lancefield grouping 
The Lancefield grouping was developed by Rebecca Lancefield in 1933 to 
distinguish streptococcal species serologically.  This grouping of streptococci is based on 
immunological differences in their cell-wall polysaccharides (group A, B, C G and F) or 
lipoteichoic acids (group D) [4].  The Lancefield test is a precipitin reaction that uses hot 
acid to extract the carbohydrate, which is then incubated with C-antigens to the surface 
carbohydrate from different streptococci [5].   
M and T grouping 
The streptococcal M protein (emm) has been used to further categorize GAS 
strains by M-serotype.  Lancefield developed a method for characterizing GAS into 
serotypes by extracting the M protein from a given strain and comparing it against 
standardized typing sera [4].  The N-terminus of the protein contains a type-specific 
moiety that is recognized by the typing sera.  However, due to difficulties with this 
technique, other methods of characterizing each GAS strain have been developed.  A 
molecular technique developed by Beall and Facklam uses PCR to amplify the 5’ hyper-
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variable region of the emm gene.  Sequence comparison is performed to identify the 
emm-type.  More than 200 M-serotypes have been recognized [6].   
GAS may also be characterized according to T antigen or pilin, which was first 
defined by trypsin resistance [6].  There are many fewer T types than M types, and a T-
type may be found with several M-types.  Strains with the same M-type may also have 
varying T-types.   
Class determination 
 GAS serotypes are divided into two classes based on the reactivity of their M 
protein with an antibody directed against the C repeat region and the presence of serum 
opacity factor (SOF) [7].  This opacity factor (OF) typing strongly correlates with 
specific M-serotypes [8].  A Class I serotype has an M protein that has a surface exposed 
C repeat region and lacks SOF.  A Class II serotype lacks the M protein repeat region 
while SOF is present.   
Diseases 
GAS is an obligate human pathogen capable of causing a wide-range of diseases 
within its host.  These may be the benign self-limiting infections such as strep throat 
(pharyngitis); life threatening invasive diseases such as necrotizing fasciitis, and post-
infection sequelae such as acute rheumatic fever.  GAS contributes a great burden to 
global human health; several hundred million people will suffer from the mild 
streptococcal infections while approximately 500,000 people will die from the more 




The throat is one of the two primary sites of a GAS infection.  These infections 
result when GAS colonizes the pharynx and associated structures.   
Pharyngitis 
The most common infection caused by GAS is streptococcal pharyngitis, better 
known as “strep throat”.  About 616 million new cases of pharyngitis occur each year [9].  
While pharyngitis can affect any age group, it is most common among children between 
5 and 12 years of age [10].  Colonization may be asymptomatic, which increases carriage 
rates among the population [4].  Transmission of the bacteria occurs primarily through 
inhalation of aerosolized droplets or direct contact with respiratory secretions, which 
makes crowding an important factor in the spread of pharyngitis [10].  The infection is 
most contagious early in the acute stage infection and up to two weeks after acquiring the 
organism, unless treated with antibiotics.  The usual incubation period is between 2 and 5 
days and displays itself with a pronounced sore throat along with fever, headache, and 
general malaise.  To diagnose a streptococcal pharyngeal infection, the current standard 
technique is to culture a throat swab on blood agar plates.  After 24-48 hours, the 
presence of GAS is verified through the formation of β-hemolytic colonies.  Rapid 
antigen diagnostic tests may also be used; while they produce more immediate results, 
they generally are less sensitive and can yield false positives [10].  Pharyngitis is readily 
treated with antibiotics, most commonly penicillin and erythromycin; however even 
without treatment a pharyngeal infection is generally self limiting and virtually all 




Scarlet fever was once a more serious and deadly disease.   Today in developed 
countries this disease is generally mild.  A benign scarlet fever infection is typically 
associated with pharyngitis [4] and is additionally characterized by a fine, diffuse red rash 
[10].  During severe cases of septic and toxic forms of scarlet fever, high fever and 
delirium may occur.  These severe cases typically occur along with more invasive 
symptoms and are caused by streptococcal pyrogenic exotoxins (SPEs) and can lead to 
systemic toxicity and death [11].   
Skin 
The second primary entry point of GAS is through the skin when GAS colonies 
the squamous epithelium. 
Impetigo 
Streptococcal impetigo, also known as pyoderma, is a skin infection of the dermis 
and epidermis, which most commonly affects the face and the lower extremities [4].  The 
characteristics of impetigo are pus-filled, bacteria-rich blisters that form on the skin that 
ooze and develop a thick crust.  Itching is the other primary symptom associated with 
impetigo. Impetigo is typically found among children between the ages 2-5 who live in 
unhealthy conditions, but may also manifest in adults following previous respiratory tract 
infections or skin diseases.   As GAS has been shown to colonize and persist on the skin 
it can quickly enter and invade the skin to cause infection following a minor trauma [12].  
Impetigo is contagious, but is easily treated with penicillin.   While impetigo itself is 




Cellulitis is a diffuse inflammation of the subcutaneous layers of the skin [13].  
Common symptoms are pinkish skin color, swelling and pain.  Skin irritations such as 
burns, animal bites, dry skin or rashes can dispose a person to cellulitis.  Diabetics or the 
elderly, who may have poor blood circulation or a weakened immune system, are also at 
risk.  Penicillin is generally used to treat the condition. 
Erysipelas 
Erysipelas in an acute infection that involves the superficial layers of skin and 
cutaneous lymphatics.  The area of inflammation is raised, and clearly demarcated from 
unaffected skin [13].  Although historically the face was the site of infections, now it is 
most common on the lower extremities.  The bacteria typically enter through the skin 
following a local trauma or abrasion.  The infection is usually treated with penicillin and 
resolves within a few weeks.   
Invasive 
Invasive disease occurs when GAS leaves the primary points of infection and 
invades normally sterile tissues.  These infections can be rapid and aggressive and result 
from a complex interaction between GAS and the human immune system.   
Puerperal Fever 
Puerperal fever, or childbed fever, while once a deadly disease in the 19th century, 
now is only seen sporadically and isolated cases.  The development of aseptic techniques, 
such as those pioneered by Semmelweiss, and antibiotics have drastically reduced the 
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number of cases, and now it is rarely fatal.  Puerperal fever can be contracted during 
pregnancy, miscarriage or abortion and is characterized by marked infection of the 
genital tract and endometrial lining.  These symptoms may be masked by abdominal pain 
and not immediately recognized following delivery.  GAS can use the endometrial lining 
to gain entry to the surrounding structures and bloodstream [1].  Once the sepsis occurs, 
fever, leukocytosis and severe pain typically alert doctors to that the more severe disease 
is present.  
Streptococcal Toxic Shock Syndrome 
Streptococcal toxic shock syndrome (STSS) is characterized by the isolation of 
the bacteria from a normally sterile site followed within 24-48 hours by shock and organ 
failure.  The severe symptoms are generally associated with GAS pyrogenic exotoxins 
(SPEs).  These superantigens over stimulate the immune system, leading to the massive 
release of pro-inflammatory cytokines that then leads to shock and tissue damage [13].  
Skin infections are the most common portal of entry for streptococcal TSS and it is often 
present alongside other deep-seated systemic infections   Since the 1980s, reports of 
STSS have become more frequent in North America and Europe.  While the elderly is the 
most common age group for this disease, many patients between the ages of 20 and 50 
with no underlying infections have also been afflicted.  Despite modern treatments, 30% 
of patients die [11].   
Bacteremia 
Streptococcal bacteremia, or the presence of the bacteria in the bloodstream, is 
most common in the very young or elderly.  Pharyngitis associated scarlet fever 
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predisposes children to bacteremia, while in the elderly, bacteremia is secondary to 
infections of the skin [11].  Bacteremia rates have been increasing in individuals between 
14 and 40 years of age, in particular among intravenous drug users.  Bacteremia is 
clinically characterized by fever, chills and shock, and is treated with antibiotic therapy 
[11].   
Necrotizing Fasciitis 
Necrotizing fasciitis is a deep-seated infection of the subcutaneous tissue that 
destroys the fascia and fat while leaving skin intact [11].  Streptococcal gangrene begins 
at the site of a trivial lesion, but within 24 hours there is aggressive development of heat, 
erythema and tenderness with rapid spreading.  Unless appropriate intervention is taken, 
this may quickly become cutaneous gangrene, and inflammation may spread along the 
fascia [13].  Shock and organ failure also appear.  In order to treat necrotizing fasciitis, 
surgical debridement is used to remove the affected areas.  Even with aggressive 
treatment, a mortality rate exceeding 50% has been observed [4].   
Post immune sequelae 
The post-immune sequelae develop after the bacteria have been cleared from the 
body.  These symptoms are an autoimmune reaction in where the antibodies against GAS 
instead attack healthy human tissue.   
Acute Rheumatic Fever 
Acute rheumatic fever (ARF) is a sequel that occurs 2-3 weeks after pharyngitis [4,14].  
Five major clinical manifestations of the disease may occur according to the criteria set 
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by Jones: inflammation of the joints (arthritis), heart (carditis), central nervous system 
(chorea), skin (erythema marginatum), or subcutaneous nodules. ARF can lead to more 
severe manifestations such as congestive heart failure and Sydenham’s chorea. ARF is an 
auto-immune disease and probably results as cross reaction between streptococcal 
components and host tissue [4].  While incidence of the disease has decreased in the 
developed world, it is still prevalent in developing countries, which makes it a leading 
cause of heart disease in children and young adults worldwide.  As an episode of ARF 
predisposes patients to recurring attacks, and these recurring attacks are the major cause 
of death and disability from rheumatic heart disease, patients are given prophylactic 
antibiotic therapy [14].  
Acute Post Streptococcal Glomerulonephritis 
Acute post streptococcal glomerulonephritis (APSGN) is the acute inflammation 
of the renal glomeruli following a streptococcal infection.  ASPGN symptoms develop 1 
to 4 weeks after a streptococcal infection, and both pharyngeal and dermal strains can 
lead to glomerulonephritis [4].  Symptoms include edema, hypertension, hematuria, 
urinary sediment abnormalities, and decreased serum complement levels, with little fever.  
ASPGN is believed to develop when streptococcal antigen-antibody complexes deposit 
on the kidney glomeruli, leading to inflammation.  Diagnosis is by urinalysis and 
treatment focuses on reducing blood pressure and edema.  The mortality rate is very low; 
fewer than 0.5% of patients die from the initial disease and fewer than 2% die or progress 




Currently there are no vaccines against GAS infection.  An effective vaccine 
would help protect millions from streptococcal infections each year, and are an important 
response to the increasing frequency of invasive disease.  An ideal vaccine would target 
children between 5 and 15, contain a conserved GAS epitope, be highly immunogenic, 
induce both IgG and IgA and not provoke cross reactions with human tissues [16].  
Vaccine development has focused on the N-terminal of the M protein since Lancefield 
had shown that antibodies against this region are both protective and bactericidal [17].  
However for this strategy, even the newest 26-valent vaccine would be limited in the 
serotypes it can protect against, and some antibodies against M protein are cross-reactive 
with human tissue.  Alternative vaccine strategies have focused on other antigens such as 
C5a peptidase, the group specific carbohydrate, and the pyrogenic exotoxins [16].  
However, at this time none of these vaccine candidates have made it to clinical trial. 
Virulence Factors of GAS 
GAS utilizes many virulence factors that allow it to colonize the host, invade 
surrounding tissues, evade the immune system and disseminate throughout the body.  
Many of these virulence factors are surface associated, while others are secreted into the 
environment (Figure 1).  Important cell associate factors include: M and M-like proteins, 
lipoteichoic acid, MSCRAMMs, streptococcal collagen like protein, C5a protease, 
capsule, serum opacity factor, streptolysin S, protein G-related α2-macroglobulin-binding 
protein (GRAB), S. pyogenes cell envelope protease (SpyCEP).  Important secreted 
factors include: streptolysin O, streptococcal pyrogenic exotoxin B (SpeB), streptococcal 
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inhibitor of complement, streptokinase, S. pyogenes NAD-glycohydrolase, 
immunoglobulin G-degrading enzyme, the superantigens (pyrogenic exotoxins) and 
DNases.  A description of the Mga-regulated virulence factors follows.
 
Figure 1 Regulation of Mga-associated virulence factors in GAS 
Overview of the complexity of regulation of virulence genes within a GAS cell.  Factors that 
regulate Mga include CovRS, TrxRS, CcpA, Hpr and RivRX.  The directly Mga-regulated genes 
include M Protein, Fba, C5a protease, SIC, SOF and SclA.  Capsule and SpeB are indirectly 
Mga-regulated in a few specific GAS strains. 
 
 Cell Associated 
M and M-like Proteins 
M protein is the major surface protein that is involved in adherence and immune 
evasion.  The M-protein, encoded by emm, is part of a gene superfamily that encodes for 
many structurally similar, or M-like proteins [18].  These M-like or M-related proteins 
have a highly conserved domain structure within the cell wall associated region of the 




























have 1 to 3 of these genes, which are arranged on the chromosome in five different 
patterns, A-E [4].  Each serotype falls into one of these patterns, which are also strongly 
associated with tissue tropism.  A-C are throat strains, D are skin strains while E infects 
both.  
The M-protein is an α-helical coiled-coiled dimer that contains four different 
repeat regions, (A-D) and is anchored to the cell wall by a LPXTGX motif.  The A region 
is hypervariable and confers serotypes specificity.  The size of the protein can vary due to 
the number or repeats in the A and B regions [19]. 
M-protein functions to protect GAS from phagocytosis by the host.  It performs 
this function by binding the complement regulatory protein H to interfere with 
opsonization of the cell and to fibrinogen [4].  The M-protein is also important for its 
ability to adhere to many different molecules, and different M proteins have different 
binding profiles.  The A repeats may bind to plasminogen, IgA, IgG, human C4b-binding 
protein and factor H.  The B repeats, which are semi-hypervariable; also bind to human 
serum albumin and fibrinogen.  The M-protein may at times be released from the cell, 
where it acts a superantigen that activates T-cells and inflammatory responses during 
invasive diseases [20].   
MSCRAMMS 
The MSCRAMMs, microbial surface component recognizing adhesive matrix 
molecules, are many different proteins that allow for attachment and adherence to 
structures on the surface of eukaryotic cells or with the extracellular matrix.  SfbX [21] 
and Fba [22] are two such proteins that are Mga-regulated.  These are two of the many 
fibronectin-binding proteins that are encoded for by GAS. 
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Streptococcal collagen-like protein 
Streptococcal collagen like protein, SclA, encoded for by sclA, is structurally 
similar to collagen and varies in length.  SclA is important for adhesion during GAS 
pathogenesis; mutants have shown attenuation for virulence and a decrease in epithelial 
cell adherence [23].  SclA can inhibit the complement pathway by binding factor H [24].  
SclA is capable of binding TAFI, a fibrolysis inhibitor, and modulate the inflammatory 
reactions through the recruitment of plasmin to the surface of the GAS cell [25].   
C5a protease 
Streptococcal C5a protease, scpA, is a surface-associated and anchored 
endopeptidase that cleaves the C5a chemotaxin of the complement system [26].  This 
action inhibits the recruitment of phagocytic cells to the site of infection, and enables 
GAS to evade the immune system [27].   
Capsule 
The capsule of GAS is composed of hyaluronic acid, and its production is 
encoded for by the has operon.  Capsule is chemically identical to the hyaluronic acid 
found in human connective tissue, which helps GAS evade the immune system through 
molecular mimicry though not all strains are encapsulated [28].  Capsule has been shown 
to be indirectly Mga-regulated in a M1 and M6 strain [29].   
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Serum Opacity Factor 
Serum opacity factor (SOF), sof, is only produced by Class II serotypes.  SOF is 
an important adhesion that helps bind streptococcal cell to high-density lipoprotein via a 
fibronectin-mediated process [30].  SOF may be bound to the surface or released from the 
cell.  Due its two functions, serum opacification and fibronectin/fibrinogen binding, it has 
been difficult to determine the role of SOF in virulence [31,32].   However, inactivation 
of sof has been shown to reduce virulence in an intraperitoneal mouse model of infection 
[31]. 
Secreted 
Streptococcal pyrogenic exotoxin 
Streptococcal pyrogenic exotoxin B, SpeB, is a cysteine protease with a 
somewhat ambiguous role in GAS.  SpeB is indirectly Mga-regulated in M1, M2, M3 and 
M49 strains [29], however a plethora of other factors also affect the activity of this 
protein.  SpeB is important for lethality in mouse models [33], resistance to phagocytosis 
[34] and fibrinogen cleavage [35], though there are studies were no effect on virulence 
were observed [36,37].  SpeB is thought to promote the prevention of complement 
activation though cleavage of streptococcal IgG-binding proteins, leading to survival of 
GAS [38,39] and cleaves the fibrinogen binding proteins that attach GAS to the host to 
promote the spread of infection [40,41]. 
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Streptococcal Inhibitor of Complement 
Streptococcal inhibitor of complement, sic, inhibits complement-mediated lysis 
by incorporation into the membrane attack complex [42].  Sic interacts with many 
components of host cells and the immune system to aid in GAS infections, these 
activities include: inactivation of LL-37 and human neutrophil α defense, which are two 
antibacterial peptides [43], aid in survival at mucosal surfaces [44] and alter the activities 
of lysozyme and secretory leukocyte proteinase inhibitor [45]. 
Regulation 
In order to adapt to the difference niches within the host, GAS encodes for many 
different regulators, which include on average 13 two-component systems, and other 
regulators.  Five of the two-component systems are involved in virulence gene regulation:  
CovRS, FasBCAX, Ihk/Irr, TrxRS and SptRS.  Other important regulators include CcpA, 
the Rgg/RopBs, the RALPs (RofA-like proteins), MtsR, and Mga.   To give an overview 
of the complexity of regulation within GAS, a description of the regulators that effect/are 
affected by Mga follows.   
Two component systems 
CovRS 
CovRS, which stands for control of virulence, is the best described two-
component system in GAS and extensive data has shown its importance in modulating 
gene expression during virulence.  CovRS was originally identified by its role in capsule 
synthesis regulation, when it’s name was CsrRS, but studies have since shown that this 
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system plays a wide spread role in regulation.  CovRS directly or indirectly regulates 
~15% of the genome, mainly through repression, and thus it is a major negative regulator 
[46].  CovRS is believed to respond to changing pH, temperature and osmolarity in the 
environment [47].  Spontaneous mutations that truncate CovS allow GAS to become 
more invasive [47–49] and can be selected for by passaging GAS through animals.  
Microarray analysis comparing wild-type and the covS mutant show marked differences 
in the transcription of many genes that are associated with virulence [50].  The regulation 
of virulence within GAS is complex, and as the master regulator within GAS, CovRS 
interacts with Mga in multiple, indirect ways by repressing the activity of CcpA, TrxRS 
and RivR, three other regulators that it directly represses [51–54].  
TrxRS 
TrxRS, two-component regulatory system X, is another two-component system 
that is directly linked to GAS virulence, and modulates Mga expression.  In vivo murine 
studies have shown that a trxR mutant is attenuated for virulence and directly repressed 
by CovR [51].  TrxR was also shown to activate the core Mga regulon, and studies done 
in the lab have shown that TrxR can directly bind to Pmga [55].  
Other Regulators 
CcpA 
CcpA, the carbon catabolite protein A, is the master regulator of carbon catabolite 
repression (CCR) that controls the use of carbon sources within a cell.  When there is 
abundance of the preferred sugar glucose, CcpA complexes with P~S46-Hpr and binds to 
catabolite operons cis-acting catabolite responsive element (cre) sites to prevent gene 
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transcription [56].  In many bacteria, including GAS, CcpA also functions as a link 
between sugar metabolism and virulence [57,58] and can affect the expression of several 
virulence factors, such as repressing streptolysin S.  Studies done in lab identified a cre 
site in the Pmga promoter and demonstrated that CcpA plays a role in activating mga 
transcription [52].   
Rgg/RopB 
Rgg or RopB for regulation of proteinase, is part of a family of transcriptional 
regulators that regulate the expression of extracellular products during stationary phase in 
a strain dependent manner [59].  Rgg is also a global transcriptional regulator which 
controls virulence, secondary metabolism and stress, and transcription factors, including 
repressing Mga expression [60].  Recently, members of the Rgg family have been shown 
to respond to small peptides, and one of these members, ComR, turns on competence 
genes in GAS, though sadly, successful transformation has not been demonstrated in the 
laboratory [61]. 
RALPs 
The RALP (RofA-like protein) family contains four regulators that act at the 
transition between logarithmic and stationary phase growth, and modulates virulence 
genes.  This family is composed of RofA, regulator of F, Nra, negative regulator of GAS, 
RALP3, and RivR, RALP iv.  These regulators show strain specific activity; Nra 
represses pilus synthesis in an M49 strain but activates it in an M53 strain [62–64].   
Furthermore, not all GAS strains will have each regulator, RALP3 has been identified in 
only a few of the sequence serotypes [65].  RofA and Nra [66,67] act to repress Mga, 
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while RivR directly binds to the Pmga promoter to activate mga expression [54].  This 
protein family is also notable, because similarily to Mga, a Phyre2 protein fold 




Mga, the multiple gene regulator of GAS, is a ubiquitous transcriptional regulator. 
The first evidence of Mga was found in a M12 strain lacking the expression of the M 
protein that was determined to have a deletion upstream of emm in a gene named virR, 
virulence regulator [68].  Separate experiments using Tn916 insertional mutagenesis of 
this upstream gene and its promoter led to decreased emm mRNA, providing evidence 
that the upstream region encoded a trans acting regulatory factor that was named Mry, M 
protein RNA yield [69].   VirR and Mry were determined to be homologous and renamed 
Mga [70].  This regulatory protein was further shown to positively control a core 
virulence regulon containing streptococcal C5a protease (ScpA), serum opacity factor 
(Sof) and type IIa IgG Fc receptor (FcRA) [71]. 
Regulon characteristics 
Transcriptome analysis of the Mga regulon showed that it included over 10% of 
the genome during exponential growth by activating some genes while repressing others 
[72].  The core regulon is composed of a small number of activated genes involved in 
adhesion, internalization, and immune evasion and in a few serotypes, auto regulation.  
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The larger secondary regulon in composed of genes that have low levels of activation or 
repression, and are probably indirectly regulated.  Some of these secondary genes are 
involved in sugar utilization, while others are part of metabolic operons.  A number of 
secondary genes are also Mga regulated in a strain or serotype specific manner [72].
 
Figure 2 The domains of the Mga protein 
The Mga protein has six described domains.  At the N terminus is the CMD, a HTH and a wHTH, 
two PRD_Mga domains, and an EIIB-like domain.  The dimerization domain is marked by the 
blue box.  The phosphorylated histidines are marked with a star [73].  
 
 Protein characteristics 
There are two alleles of Mga but each serotype has only one.  The class 1 Mga 
allele is found in strains with the A-C chromosomal organization, which are SOF 
negative, while the class 2 are found with the D and E chromosomal arrangements and 
are SOF positive [74].  There is a 97% amino acid sequence identity within each allele 
and a 21% amino acid sequence difference between the two alleles.  Most of this 
variation lies within the C-terminus.  Studies so far have shown that these two alleles 
function in a similar manner [73] (Hondorp, 2012, unpublished). Mga is a 62-kDa protein 
that contains six predicted domains (Figure 2). At the N-terminus there is a conserved 















Mga domain (CMD) with unknown functions, though mutations within this domain lead 
to transcriptional defects [75], a helix-turn-helix domain, HTH-3 and a winged helix-
turn-helix domain, wHTH-4, that allow for direct transcriptional regulation. Mga contains 
two phosphotransferase regulatory domains that are located near the center of the amino 
acid sequence, PRD-Mga 1 and PRD-Mga 2, which link regulation of the protein to the 
sugar status of the cell.  A EIIBGAT-like domain is located at the C-terminus and is 
necessary for dimerization and transcriptional activation within a GAS cell [73]. 
DNA binding 
Mga directly activates its core primary genes through DNA binding and probably 
indirectly regulates the secondary genes of the regulon [29].  A binding site consensus 
sequence for Mga was formed by biochemical analysis of core Mga regulated promoters 
in the M6 strain JRS4.  DNase I footprint analysis of the emm and scpA promoters 
determined a 45 base pair (bp) binding site centered at -54 relative to the start site of 
transcription; this is about twice as large as other known prokaryotic transcriptional 
regulators [76].  In addition, this binding site does not contain any internal symmetry, 
suggesting that only a single binding site is present.  When the Pmga promoter was 
analyzed, two binding sites of 59 bps were identified, centered at -104 and -185 bps 
upstream of the start of transcription [77].  Analysis of the PsclA (streptococcal collagen 
like protein) promoter found two 45 bp binding sites based on the previously determined 
consensus sequence, one centered at -54 and the other at -175; however only the distal 
binding site was active in vivo [78].  While all of these sites have been shown to interact 
with Mga by DNaseI footprint or EMSA, alignments show less than 50% sequence 
identity.  By using this “Mga binding site” (MBS) consensus sequence, additional 
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binding sites can be found in other GAS strains, however with each new discovered site 
added, the percent identity decreases.  Three types of Mga regulated promoters have been 
categorized based on the location and number of MBSs (Figure 3).  
 
Figure 3 Architecture of Mga Regulated Promoters 
There are three categories of Mga-regulated promotors divided according to the size, number and 
location of the Mga binding site [78]. 
 
 The first type of promoter, category A, contains one binding site centered at -54 
bps upstream and overlapping the promoter.  The category B type of promoter contains a 
single binding site centered either -175 or -287 bps upstream from the start of 
transcription.  The final type of promoter, category C, is Pmga, which has two 59 bp 
binding sites located upstream from the transcriptional start site [78].   
Two HTH DNA binding domains within the N terminus of Mga were predicted 
from the amino acid sequence.  Each was inactivated by mutagenesis and assessed for 
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all Mga regulated promoters was dependent on wHTH-4 while HTH-3 appears to be an 
accessory for binding at Pmga [78].  Sequence alignments show a 100% amino acid 
sequence conservation of wHTH-4, while HTH-3 is also identical between Mga of the 
same allele, but only 90% conserved between the alleles [79].  Furthermore Mga from 
one allele can also complement Mga from the other allele in vivo [80].  This data suggests 
that the great variation in Mga binding sites is not due to the protein but instead arises 
from the interactions with the nucleotides of the binding site.   
Regulation  
The signal that controls Mga expression is as of yet unknown, but experiments 
done in the lab have shown that the PTS, phosphoenolpyruvate transferase system, is an 
important part of this regulation.  Mga contains two PRD domains that most closely 
resemble the mannose operon activator MtlR from G. stearothermophilus.  Mga 
possesses three conserved histidines, 2 in PRD-1 and 1 in PRD-2 at residues 204, 270 and 
324 (Hondorp, 2012, unpublished).  By qRT-PCR of the Mga-regulated genes arp and 
sof, a double phosphometic mutant (H204D/H270D) Mga has greatly reduced activity.  
The double alanine mutation also has a small but significant decrease in Mga activity.  By 
in vitro phosphorylation where the PTS system was reconstituted, a Mga triple alanine 
mutant (H204A/H270A/H324A) has a dramatic decrease in phosphorylation compared to 
wild-type. 
A second key component of Mga regulation is the dimerization state of the 
protein.  Immunoprecipitation experiments have shown that the inactive Mga D/D protein 
is also unable to form homodimers, though this protein binds DNA comparable to wild-
type (Hondorp, 2012, unpublished).  At the C-terminus Mga has an EIIBGAT-like domain. 
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Removing this domain prevents dimerization of the protein, and transcriptional 
activation, although this protein also binds to DNA at wild-type levels (Hondorp, 2012).  
EIIB domains are phosphorylated on a cysteine residue, which serves as another potential 
regulatory site, however in Mga this residue is a glutamic acid, but the importance of this 
change is unknown.  However it is clear that simply binding DNA is not sufficient for 
Mga activity, phosphorylation and dimerization are key elements to Mga’s function.     
DNA Binding Proteins 
Functions 
DNA binding proteins perform many functions in the cell and are essential for 
replication of the chromosome, repair of DNA, packaging of the chromosome, and 
regulation of gene expression.  DNA-protein interactions can be general or specific to 
particular DNA sequences.  The primary means by which DNA-binding proteins identify 
their target DNA is through sequence preference.   
Initial hypotheses of how DNA and proteins interacted predicted that there would 
be a code that that aligned amino acids to DNA sequences: experiments have shown that 
these hypotheses were far too simplistic.  Many families of DNA binding domains have 
been identified that interact with a huge variety of potential DNA sequences.  While there 
is no code for which side chains recognize which bases, these proteins do follow a 
general set of rules that allow for site-specific recognition [81].   While hydrophobic 
interacts do occur, hydrogen bonding is critical, between 1 and 2-dozen hydrogen bonds 
form along a protein-DNA interface.  Structure is a key component of DNA recognition, 
both the folding of the protein itself and DNA sequence specific structures. The site-
specific recognition occurs through contact with both the phosphodiester backbone and 
 24 
 
the bases.  These contacts occur mostly through interactions with the amino acid side 
chains and the bases within the major groove.  Most major DNA binding motifs have an 
α-helical region that fits into the major groove of B-DNA, though β sheets and extended 
regions of polypeptide chain may play a critical role in some proteins.  Purine contacts 
are particularly important as they are larger and have more hydrogen-bonding sites.  
Hydrogen bonds and/or salt bridges are generally formed with the phosphodiester oxygen 
in the DNA backbone.  Finally, usually multiple binding domains are often necessary for 
site-specific recognition [81].   
DNA Binding Domains 
Helix-turn-Helix family 
When the first crystal structures of the λ cro protein, E. coli CAP and the DNA-
binding domain of the λ repressor were compared, all three proteins contained a similar 
helix-turn-helix (HTH) motif and was the first identified DNA binding domain [81]. The 
HTH family is widespread in both prokaryotes and eukaryotes, where it forms the basis 
of the homeodomain. At its simplest a HTH motif is composed of two short α helices 
which are oriented nearly perpendicular, connected by a three amino acid linker, or turn 
[82].  The first helix, or preceding helix, sits along the phosphodiester backbone, while 
the second helix, or recognition helix, fits inside the major groove to contact the bases.  
However, it would be a mistake to focus only on the recognition helix to understand the 
HTH’s protein-DNA contacts, as both the preceding helix and polypeptides outside the 
domain play a role in recognition. 
The HTH is not separate stable motif and depends on its surrounding domain to 
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give it shape and function [81].  There are many subfamilies within this group that are 
characterized by the structures that flank the HTH.  This motif can associated within 
different structures; in the CAP protein, the HTH is held by β-sheets, while in the λ 
repressor it is associated with α-helices, leading to many variations on the basic form.  
One common variation is the winged HTH (wHTH), where the HTH is followed by 1 or 
2 β-hairpin turns [83].  The canonical wHTH has wings, which are extended loop 
structures, three β strands and three α helices, in the topological order Helix1, β-strand1-
Helix2-turn-Helix3-β-strand2, Wing1-β-strand 3-Wing2 [83].  Helix 2 and 3 make up the 
preceding and recognition helices, respectively, and while helix 3 makes most of the site-
specific DNA contacts the extended structures play a part in DNA recognition. 
Helix-loop-helix 
The helix-loop-helix (HLH) contains two domains, a dimerization domain and a 
DNA-binding domain [81] and has some similarities to the leucine zipper motif.  The 
HLH dimer is a left-handed, four α-helical bundle with a loop connecting each dimer’s α-
helices [84].  The basic region of each dimer is inserted into the major groove where it 
contacts a DNA hexamer that commonly has the sequence CANNTG [84].   As HLH 
proteins may form both hetero and homodimers great control over gene activity can be 
exerted [81]. 
Zinc Finger 
 The zinc finger motif was first identified in the Xenopus transcription factor IIIA 
(TFIIIA) [81] and is part of a superfamily common in eukaryotes but relatively rare in 
prokaryotes [85]. The zinc finger is not only a DNA-binding domain; it is also a protein-
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RNA and protein-protein interaction domain.  In the presence of zinc, the two antiparallel 
β sheets and an α helix fold around the zinc ion.  These fingers have relatively few fully 
conserved residues as most structural stability is due to the coordination of the zinc ion 
with the conserved hydrophobic core [85].  DNA-binding usually requires 2 to 4 tandem 
arranged fingers; if only 1 or 2 are present other secondary structures assist with 
recognition.  The α helix of each finger sits in the major groove, and the protein wraps 
around the DNA as each successive α helix binds.  Each finger docks in a similar manner 
and contacts an overlapping four base sub site, however most base contacts are formed 
with three bases on one strand on the DNA [85].  An enlarged major groove is another 
common feature of zinc-finger protein-DNA interactions.  
Leucine Zipper 
The leucine zipper (LZ) DNA-binding domain was first discovered as a conserved 
motif in eukaryotes [81] and the structure was first determined for yeast transcription 
factor GCN4 [84].  Like the HLH this motif is composed of two domains, a dimerization 
region and the DNA-binding motif that is characterized as a heptad repeat of leucines 
over 30 to 40 residues and a conserved repeat of hydrophobic residues that is located to 
the N terminus of the leucines.  Biochemical evidence suggesting that the LZ forms a 
structure of two parallel α helices in a coiled-coiled arrangement that resembles a fork 
[84].  To bind DNA a relatively straight basic region of each dimer is positioned into the 
major groove to contact a half-site of 8 to 10 bps [84] where it makes contacts with the 
bases and phosphodiester backbone.  The dimerization domain contributes to binding 
specificity by determining which LZ containing proteins will form stable dimers, which 
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also allows for fine-tuning to regulation, and guides the basic region into the major 
groove [84]. 
Beta Ribbon Motif 
 A small family of bacterial repressors which includes MetJ, Arc and Mnt, bind to 
DNA using antiparallel β sheets which is called the beta ribbon motif [81].   The domain 
contains a β sheet with two α helices; when MetJ dimerizes the β sheets align into an 
antiparallel β conformation that the α helices stabilize.  Each β sheet enters the major 
groove and binds to a half site, resulting in a tetramer.  Arc and Mnt appear to behave in a 
similar manner.  Other regulators may contain this β-ribbon motif, but not enough is 
known to identify them based on sequence; Arc and Mnt were not confirmed to have this 
motif until structural studies were performed [81]. 
 RNA Polymerase 
The Holoenzyme 
The first step in gene expression is to transcribe DNA into RNA, a process that is 
catalyzed by RNA polymerase (RNAP).  The central function of this process makes 
RNAP the key target of transcriptional regulation in bacteria.  The idea of this enzyme 
was first formulated in the 1950s alongside the discovery of mRNA, and in the early 
1960s Audrey Stevens and Jerard Hurwitz created cell-free extracts from E. coli that 
produced RNA [86].  This enzyme extract possessed the ability to catalyze a new RNA 
chain on its own, but only from a DNA template.  Further studies of this enzyme were 
undertaken to understand its function. When Richard Burgess and his colleagues passed 
the RNA polymerase holoenzyme over an anion exchange column, they identified 3 
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peaks, one which contained the holoenzyme, one that contained the core and one that was 
σ factor [87]. This core enzyme is composed of α2ββ', which retains its transcription 
function, but requires an additional σ factor to transcribe from intact DNA, and composes 
the holoenzyme of α2ββ'σ.  There is an additional ω subunit that is not necessary for 
transcription and Gram-positive bacteria have a δ subunit of undetermined function as 
well [88].  While core RNAP is sufficient for elongation and termination, the σ factor is 
necessary for transcriptional initiation [89].  The main, or housekeeping, σ factor is called 
σA, and contains four domains that are highly conserved among bacteria [90].  In E. coli, 
and other Gram-negative bacteria, σA is also known as σ70, based upon the size of the 
protein, while in Gram-positive bacteria σA is only 43 kDa in size, the result of a ~245 
amino acid deletion between domain 1 and 2 [90]. 
Steps of transcription 
There are three steps transcription: initiation, elongation and termination.  
Initiation can be further divided into four steps as well: formation of a closed promoter 
complex, conversion from a closed promoter complex to an open promoter complex, 
polymerization of short nucleotides while the polymerase remains at the promoter, and 
promoter clearance, when the transcript becomes long enough to form a stable hybrid 
with the template strand.  At this point the polymerase moves into elongation 
conformation, and dissociates from σ factor [91].  In order to initiate transcription, the 
holoenzyme must first recognize and bind to promoter DNA.  This function is performed 
by σ factor, which binds to the core.  σ factor is bound to the β’ subunit, and this allows 
domain 2.4 and 4.2 of σ factor to be exposed to solvent and positioned to bind to the 
highly conserved elements of promoter DNA [92].  Domain 2.4 of σ recognizes the -10 
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hexamer with the consensus sequence TAtaaT.  Domain 4.2 of σ recognizes the -35 
hexamer with the consensus sequence TTGaca.  The space in between, called the 
discriminator, is also an important determinant of promoter strength, and 17 bp is ideal.  
The -10 sequence has been shown to be more important for recognition than the -35 and 
the presence of an extended -10 (TGnTAtaaT) can compensate for a weak or absent -35 
site [89]. The similarity to the consensus sequence and spacing of the -10 and -35 both 
contribute to promoter strength.  σ factor plays other important roles as a target for 
transcription activators, it assists in melting the promoter near the transcription start site, 
it inhibits non specific interactions and serves to clear and release RNAP from the 
promoter [93].
 
Figure 4 Class I and Class II Activators 
Class I transcription factors (orange) are found bound to DNA upstream of the promoter and 
make protein-protein contacts with the C terminal domain of the α subunit.  The Class II 
transcription factor (blue) binds adjacent to and overlapping the -35 site to stabilize σ factor at 
weak promoters.   
 
 Activation and Repression 
Within a cell there is limited RNAP and σ factors available.  In bacteria the most 











specifically through interactions with σ and the α subunit [94]. Bacteria control the initial 
of transcription by interactions with two main targets on the holoenzyme [95].  In Class I 
activation the transcription factor binds upstream of the promoter and interacts with the 
α-CTD (C terminal domain) in order to activate transcription (Figure 4). The α-CTD is a 
readily accessible target and its flexibility allows RNAP to interact with transcription 
regulators up to 100 bps upstream.   It also has potential non-specific DNA binding 
activity that could be stabilized by protein-protein interactions to enhance gene 
expression.  In Class II transcriptional activation, Class II factors bind to sites 
overlapping the -35 and interact with domain 4 of σ instead of the α-CTD [96]. Protein-
protein interactions between the transcription factor and σ domain 4.2 stabilize DNA 
binding to overcome the limitations of a weak consensus -35 site [97].  As σ association 
with the core is necessary for promoter recognition, anti-σ factors are also used to control 
when a particular σ is available, allowing the cell to respond to changing environmental 
signals. While many bacteria have a variety of additional alternative σ factors to control 
gene expression, GAS has only one other σ factor, which is not connected to Mga [98].  
Transcription factors may also act independently of RNA polymerase.  The MerR 
family of transcription factors activate transcription by binding to the DNA ([99].  These 
promoters have a non-optimal 20 bp space between the -10 and the -35.  The MerR 
proteins bind to this spacer, and through DNA distortion reposition the -10 and -35 and 
allow transcription to occur [100,101].  Overall, the cooperative effect of weak protein-
protein interactions can lead to strong stimulation, or repression, of gene expression but 
only occur at the right promoter and promoter orientation. 
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Transcription factors may also act indirectly through the relief of repression.  In 
the cell DNA is tightly compacted and when factors bound to the DNA such as HNS, 
histone for nucleoid structuring, IHF, integration host factor and FIS, factor for inversion 
stimulation, are disrupted, derepression of transcription occurs [102]. 
Repression of transcription can occur in several different manners.  The simplest 
of these ways is where the repressor sterically hinders RNA polymerase from interacting 
with the promoter or interferes with its recruitment [95].  A repressor may bind to distal 
sites that create a DNA loop that then blocks RNA polymerase.  Repressors can also act 
to modulate other transcription factors, for example in E. coli the protein CytR binds to 
CRP, preventing it from activating transcription [95]. 
The modulation of expression for most genes is regulated by multiple signals. 
Multiple transcription factors may activate or repress to regulate a given promoter.  Four 
general mechanisms have been described for these interactions [95].  In the repositioning 
mechanism, the binding of a second activator can shift the first activator, which allows 
transcription to then occur.  Alternatively, the second activator may bend the DNA, 
allowing the first activator to interact with RNA polymerase.  Two transcription factors 
can make two independent contacts with RNA polymerase.  This may be two class I 
activators interacting with each α subunit, or one class I and one class II activator 
stabilizing RNA polymerase though contacts with the α and σ subunits.  In the 
cooperative binding method, the binding of one activator is dependent on binding a 
second activator.  In the antirepression method, an antirepressor binds to the repressor, 
and allows another activator to then promote transcription.   
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Phosphoenolpyruvate phosphotransferase system (PTS) 
Introduction 
The phosphoenolpyruvate phosphotransferase system (PTS) is a widely conserved 
pathway by which bacteria transport and utilize sugars.  As GAS does not possess a 
functional TCA cycle, the PTS is the primary means by which GAS ferments energy.  
Furthermore the PTS has been linked to virulence in GAS and other Gram-positive 
bacteria. 
The PTS was first identified in E. coli, by Kundig, Ghosh and Roseman [103].  
This system uses PEP to phosphorylate and transport various hexoses by a two-step 
reaction catalyzed by the general protein EI to a sugar specific EII protein using Hpr as 
an intermediate phosphor donor.  PTS-regulation of the cell is accomplished through 
these changes in phosphorylation state. 
Components 
The PTS system widely conserved in bacteria and is composed of the general 
proteins EI and Hpr, and many sugar specific membrane bound EIIs.  EI, which is 
encoded by ptsI, is a protein of about 63 kDa shows significant sequence identity 
between Gram-positive and Gram-negative bacteria [103].  EI has two domains, an N 
terminal phosphorylation domain, and a C terminal PEP binding domain, which is also 
necessary for dimerization.  In the presence of Mg2+, EI auto phosphorylates at the N-3 
position of the imidazole ring of a conserved histidine (His-15 in GAS) [103].  Hpr, 
encoded by ptsH, is a protein of only 90 residues.  In most enteric bacteria and firmicutes, 
the His-15 is phosphorylation on the N-1 residue of the imidazole ring.  However in some 
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Gram-negative and low G+C Gram-positive bacteria, which includes GAS, Hpr can also 
be phosphorylated by HprK, Hpr kinase, on Ser-46 [103]. This phosphorylation site is not 
part of the phosphotransfer, but is a regulatory site which can reduce the transfer rate of 
P~EI to Hpr 100 fold.   EIIs are the sugar specific transport and phosphorylation proteins 
of the PTS.  The EII consists of an integral membrane domain that faces both the 
periplasmic and cytosolic space and may be composed of up to four separate proteins.  
There are four superfamilies with distinct evolutionary origins as determined by 
phylogeny that the various EIIs can be divided into: the glucose-fructose-lactose super 
family, the ascorbate-galaticol superfamily, the mannose family, and the 
dihydroxyacetone family [103].   
Regulation of/by the PTS is accomplished by two parallel and overlapping 
pathways, carbon catabolite repression (CCR) by CcpA/Cre and by phosphorylation of 
phosphotransferase regulatory domain (PRD) containing proteins.  During CCR, the Hpr 
kinase phosphorylates Hpr on serine residue 46, which makes it a substrate to bind CcpA 
[56].  The P~Ser-Hpr-CcpA complex then binds to cre sites to control the expression of 
secondary sugar operons.  PRD containing transcriptional regulators, which many be 
activators or antiterminators, are very common in Gram-positive bacteria [104].  With the 
exception of CsiE from E. coli, all known PRD containing proteins have a duplication of 
the PRD where the N-terminal PRD is PRD-1 and the C-terminal PRD is PRD-2.  A 
classic PRD containing protein has an essential histidine and a conserved arginine spaced 
7 residues downstream, a strongly conserved glutamate at amino acid 57, and often a 
conserved histidine at residue 63.  Each PRD contains 1 or 2 histidines that serve as 
targets of phosphorylation by P-His-Hpr.  The phosphorylation effects the dimerization of 
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the proteins, and which histidine residue that is phosphorylation effects the activity of the 
protein; the phosphorylation of one PRD may activate, while the phosphorylation of the 
other PRD may repress [104]. 
PTS and Virulence 
In Gram-positive bacteria experiments have shown a link between carbon 
metabolism and virulence.  The importance if CcpA in GAS virulence has been 
established (Kinkel, 2008, Shelbourne, 2008).  Our lab has also shown that a ptsI (EI) 
mutant has a hypervirulent phenotype at the site of infection in a murine skin model 
(Gera, unpublished).  Phosphomimetics of the PRD domains in Mga lead to the down-
regulation of Mga regulated genes in vivo, and are attenuated for virulence in skin model 
mouse infection (Hondorp, et al, in review).  However, the PTS has not been directly 
shown to control Mga in vivo.    
Summary 
The experiments performed in the following studies were undertaken in order 
understand how Mga interactions at the promoter allow it to function as a transcription 
factor.  We first dissected the protein-DNA interactions between Mga and a model 
category A promoter (Pemm) to understand how this process occurs, and then used this as 
a model for Mga interactions at other binding sites.  To understand how Mga interacts 
with RNA polymerase, we studied protein-protein interactions between the α-CTD or 
domain 4 of σ factor.   Studies were performed to determine the dimerization of the 
protein in solution.  Finally In vitro phosphorylation-transcription assays were performed 




Materials And Methods 
Bacterial strains and media  
Bacterial strains and plasmids used in this study are shown in Table 1.  GAS 
strain MGAS5005 (covS) is a well-characterized M1T1 invasive strain that has a 
sequenced genome available [105].  GA40634 is a M4 strain containing a different mga 
allele than MGAS5005.  KSM547 is the Δmga derivative of GA40634.  One Shot® 
TOP10 Electrocomp™ E. coli (Stratagene) was used for site directed mutagenesis 
cloning.  E. coli DH5α  was used for plasmid construction.  E. coli C41 [DE3], a 
derivative of BL21[DE3], was used for protein expression [106].   E. coli BTH101 and 
DHM1 were used for the bacterial 2 hybrid assays.  E. coli was grown in Luria-Bertani 
(LB) for plasmid construction.  E. coli was grown in ZYP Auto-induction media [107]. 
GAS was cultured in Todd-Hewitt medium supplemented with 0.2% yeast extract (THY) 
and growth was assayed by absorbance using a Klett-Summerson photoelectric 
colorimeter with the A filter.  Antibiotics were used at the following concentrations: 
ampicillin at 100 µg mL -1 for E. coli; spectinomycin at 100 µg mL -1 for E. coli and 
GAS; and kanamycin at 50 µg mL-1 for E. coli and at 300 µg mL-1 for GAS. 
DNA manipulations 
Plasmid DNA was isolated from E. coli using the Wizard® Plus SV Miniprep 
system (Promega).  DNA fragments were gel purified from agarose using the Qiaquick 
Gel Extraction kit (Qiagen) or the Wizard® SV Gel and PCR Clean-Up system 
(Promega).  PCR for cloning and generating probes was performed using Taq DNA 
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polymerase (New England Biolabs, NEB).  PCR for site directed mutagenesis was 
performed using Pfu Ultra HF DNA polymerase (Stratagene).  DNA sequencing was 
performed either using the SequiTherm Excel™ II DNA Sequencing kit (Epicentre, Inc.) 
or by Genewiz, Inc.   
Construction of Luciferase plasmids 
Pemm was amplified from genomic DNA using M1 Pemm L and M1 Pemm R.  
PscpA was amplified from genomic DNA using M1 PscpA Bam L and M1 PscpA Xho R.  
PCR products were ended filled using T4 polymerase (NEB) and blunt ligated into Zero 
Blunt® TOPO PCR Cloning Kit (Invitrogen).   Psic was amplified from genomic DNA 
using the primers M1 Psic Luc BglII and M1 Psic Lux XhoI.  PsclA was amplified from 
genomic DNA using SF370 PsclA BglII and SF370 PsclA XhoI, and PsclA without 
MBS1 was amplified from genomic DNA using SF370 PsclA w/o MBS1 BglII and 
SF370 PsclA XhoI.  Mutagenic oligonucleotide pairs (Table 2) were synthesized to 
introduce point mutations into the Mga binding site using the QuikChange® Site 
Directed Mutagenesis Kit (Stratagene).  Mutations were verified by DNA sequencing.  
pKSM720 (Table 1) was digested with BglII and XhoI and gel purified.  Each insert was 
digested with BamHI and XhoI and gel purified.  The inserts were ligated into pKSM720.  
Plasmids were verified by DNA sequencing and transformed into MGAS5005. 
Luciferase Assay 
Luciferase assays were performed as described previously [57].  MGAS5005 
containing each luciferase plasmid were grown in 13 mLs Todd-Hewitt with 
spectinomycin at 37°C.  Upon reaching Klett 20, 500 µL samples were taken 
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approximately every 15 Klett units until into stationary phase to assess activity across 
growth.  At least three replicates were sampled at Klett 80 (mid-logarithmic phase) to 
compare percentage luciferase activity of each point mutation to wild-type.  Samples 
were pelleted, supernatant was discarded and the samples were stored at -20°C overnight.  
The luciferase assay was performed using the Luciferase Assay System (Promega).  The 
samples were resuspended in 1x lysis buffer (Promega) to normalize them to cell units 
according to the equation 4.5 = (x mL)(65 Klett units/2).  The luciferase assay was read 
using a Centro XS3 LB 960 luminometer (Berthold Technologies), into which 50 µL of 
Luciferin-D reagent was directly injected.   
Expression and Purification Mga-His proteins from E. coli 
Mga1-His6 and Mga4-His6 was purified as described previously [73].  E. coli 
C41(DE3) containing the plasmid pMga1-His or pKSM801 were grown in ZYP Auto-
induction media for ~62 hours at 37°C.  Cells were harvested by centrifugation at 4°C.  
The pellet was resuspended in NiNTA Lysis Buffer (50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole, pH 8.0), then incubated on ice with lysosyme for 30 minutes followed by 
sonication using a Branson sonifier 450 with a tapered microtip (setting 6, 50% duty 
cycle) pulsing 6 x 30 seconds with 1 minute breaks on ice.  The lysate was spun for 
clarification at 12000 rpm 3-4 times, then passed through a 0.45 µM syringe filter.  The 
lysate was loaded on a 750 µL NiNTA agarose column (Qiagen), washed 20, 50, 70 and 
90 mM imidizole Wash Buffer and eluted with 250 mM Imidizole Elution buffer.  
Protein was detected by Coomassie staining.  Fractions were dialyzed overnight at 4°C 
into 50 mM HEPES Citrate pH 7.5 with 50 mM EDTA.  EDTA was washed out with 50 
mM HEPES Citrate pH 7.5 and determined to be EDTA free by analysis with 4-(2-
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pyridylazo)resorcinol (PAR).  100 µL of flowthrough was mixed with 10 µL 0.1 M 
ZnSO4 and 1 µL 10 mM PAR.  When EDTA is removed, the solution changes from 
yellow to red.  Protein concentration was analyzed by absorbance at 280 nm with the 
extinction coefficient of ε280 of 59650 M-1 cm-1 and Coomassie staining. 
Expression and Purification of Mga4-CBP from E. coli 
E. coli C41[DE3] containing pKSM289 were grown under the same conditions as 
pMga1-His and pKSM801.  Pellets were resuspended in 1-4 volumes CaCl2 Binding 
Buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM β-mercaptoethanol, 1.0 M 
MgAcetate, 1.0 mM imidazole, 2 mM CaCl2) with 1x protease inhibitor (Roche). The 
cells were then incubated on ice with lysosyme for 30 minutes followed by sonication 
using a Branson sonifier 450 with a tapered microtip (setting 6, 50% duty cycle) pulsing 
6 x 30 seconds with 2 minute breaks on ice.  The lysate was spun for clarification at 
12000 rpm 3-4 times, then passed through a 0.45 µm syringe filter.  The lysate was 
loaded onto a 1 mL Calmodulin Resin column and washed 2 times with 10 mLs CaCl2 
binding buffer.  Mga4-CBP was eluted in 8 mLs CBP elution buffer (50 mM Tris-HCl, 
pH 8.0, 10 mM β-mercaptoethanol, 2 mM EGTA, 150 mM NaCl).  Fractions were then 
dialyzed overnight against 4 L 50 mM HEPES/Citrate at 4°C, then washed and 
concentrated as described for Mga-His6.  The protein was assessed by Western blot and 
Coomassie staining.   
Electrophorectic Mobility Shift assay (EMSA) 
Electrophoretic mobility shift assays (EMSAs) were performed as described 
previously [76]. Briefly, 49-bp DNA probes were generated by annealing oligonucleotide 
pairs representing wild-type Pemm1, PscpA1, Psic1, and respective point mutations. Each 
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gel-purified oligonucleotide pair (12.5 µM) was mixed with 10 mM Tris-HCl (pH 8.0) 
and 5 mM MgCl2, heated to 85°C for 5 minutes, and allowed to anneal by slowly cooling 
to room temperature. Annealed oligonucleotides were end labeled with [γ-32P] ATP 
using T4 polynucleotide kinase (NEB). Mga1- His6 (2.5 µM) was incubated with 0.1 nM 
each probe in band shift buffer [20 mM HEPES (pH 7.5), 1 mM EDTA, 0.6 mM 
dithiothreitol [DTT], 60 mM KCl, 5 mM MgCl2, and 50 ng/µl poly(dI-dC)] for 20 
minutes at room temperature.  Loading dye (5% Ficoll, 0.1% bromophenol blue) (1/5 
volume) was added, and each sample was separated on a 5% polyacrylamide gel at 140 
V. The gels were then dried for 1 hour at 80°C, exposed to a phosphorimager plate, and 
scanned using a FLA-1500 phosphorimager (GE Healthcare). 
DNaseI Footprint Analysis 
Probes were generated by uniquely end labeling primers, and PCR amplifying 
with one labeled primer and one cold primer.  Each PCR product was run across a 5% 
PAGE gel, extracted by the crush and soak method, and PCR purified using the QiaQuick 
PCR Purification kit (Qiagen). Binding reactions were set up as in EMSA.  After 
reaching equilibrium the 1 µL Turbo™ DnaseI (Ambion) was added to each reaction for 
90 seconds.  The reaction was precipitated with 150 µL of DnaseI stop buffer (570 mM 
NH4OAc, 50 µg/mL tRNA, 80 % v/v ethanol).  The reactions were then washed twice 
with 70% ethanol, dried under vacuum and resuspended in 5 µL DNaseI gel loading dye 
(80% formamide, 1 x TBE, 0.1% xylene cyanol, 0.1% bromophenol blue).  Reactions 
were separated on a 6% sequencing gel alongside a Sanger sequencing ladder.  Gels were 
dried for 1 hour at 80°C, exposed to a phosphor imager plate and scanned using a FUJI-
FLA-1500 or FLA-5000 phosphor imager. 
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Methylation Protection and Interference Assay 
Binding reactions were set up as in EMSA to shift 50% of the probe with the 
following modifications.  For the interference assay, probes were methylated prior to 
incubation.  ~300,000 cpm of each probe was incubated with 100 µL 2x DMS buffer(120 
mM NaCL, 20 mM Tris-HCl, pH 8.0, 20 mM MgCl2 and 2 mM EDTA)  and dH2O to a 
volume of 200 µL.  1 µL of DMS was added and the Pemm-R probe was incubated for 1 
min 10 seconds, and the Pemm-L probe was incubated for 1 min 15 seconds, at room 
temperature to obtain approximately one methylation site per probe.   The reaction was 
stopped with the additional of 50 µL cold DMS stop buffer (1.5 M NaAcetate, pH 7.0, 1 
M 2-mercapto-ethanol) followed by an ethanol precipitation. For the protection assay, 
after the binding reaction had been performed, 20 µL 0.01% DMS was added to the 
reaction and incubated for 2 minutes.  1/10 volume of 250 mM dithiothreitol (DTT) was 
added and then the reaction separated on a 5% PAGE gel and exposed to film.  Shifted 
and unbound probe were excised from the gel and extracted using the crush and soak 
method, followed by PCR purification. To reveal the modified As and Gs, the probes 
were then dried and resuspended in 30 µL of 10 mM sodium phosphate, pH 6.8 and 1 
mM EDTA.  The probes were incubated for 15 minutes at 92°C, then 3 µL 1 M NAOH 
was added for another 30 minutes.  320 µL of 500 mM NaCL, 50 µg/mL tRNA and 900 
µL ethanol were added to perform an ethanol precipitation.  The probes washed once with 
70% ethanol, dried and resuspended in DNaseI load dye.  Reactions were run on a 6% 
sequencing gel alongside a Maxam-Gilbert sequencing ladder [108].  Gels were dried for 
1 hour at 80°C, exposed overnight to a phosphor imager plate and scanned using a FUJI 
1500 phosphoimager.   
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Uracil and Missing Thymine Interference Assay 
Binding reactions were done as previously described with the following 
modifications:  probes were generated in a reaction that had a 1/20 dUTP:dTTP ratio, so 
that one thymine was modified per binding site.  For the missing thymine interference 
assay probes were digested with uracil-glycosolase (NEB) for 1 hour at 37°C, followed 
by PCR purification prior to incubation in the binding reaction.   The binding reactions 
were set up to obtain 50 % shifted probe, run on a 5% PAGE gel and exposed to film.  
The bound and unbound fractions were extracted by crush and soak, followed by PCR 
purification.  At this time the probes from the uracil interference assay were also digested 
with uracil glycosylase.  The probes were then dried down and resuspended in 50 µL 1M 
piperidine to generate strand breaks.  The reaction was incubated at 90°C for 30 minutes, 
then placed on ice.  120 µL n-Butanol, 50 µL 1% SDS was added and the upper phase 
was extracted.  This was repeated with 50 µL n-butanol, and then the probes were dried.  
The probes were resuspended in 50 µL dH2O, redried, then resuspended in 10 µL DnaseI 
gel loading dye.   The reactions were separated on a 6% sequencing gel run at 1700 V for 
1.5 hours, dried for 1 hour at 80°C, then exposed overnight to a phosphoimager plate.   
In vitro Transcription 
In vitro transcription reactions were performed as follows [98].  5-10 µL of RNA 
polymerase was mixed with 1-3 µL of σ per reaction and incubated on ice for at least 10 
minutes.  A 20 µL reaction containing 4 µL 5x Transcription buffer (330 mM Tris-Ac, 
pH 7.9, 10 mM MgAc, 0.1 mM DTT), 1 µM DNA template, 0.5 µL Rnase Inhibitor 
(NEB), 0-5 µL 50 mM HEPES/Citrate, pH 7.5, 5-0 µL 5 µM Mga1-His6 was incubated at 
RT for 20 minutes.  6-11 µL holoenzyme was then added to the reaction and incubated at 
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37°C for 10 minutes.  1 µL NTP mix (1 µL each 10 mM ATP, GTP, CTP, [γ]32P UTP and 
dH2O) was added and incubated for 5 minutes at 37°C.  1 µL cold UTP was added and 
incubated for 5 minutes at 37°C.  The reaction was then stopped with 12.5 µL Stop buffer 
(80% formamide, 12.5% 0.5% bromophenol blue, 20 mM EDTA, brought to volume in 
1X TBE).  Reactions were denatured for 5 minutes at 80°C then spun briefly.  30-35 µL 
of the reaction or 6 µL was then loaded on a 6% sequencing gel alongside a sequencing 
reaction to determine the size of transcripts.  
In vitro Phosphorylation-Transcription 
In vitro phosphorylation of Mga-His6 was performed as described by Hondorp, et 
al, (in review).  1 µL 5 µM His6-EI in 50 mM HEPES, pH 7.5, 1 µL 20 µM His6-Hpr in 
50 mM HEPES, pH 7.5 with 1 µL 60 µM Mga4-His6 was added to a 20 µL reaction 
containing 10 mM MgCl2/50 mM HEPES, pH 7.5.  The phosphotransfer was initiated by 
adding 1 µL [32P]-PEP (~750,000 cpm in 50 mM HEPES, pH 7.5) and incubating for 20 
minutes at 37°C.  5 µL 5x cracking buffer was added to each reaction, then placed on ice.  
20 µL was loaded on a 10% SDS-PAGE gel and run at a constant 20 mAmps until the 
dye front reached the bottom of the gel.  The gel was dried without heat for 5 minutes, 
then exposed to a phosphoimager cassette.   
To perform the in vitro transcription assay, the phosphorylation reaction was 
modified to contain 1 µM DNA template, 1 µL 20 µM Mga-His and 50 mM MgCl2.  The 
phosphorylation/DNA-binding was incubated for 20 minutes at 37°C, then the in vitro 
transcription assay was performed as described previously.   
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ChAP (Chromosome Affinity Purification) 
ChAP assays were performed as described by Anbalagan et al with modifications 
[109].  The strain KSM547, the M4 GA40634 isogenic mga- strain containing either 
pLZ12-Spc or pKSM808 was grown overnight in 10 mLs THY supplemented with 
kanamycin 300 and spectinomycin 100.   A 1/20 dilution of the overnight culture was 
used to inoculate 75 mLS THY supplemented with spectinomycin to mid-logarithmic 
phase, Klett 75-80 at 37°C.  The cells were then incubated on ice for 10 minutes.  
Proteins were crosslinked to DNA with 1% formaldehyde for an additional 30 minutes 
with gentle stirring every five minutes.  The crosslinking was stopped by adding 1M 
glycine to a final concentration 125 mM and incubated on ice for another 5 minutes.  The 
cells were pelleted by centrifugation and then washed twice with PBS, pH 7.3.  The pellet 
was resuspended in 500 µL of IP Buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl).   2.5 
µL PlyC/5 mLs cells was added to lyse the cells and incubate on ice for 20 minutes.  An 
additional 500 µL IP buffer and 1x protease inhibitor (Roche, in IP buffer) was then 
added.  DNA was sonicated with a target size of ~400 bp.  The cells were spun for 20 
minutes at 15 000 x g and the supernatant was collected.  A 20 µL sample was removed 
for Western analysis.    In order to perform the affinity purification 50 µL of the NiNTA 
agarose slurry (Qiagen) was washed three times with IP buffer.   The NiNTA agarose was 
added to the supernatant and incubate from 15 min at 4°C with rocking.  The slurry was 
spun briefly at 15 000 rpm and the supernatant was removed.  500 µL of IP Wash Buffer 
(IP buffer with 10 mM imidazole) was gently added and inverted to mix.  The slurry was 
then washed in the same manner with 20 mM and 50 mM imidazole IP Wash Buffer.  
250 µL 250 mM Imidazole Elution Buffer was then added to the slurry and incubate 5 
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min at 4°C with rocking.  The slurry was spun at 15 000 rpm for 5 minutes and the 
supernatant was collected.  A 10 µL sample was removed for Western analysis.  The 
formaldehyde induced crosslinks were then reversed by incubating the supernatant at 
65°C overnight (6 hours).  150 µL TE containing glycogen (0.27 mg/mL) and proteinase 
K (100 µg/mL) was added and incubated for 2 hours at 37°C to digest proteins. The 
supernatant was extracted once with equal volume phenol-chloroform and washed with 
an equal volume isoproponal and incubate overnight at -20°C.  The DNA was spun for 10 
minutes at 15 000 rpm to remove the isopropanol and washed once with 100 µL 70% 
ethanol.  The DNA was dried under vacuum without heat and resuspended in 50 µL 
dH2O.  The DNA was then assessed by quantitative PCR.  Samples were submitted for 
library formation and Illumina sequencing at IBBR.  
Quantitative PCR 
DNA collected from the ChAP assay was analyzed by qPCR for enrichment of 
Mga specific DNA binding sites in the cells containing Mga versus the empty vector 
control.  5 ng of DNA was added to a Sybr Green Master mix (Applied Biosystems) 
containing 5 µg of each specified real-time primer.  The real-time RT-PCR experiments 
were completed using a Lightcycler 480 (Roche) and binding sites were detected in the 
relative quantification mode.  Samples were compared to mga- gyrA gene levels, with the 
levels presented representing ratios of the values in the mutant/values in the wild-type. 
Sedimentation Equilibrium 
Sedimentation measurements were performed in an XLI analytical ultracentrifuge 
(Beckman Coulter) using cells equipped with 2-hole (3 mm or 1.2 cm path length) 
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charcoal-filled epon centrepieces. Mga4-His6 or Δ139Mga4-His6 was first dialysed 
overnight into 50 mM HEPES/Citrate containing 100 mM NaCl at 4°C. Full-length 
Mga4-His6 prepared at 7.5, 20 and 30 µM was centrifuged at 14, 16, 18, 20 and 22 K 
r.p.m. and truncated Δ139Mga4-His6 prepared at 7.5 and 30 µM was centrifuged at 18, 20 
and 22 K r.p.m. The data were first analysed WinNonLin for a single species model in 
[110] to obtain the reduced buoyant molecular mass, s, from which the molecular weight 







where M is the molecular weight, v is the partial specific volume obtained using 
SEDNTERP (http://www.rasmb.bbri.org) 0.7437 cm3 g-1 for Mga4-His6 and 0.7445 cm3 
g-1 for Δ139Mga4-His6, ρ is the buffer density, R is the gas constant, T is the temperature 
in Kelvin and ω is the angular velocity. The data for the full-length protein, which 
yielded a molecular weight higher than that expected for the monomer, was further 
subjected to analysis using monomer–oligomer models. The nine data sets were globally 
analyzed using a monomer-dimer model to obtain an association constant, Ka, using the 
equation: 
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where ct is the total concentration at position r, δ is the baseline offset, cm(ro) is the 
concentration at the reference radial position ro, and σm is the reduced molecular weight 
of the monomer. The association constants, which are obtained in absorbance units from 
the analysis, are reported as molar equilibrium dissociation constants or KDIM.  The 
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quality of each analysis was assessed by the square root of variance of the fit and the 
distribution of residuals. 
 
DRACALA (Differential Radial Capilary Action of Ligand Assay) 
Binding reactions were performed as for EMSA.  5 μL was spotted in triplicate on 
a nitrocellulose membrane and allowed to dry.  Blots were exposed overnight to a 
phosphorimager plate and scanned using a FUJI-phosphoimager.  Densitometry was 
performed using Multigauge.  The equations  
FB = (IInner – IBackground)/(ITotal)  
and 
IBackground = AInner x ((ITotal – IInner)/(ATotal – AInner)) 
where FB is the fraction bound, I is intensity and A is area were used to calculate the 
amount of DNA bound for each protein concentration.  The data was then plotted using 
the GraphPad Prism and used to calculate Kd [111].   
Construction of Bacterial-Two-Hybrid plasmids 
To create a N-terminal T18-tagged σ, α and δ, the plasmid pT18C-link was 
digested with BamHI and EcoRI, then gel purified.  rpoD (σ) was amplified using the 
primers T18C-rpoD-L and T18C-rpoD-R, rpoA (α) was amplified using the primers 
T18C-rpoA-L and T18C-rpoA-R, and rpoE (δ) was amplified using the primers T18C-
rpoE-BamHI and T18C-rpoE-EcoRI from MGAS5005 gDNA, digested with BamHI and 
EcoRI, then ligated with pT18C-link, to create the plasmids pKSM223 (pT18C-σ), 
pKSM224 (pT18C-α) and pKSM237 (pT18C-δ).    
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To create A C-terminal T18 or T25-tagged σ, α, δ, Mga1 and Mga1-Δ139, the 
plasmid pT18N-link and pT25N-link were digested with HindIII and BamHI, then gel 
purified.  rpoD was amplified using the primers T18N-rpoD-HindIII and T18N-rpoD-
BamHI, rpoA was amplified using the primers T18N-rpoA-L and T18N-rpoA-R, and 
rpoE was amplified using the primers T18N-rpoE-HindIII and T18N-rpoE-BamHI from 
MGAS5005 gDNA the digested with HindIII and BamHI.  mga was amplified from 
MGAS5005 gDNA using the primers T25N-Mga-L and T25N-Mga-R, then bluntly 
ligated into pCRII-Blunt-TOPO to create T25N-Mga-TOPO.  mga was then digested with 
HindIII and BamHI and gel purified.  mga1-Δ139 was amplified from MGAS5005 gDNA 
using the primers T25N-Mga-ΔΔ139-HindIII and T25N-Mga-Δ139-BamHI, then 
digested with BamHI and HindIII.  These were then ligated into pT18N-link or pT25N-
link to create the plasmids pKSM225 (pT18N-σ), pKSM228 (pT18N-α), pKSM229 
(pT25N-α), pKSM230 (pT25N-δ), pKSM233 (pT18N-δ), pKSM226 (pT25N-Mga), 
pKSM227 (pT18N-Mga) and pKSM236 (pT25N-Mga-Δ139). 
To create a C-terminal T18-his-σ and T18-his-α, pT18N-link was digested with 
EcoRI and HindIII and gel purified.  His-rpoA was amplified from pKSM234 using the 
primers T18N-rpoA-EcoRI and T18N-his-rpoA-HindIII, and his-rpoD was amplified 
from pKSM246 using the primers T18N-his-rpoD-EcoRI and T18N-his-rpoA-HindIII, 
then digested with EcoRI and HindIII, and ligated into pT18N-link to create pKSM277 
(pT18N-his-α) and pKSM278 (pT18N-his-σ). 
Bacterial-Two-Hybrid 
The selected plasmids for analysis were co-transformed (5 ng each for the 
negative controls, 100 ng each for the experimentals) into BTH101 and outgrown for 1 
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hour at 37°C.  The bacteria were plated a MacConkey agar supplemented with 1% 
maltose and 1 mM IPTG and placed at 30°C overnight.  Following overnight incubation, 
colonies were patched on fresh plates, placed at 30°C and monitored for a color change of 
white to pink until the negative controls reverted.   
Alternatively plasmids were plated on LB agar supplemented with 1 mM IPTG,  
and 2 mM X-gal, placed at 30°C, and monitored for a color change of white to blue until 
the negative controls were reverted.  After an overnight incubation, single colonies were 
used to inoculate LB media and grown to an OD600 of 1.5-1.7.  100 µL of cells were 
washed three times in saline, then spotted on A+M minimal media (3.6 µM FeCl3, 40 µM 
MgCl2, 0.1 mM MnCl2, 10 mM NH4Cl, 75 µM Na2SO4, 0.5 mM KH2PO4, 1.2 mM 
NH4NO3, 1 mM MgSO4, 0.8% glucose, 0.0001% thiamine, 0.2% caseine hydrolysate, 
0.008% x-gal, 100 µg/mL Amp, 25 µg/mL Kan, 1 mM IPTG, 1.5% agar) and monitored 
for a color change of white to blue at 30°C. 
Bacterial-Two-Hybrid Western Blots 
A single colony each of pMga1-His, pKSM277 (pT18N-His6-α) and pKSM278 
(pT18N-His6-σ) in C41[DE3] was used to inoculate 30 mLS ZYP-5052.  One set of 
flasks was placed at 30°C and grown for ~48 hours.  One set of flasks was grown for ~8 
hours at 37°C, then grown ~14 hours at RT.  For total protein 100 µL was collected from 
each flask, the media was removed, then the pellet was resuspended in 1x cracking 
buffer.  To isolate soluble proteins, 750 µL was collected from each flask and pelleted.  
The pellet was resuspended in 150 µL B-Per Reagent (Pierce), vortexed for 1 minute, 
spun at 150000 rpm for 5 minutes, then the supernatant collected.  12.5 µL of each whole 
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cell sample and 25 µL of each soluble fraction was then run on a 10% SDS-PAGE gel, 
and probed for α-his by Western blotting. 
Immunoblots 
Protein samples were run on 10 or 12% SDS-PAGE gels with 4% stacking gel for 
approximately 50 minutes at 180 V.  Proteins were transferred to nitrocellulose 
membranes using the Mini-Protean apparatus (Bio-Rad) in 1x transfer buffer (25 mM 
Tris base, 0.2 M glycine, 20% methanol).  Membranes were blocked for 1 hour at room 
temperature in blocking solution (5% (w/v) dried milk in PBS-tween).  For the detection 
of His-tagged proteins, blots were incubated with a 1:1 000 diultion of α-His antibody 
(Roche), 0.4 mg/mL of α-CBP antibody (Genscript) for CBP-tagged proteins, and 1:1 
000 of the polyclonal anti-rabbit Mga4 antibody, for two hours at room temperature, 
followed by three 5 minute washes with PBS-tween.  Blots were incubated with 1:20 000 
α-mouse-HRP (His-tagged proteins), 1:20 000 α-rabbit-HRP (for CBP-tagged proteins 
and Mga) for 1 hour in blocking solution followed by three washes.  Blots were 
visualized using the SuperSignal West Femto Substrate (Thermo Scientific) and a LAS-
3000 CCD camera (FujiFilm). 
In vitro Co-Affinity Purification 
12 µL RNAP + 2µL σ was pre-incubated on ice for 10 minutes.   A 40 µL reaction 
of 10 µL of ~ 20 µM Mga4-CBP and in 50 mM HEPES, pH 7.9, 75 mM MgAc was 
incubated for 20 minutes at RT with 10 µL Mga1-His6.  When assessing the pulldowns in 
the presence of a MBS, 1 µM template DNA was also included at this time. Holoenzyme 
was added and the reaction was incubated for 20 minutes at RT.  20 µL NiNTA agarose 
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was added, then the reaction was incubated for 10 minutes at RT with gentle rocking.  
The reactions were washed 2 times 100 µL 20 mM Imidazole, 50 mM HEPES, pH 7.9, 
10 mM MgAc by centrifugation.  40 µL 250 mM Imidazole, 50 mM HEPES, pH 7.9, 10 
mM MgAc was added, then the reactions was incubated at RT fo 5 minutes with gentle 
rocking before the final elution was collected.  The co-purified proteins were assessed by 
immunoblots probing for α-CBP and α-His.  
Purification of RNA Polymerase 
300 mLs to THY broth was inoculated with a 1/20 dilution of the strain JRS4-
Polhis and grown to late logarithmic phase (~Klett 130) [98].  The cells were then 
harvested by centrifugation, and frozen at -80°C.    The cells were resuspended in 1 mL 
of ice cold Lysis Buffer P (300 mM NaCl, 50 mM Na2HPO4 and 5% glycerol)l.  2.5 µL 
PlyC/10 mLs cell culture was added, then incubated on ice for 20 minutes.  100 µL 25x 
protease inhibitor (Roche) (in Lysis Buffer P) was then added.  DNA was sheared by 
sonication using a Branson sonifier with the settings microtip 5, 50% duty cycle for 20 
seconds.  The lysate was then spun for clarification and passed through a 0.45 µm filter 
and passed over a 750 µL column of washed NiNTA agarose.  The agarose was washed 
with 20 mLs Lysis buffer P containing 20 mM imidazole and eluted with 8 mL of Lysis 
buffer P containing 400 mM imidazole.  Fractions were immediately concentrated by 
centrifugation and dialyzed for 2 hours against 1x Transcription buffer (33 mM Tris-Ac, 
pH 7.9, 10 mM MgAc, 0.1 mM DTT) at 4°C.  For use in the in vitro AP assay, RNAP 
was dialyzed against 50 mM HEPES, 10 mM MgAc for 2 hours at 4°C.  After checking 
for the β and β’ band by Coomassie staining, 5% glycerol was added and RNAP was 
aliquoted and frozen at -80°C. This purification should be completed in 1 day for best 
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results.  Aliquots were freshly thawed for each use, and the protein stays active for ~1 
month under these conditions. 
Purification of His6-α, His6-α-ΔCTD, His6-αNTD-σ4, His6-σ and His6-σΔ4 
1 L of ZYP-5052 inoculated with C41[DE3](pKSM234) or C41[DE3](pKSM553) 
was grown for ~16 hours at 37°C, or with C41[DE3](pKSM235) for ~48 hours at 37°C. 
C41[DE3](pKSM246) and C41[DE3](pKSM279) were grown for 8 hours at 37°C, then 
RT for ~ 16 hours.  Cells were harvested by centrifugation.  Pellets were then treated as 
described for the Mga1-His6 protein purification.  The lysate was passed over a 750 µL 
NiNTA agarose column, washed with 20 mLs 20 mM imidazole NiNTA wash buffer and 
10 mLs 50 mM imidazole NiNTA wash buffer, and eluted into 7 fractions with 8 mLs 
NiNTA elution buffer.  Fractions were checked for purity by Coomassie staining.  
Fractions were then dialyzed overnight into 1x Transcription buffer at 4°C.  After any 
precipitate was removed, fractions were aliquoted and stored at -80°C.  
Purification of σ  
σ factor was purified from E. coli following the protocol of Burgess [112].  An 
overnight culture of BL21[DE3](pLysS)(pEU7534) containing the GAS σ factor was 
used to inoculate 2x 500 mL flasks of LB with Amp 100 µg/µL and grown at 37°C to 
OD600 of 0.8.  The culture was induced with 1 mM of IPTG for 30 minutes.  Rifampicin 
was added at 150 µg/mL and then the culture was grown for an additional 3.5 hours.  
Cells were harvested by centrifugation and stored at -80°C.  The pellet was resuspended 
in 30 mLs Buffer A (50 mM Tris-HCl, pH 7.9, 5% glycerol, 0.1 mM EDTA, 50 mM 
NaCl, 0.1 mM DTT) with 1x protease inhibitor, then sonicated as previously described.  2 
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mLs of 20% sodium deoxycholate (NaDOC) was added, mixed, then incubated for 10 
minutes at 4°C.  The lysate was then centrifuged at 13000 rpm for 10 minutes at 4°C and 
the supernatant was discarded.  The pellet was resuspended in 20 mL buffer A + 2% 
NaDOC and centrifuged for an additional 10 minutes and the supernatant was discarded.  
The pellet was resuspended in 40 mL buffer A + 0.4% Sarkosyl and incubated for 20°C 
for 30 minutes.  After centrifugation then supernatant was collected and diluted to 400 
mLs by adding buffer A in increments of 80 mLs, with 10-15 minutes between each 
addition, while at 4°C.  The supernatant was dialyzed twice for 8 hours against 4 Ls of 
buffer A at 4°C.  The supernatant was spun and passed through a 0.45 µm filter to 
remove any precipitate and then loaded onto a HiTrap Q FF anion exchange column by 
FPLC.  The column was washed for 15 minutes (4mL/min) with buffer A, then eluted for 
60 minutes with a linear gradient from buffer A to buffer B (Buffer A + 1 M NaCl) and 
collected in 5 mL fractions.  20 µL of fractions with the highest OD280 peak were then 
analyzed by Coomassie staining.  Fractions with a strong and pure 55 kDa band were 
pooled and dialyzed against 1 L storage buffer (buffer A + 45% glycerol) overnight at 
4°C.  
Creation of Mutant RNA Polymerases 
RNAP, his6-α and his6-α-ΔCTD were purified as previously described with the 
following modifications.  After concentrating to ~1 mL, RNAP was dialyzed into 
Fold/Refold buffer (Transcription Buffer + 5% glycerol) at 4°C for 2 hours, changing 
twice.  RNAP was then divided in 2 fractions and dialyzed into Fold/Refold buffer with 
0.1 M GuaHCl for 2 hours at, 1.0 M GuaHCl for 2 hours and 6.0 M GuaHCl for 30 
minutes, at 4°C.  To the fraction α, 100 µL of his6-α and to fraction Δ, 100 µL of his6-α-
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ΔCTD was added in excess to RNAP, then immediately dialyzed into 1 L Fold/Refold 
buffer for 2 hours, changing 1 time at 4°C.  The samples were spun in a 100 kDa 
centricon (Ambion) to remove unincorporated subunits, and Fold/Refold buffer was 
added to maintain volume.  Coomassie and Western blotting were performed to assess 
purity and the presence of the β’, α, α-Δ-CTD components. 50 µL aliquots were made 
and stored at -80°C.   
Construction of Protein Expression vectors 
In order to overexpress and purify the N-terminal his tagged α, α-ΔCTD, α-
Δ1/3CTD and α-Δ2/3CTD, the plasmid pProEX-htb was digested BamHI and XbaI, then 
gel purified.  The rpoA (α subunit) was amplified using the primers RpoA-His-Tag-L and 
RpoA-His-Tag-R, the α-ΔCTD was amplified using the primers RpoA-His-Tag-L and 
RpoACTD-His-Tag R, α-Δ1/3CTD was amplified using the primers RpoA-His-Tag-L 
and RpoA-Trunc1-XbaI, and α-Δ2/3CTD was amplified using RpoA-His-Tag-L and 
RpoA-Trunc2-XbaI from MGAS5005 gDNA, digested with BamHI and XbaI, then 
ligated into pProEX-htb to create the plasmids pKSM234 (pProEX-htb-α), pKSM235 
(pProEX-htb-a-ΔCTD), pKSM282 (pProEX-htb-α-Δ1/3CTD) and pKSM283 (pProEx-
htb-α-Δ2/3CTD). 
In order to over express and purify the C-terminal his tagged α, α-ΔCTD, α-
Δ1/3CTD and α-Δ2/3CTD, the plasmid pET21a was digested with NdeI and HindIII, 
then gel purified.  The full length α subunit was amplified using the primer RpoA-
pET21A-HindIII and RpoA-pET21A-NdeI, the α-ΔCTD was amplified using the primers 
RpoA-pET21a-NdeI and RpoACTD-pET21a-HindIII, α-Δ1/3CTD was amplified using 
the primers RpoA-pET21a-NdeI and RpoA-Trunc1-HindIII and α-Δ2/3CTD was 
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amplified using the primers RpoA-pET21a-NdeI and RpoATrunc2-HindIII from 
MGAS5005 gDNA, then digested with NdeI and HindIII and ligated into pET21A to 
create the plasmids pKSM291 (pET21a-α-ΔCTD), pKSM292 (pET21a-α), pKSM296 = 
(pET21a-α-Δ1/3CTD) and pKSM297 (pET21a-α-Δ2/3CTD2/3). 
To over express and purify a N-terminal his-tagged σ or σ-Δdomain4, the plasmid 
pProEX-htb was digested with BamHI and XbaI, then gel purified.  σ was amplified 
using the primers Sigma-his-BamHI and Sigma-His-XbaI, and σ-Δdomain4 was 
amplified using the primers Sigma-his-BamHI and Sigma-hisdelta4+stop-XbaI from 
MGAS5005 gDNA, then digested with BamHI and XhoI and ligated into pProEX-htb to 
create the plasmids pKSM246 (pProEX-htb-σ) and pKSM279 (pProEX-htb-σ-
Δdomain4). 
To overexpress and purify a N-terminal his tagged αNTD-σdomain4, the plasmid 
pProEX-htb was digested with BamHI and XbaI.  αNTD was amplified from gDNA 
using the primers RpoA-His-tag-L and RpoA-NTD-R.  σdomain4 was amplified from 
gDNA using the primers σdomain4 overlap and Sigma-his-XbaI.  The fragments were 
joined by Splicing by Overlapping Extension-PCR (PCR-SOE) using the primer RpoA-
His-tag-L and Sigma-his-XbaI, digested with BamHI and XbaI and ligated into pProEX-
htb to create the plasmid pKSM553. 
In order to create a M1 Mga HTH-3/4 or M1 Mga HTH-4, protein for 
purification, M1 Mga HTH 4a and M1 Mga HTH 4b were used to introduce the alanines 
into the recognition helix in pKSM805 or pKSM874 by Site directed mutagenesis.  
Mutations were confirmed by sequencing.   pET21a and the SDM template plasmid were 
digested with NdeI and XhoI.  The 1.5 kb band containing the mutation and the 4.5 kb 
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band from pET21a were gel purified and ligated to create the plasmid pKSM249 (Mga1-
HTH3/4-His6) and pKSM250 (Mga1-HTH4-His6). 
In order to express and purify the C-terminus of Mga (PRD1, PRD2 and the EIIB 
domains) or the N terminus of Mga (CMD, HTH-3 and wHTH-4) pET21a was digested 
with NdeI and XhoI and gel purified.  The C-terminus of Mga was amplified from 
MGAS5005 gDNA using the primers Mga-XhoI and M1-C-Mga-NdeI, digested with 
NdeI and XhoI and ligated into pET21a to create the plasmid pKSM264 (pET21a-
CMga).  The N-terminus of Mga was amplified using the primers Mga1-NdeI and 
MgaN180-XhoI, digested with NdeI and XhoI, the ligated into pET21a to create the 
plasmid pKSM265  (pET21a-N180Mga). 
To over express and purify a C-terminal CBP-His tagged Mga1, Mga4, Mga4-
Δ139 and Mga4-Δ29, the plasmid pCal-C was digested with NcoI and BamHI, then gel 
purified.  Mga1 was amplified using the primers Mga1-CBP-NcoI and Mga1-CBP-BglII 
from SF370 gDNA, Mga4 was amplified using the primers Mga4-CBP-NcoI and Mga4-
CBP-BglII, Mga4-Δ139 was amplified using the primers Mga4139-CBP-NcoI and 
Mga4139-CBP-BglII, Mga4-Δ29 was amplified using the primers Mga4139-CBP-NcoI 
and Mga429-CBP-BglII, then digested with NcoI and BglII and ligated into pCal-C to 
create the plasmids KSM288 (pCal-C-Mga1), pKSM289 (pCal-C-Mga4), pKSM550 
(pCal-C-Mga4-Δ139) and pKSM299 (pCal-C-Mga4-Δ29).   The plasmid pET21a was 
then digested with NdeI and XhoI and gel purified.  Mga4 was amplified from pKSM289, 
Mga4-Δ139-CBP was amplified from pKSM550 and Mga4-Δ29-CBP was amplified 
from pKSM299 using the primers Mga4-CBP-NdeI and Mga4-CBP-XhoI, digested with 
NdeI and XhoI and ligated into pET21a to create the plasmids pKSM298 (pET21a-
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Mga4-CBP), pKSM551 (pET21a-Mga4-Δ139-CBP) and pKSM552 (pET21a-Mga4-
Δ29-CBP).   
To over express and purify a C-terminal his tagged RofA and RivR, pET21a was 
digested with NdeI and XhoI.  RofA was amplified using the primers M1-RofA-NdeI and 
M1-RofA-XhoI and rivR was amplified using the primers M1-RivR-NdeI and M1-RivR-
XhoI from MGAS5005 gDNA, digested with NdeI and XhoI and ligated into pET21a to 
create the plasmids pKSM269 (pET21a-RofA) and pKSM270 (pET21a-RivR).  In order 
to overexpress and purify a N-terminal His-MBP tagged RofA and RivR, the plasmid 
pVL847 was digested with NdeI and XhoI.  RofA was amplified using the primers RofA-
NdeI and RofA-MBP-his-XhoI and RivR was amplified using the primers RivR-NdeI 
and RivR-MBP-his-XhoI from MGAS5005 gDNA, digested with NdeI and XhoI and 






Nucleotides Critical for the Interaction of the Streptococcus pyogenes 
Mga Virulence Regulator with Mga-Regulated Promoter Sequences 
Introduction 
Regulation of gene expression in response to changing stimuli allow bacteria to 
rapidly adapt to their constantly changing environment.  Control of transcription is often 
mediated by direct interactions between target gene promoters and specialized DNA- 
binding proteins that either enhance (activate) or inhibit (repress) RNA polymerase-
mediated initiation [96].  Transcription factors possess DNA-binding domains that allow 
them to recognize and specifically bind to a conserved DNA sequence (binding site) 
within their target promoters.  A conserved family of DNA binding motifs found within 
many prokaryotic transcription factors, as well as in eukaryotic cells, is the helix-turn-
helix (HTH) domain [113].  The second helix in the HTH fold is often called the 
“recognition” helix because it forms the principal DNA-protein interface by inserting into 
the major groove of the DNA to interact with specific nucleotides; however, DNA 
contacts may vary across the fold [113].  HTH domains can be quite diverse in structure, 
with the winged HTH (wHTH) possessing an additional C-terminal β-strand hairpin 
[113].  In order to differentially regulate gene expression, DNA-binding proteins must be 
able to discriminate specific sequences.  These sequences often contain a dyad symmetry 
reflecting that dimers and other multimers of the DNA-binding protein interact with the 
DNA [81]. 
Mga, the multiple gene activator of GAS, regulates expression of approximately 
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10% of the genome [72].  The core regulon is composed of a small number of key 
virulence factors that Mga activates through binding to their promoter DNA, including 
genes encoding M protein (emm), M-like proteins (arp and mrp), C5a peptidase (scpA), 
and the streptococcal inhibitor of complement (sic) [72].   
Based on studies primarily done in the serotype M6 strain JRS4, three categories 
of Mga-regulated promoters (categories A, B, and C) were proposed based on the number 
of binding sites and their position relative to the start of transcription [78].  Category A 
promoters (Pemm and PscpA) were defined using DNase I footprinting; these promoters 
are composed of a single 45-bp binding site centered at -54 from the start of transcription 
overlapping the -35 hexamer [76].  A category B promoter (PsclA and Psof) was defined 
by sequence alignment, electrophoretic mobility shift assay (EMSA) analysis, and in 
vitro transcription.  These promoters have a single 45-bp binding site that is located 
further upstream (-168) from the start of transcription [78,114].  A category C promoter 
(Pmga), defined by DNase I footprinting, is composed of two 59-bp binding sites located 
far upstream (-100 and -181) from the start of transcription [77].  Based on the positions 
of putative binding sites, category A appears to be the most common pattern among Mga-
regulated promoters in sequenced GAS strains.  Interestingly, sequence alignments of 
these binding sites exhibit very low sequence identity, making it difficult to determine 
how Mga interacts with its promoters.  In this study, we dissect the protein-DNA 
interactions between Mga and a model category A promoter (Pemm) to understand how 
this process occurs and test whether these findings can be applied to other Mga- regulated 




Characterization of MBSs in the M1T1 MGAS5005.  
Published biochemical analyses of Mga binding sites (MBSs) (EMSA, DNase I 
footprinting) have focused on a single serotype M6 GAS strain JRS4 [76,77].  To 
determine whether Mga-promoter interactions were conserved in other GAS serotypes, 
Mga binding sites for Pemm and PscpA, two category A promoters [78], were 
characterized in the invasive M1T1 strain MGAS5005.  The Mga-regulated sic gene is 
found exclusively in M1 GAS and possesses a predicted category A promoter (Psic) 
based on sequence alignment with M6 sequences; therefore, direct DNA binding studies 
on Psic were also performed.  Each promoter was amplified from the MGAS5005 
genome and was cloned in front of a promoterless firefly luciferase (luc) gene in the 
reporter plasmid pKSM720 [52] for analysis in wild-type MGAS5005 and in the isogenic 
mga-inactivated strain KSM165L.5005 (Figure 5A).  Luciferase activity was assessed at 
mid-logarithmic phase (80 Klett units) at a point associated with maximal Mga activity.  
The Pemm-luc promoter showed the highest luciferase activity (1.6 x 105 relative 
luciferase units [RLU]), Psic-luc showed intermediate activity (8.7 x 103 RLU), and 
PscpA-luc exhibited the lowest activity (2.7 x 102 RLU) at this time point (data not 
shown).  All three promoters showed significantly reduced luciferase activity in the mga 
inactivated KSM165L.5005 compared to the wild-type (Figure 5A), confirming the Mga-
dependent transcriptional activation of Pemm, PscpA, and Psic in the M1T1 background. 
EMSAs using 0.1 nM double-stranded 49-mer oligonucleotide probes of each 
promoter binding site and various amounts of purified Mga1-His6 protein found that Mga 




Figure 5 Determination of M1T1 Pemm1, PscpA and Psic Mga Binding Sites 
(A) Relative Mga-regulated promoter activity determined by luciferase assay at mid-logarithmic 
phase for Pemm-luc, PscpA-luc, and Psic-luc reporter plasmids in wild-type M1T1 MGAS5005 
GAS (black bars) and isogenic mga-inactivated strain KSM165L-5005 (white bars). Data are 
expressed as percentages of relative luciferase activity (relative light units [RLU]) in the wild-
type background (100%) compared to the mga mutant. (B) Relative Mga-binding activity for 
Pemm, PscpA, and Psic determined by EMSA. Mga1-His6 (2.5 μM) was incubated with a 0.1 nM 
concentration of each double-stranded oligonucleotide probe, and densitometry was used to 
quantify the percentage of probe shifted versus total probe added based on a saturating shift. (C) 
DNase I footprint analysis of Mga1-His6 to antisense strand of Pemm, PscpA, and Psic from strain 
MGAS5005. Labeled probe was incubated with increasing amounts of Mga1-His6 (0, 0.7, 1.5, 
and 2.5 μM [the amount of Mga1-His6 indicated by the height of the black triangle above the 
lane]). Protected regions are indicated by vertical black bars to the sides of the gels. The positions 
were determined by DNA sequencing ladders. (D) Locations of DNase I footprints of both 
strands (bold nucleotides) within M1T1 Pemm1, PscpA, and Psic. The numbering of the predicted 
starts of transcription (+1 [black arrow]) and -10/-35 hexamers are based on those experimentally 


















































protein, Mga shifted 62% of the Pemm1-MBS 49-mer probe, 60% of the Psic1-MBS 49-
mer probe, and 35% of the PscpA1-MBS 49-mer probe (Figure 5B).  To delineate the 
nucleotides bound by Mga, DNase I footprint assays were performed on both strands of 
each of the three MGAS5005 promoters using increasing amounts of purified Mga1-His6 
(Figure 5C, antisense; data not shown, sense).  In each case, Mga protected a 45-bp 
region of DNA immediately upstream of the -35 region (Figure 5D) that correlated 
exactly with the binding sites predicted by sequence alignments to the established M6 
category A binding sites (Figure 6A)
 
Figure 6 Conservation of nucleotides in known Mga binding sites 
(A) ClustalW nucleotide alignment of category A, B, and C Mga binding sites identified by 
DNase I footprinting (Pemm, PscpA, and Pmga) or overlapping EMSA (PsclA) in the serotype 
M6 strain JRS4 [76].  Conserved nucleotides are in all sequences are in red, conserved 
nucleotides in n-1 sequences are orange, conserved nucleotides in n-2 sequences are brown.  Gaps 
introduced to maximize sequence alignment are indicated by dashes. (B) ClustalW nucleotide 
alignment of category A Pemm and PscpA Mga binding sites from M6 JRS4 and M1T1 
MGAS5005 GAS. (C) Sequence of Pemm1 49-mer double-stranded oligonucleotide probe 
encompassing the 45-bp Mga binding site [73] used in this study (Table 7). Nucleotides are 






M1 Pemm 49-mer Mga Binding Site 









    CATTTA GGTCAAAAAGGTGGCAAAAGCTAAAA  AAGCTGGTCTTTA!
  AGCAAGCAAGGCCAAAAAC TGAGAAAGTCCTAAA  AAGC TGGCCTT!
   ACAAGCA  GTCAAAAAA AGTAACATTTCAAAA  AAGAGTGACCTTA!
  AAATTAGGTTCAAAAAATATAAAAAAATATAAATTAAGACCTCTTTTAAAATAAAAGAGC!
ATCCATTTTTGGGTCACATTTTATAATATGTTTTATA  AATAATGAACAAAAAGG!
20 40 60 
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Comparison of Mga binding sites between different promoter categories.  
The goal of this study was to identify the nucleotides within a Mga binding site 
that are important for interacting with Mga, resulting in functional activation of 
transcription.  A sequence alignment using a modified ClustalW of the published Mga 
binding sites (Pemm6, PscpA, PsclA, Pmga1, and Pmga2) from M6 JRS4 [76,77] with the 
M1T1 MGAS5005 sites (Pemm1, PscpA, and Psic) representing all three categories of 
Mga-regulated promoters, exhibits only 13.4% nucleotide identity (Figure 6B).  This 
variability across the different types of binding sites has made it difficult to define a “core 
DNA-binding sequence.”  However, Mga binding sites from comparable promoters found 
in other GAS serotypes exhibit much higher nucleotide similarity, as seen with Pemm and 
PscpA from M1T1 and M6 GAS, which shows a nucleotide identity of 49.1% (Figure 6B, 
asterisks).  Because Pemm is conserved in many GAS serotypes, is strongly regulated by 
Mga, and shows one of the highest transcript levels of any GAS gene in vivo (6), the 45-
bp M1T1 Pemm1 from strain MGAS5005 was chosen as the paradigm Mga binding site 
for the studies described here (Figure 6C, shaded region).  Conserved nucleotides found 
to be important for Mga binding and activation in Pemm were then tested in other 
category A Mga-regulated promoters (PscpA and Psic). 
Biochemical analysis of the Pemm1 Mga binding site.  
Biochemical assays were performed to assess the role of each thymine, adenine, 
and guanine of the Pemm binding site for Mga interaction.  The methyl group of thymine, 
nitrogen-3 of adenine and nitrogen-7 of guanine have all been identified as points of 
contact between protein and DNA [115,116].  Therefore, biochemical assays that 
specifically disrupt these potential sites of Mga interaction were chosen.  In each assay, 
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Mga1-His6 was incubated with a randomly modified 226-bp M1 Pemm PCR probe so that 
50% of the probe was bound, and separated by EMSA.  Strand scissions were then 
induced in the bound and free DNA fractions to reveal the modified nucleotides, followed 
by separation on a 6% acrylamide sequencing gel.  Nucleotides important for DNA 
binding are those found in the free DNA lane but are diminished or missing in the bound 
DNA lane. 
Uracil interference assays were used to target the thymines in the binding site by 
randomly replacing them with uracil during the PCR amplification of the probe using a 
dTTP/dUTP ratio that gave one substitution per binding site (Figure 7A, bottom gel).    
Nucleotides in the binding site were numbered 5’ to 3’ using the Pemm1 49-mer Mga 
binding probe as a reference (Figure 6C).  On the sense strand, thymine 39 (T39) was 
reduced (64% of free) in the bound fraction, while on the antisense strand T13 was also 
diminished (49%) in the bound fraction (Figure 7A, bottom gel, and C).   
In missing thymine interference assays, incorporated uracils were cleaved by a 
uracil DNA deglycosylase, leaving only the sugar phosphate backbone prior to incubation 
with protein (Figure 7A, top gel).  On the sense strand, T11 (28%) and T39 (45%) were 
identified as being important for binding (Figure 7C), and on the antisense strand, T13 
(48%), T33 (12%), T34 (7%), and T35 (7%) were also reduced in the bound fraction 
(Figure 7A, top gel, and C). 
Methylation protection assays were performed to identify those guanines or 
adenines protected from methylation by Mga binding (Figure 7B, top gel).  Guanines are 
methylated on the nitrogen-7 position in the major groove of the DNA helix, while 




Figure 7 Biochemical analyses of Mga binding to Pemm 
A 226-bp Pemm1 probe was subjected to various chemical mutagenesis strategies to obtain one 
mutation per binding site. The resulting probes were assayed by EMSA using Mga1-His6 such 
that 50% of the probe was bound, followed by excision of bound and free probe. (A and B) 
Missing thymine and uracil interference assays (thymines) (A) and methylation protection and 
interference assays (adenines and guanines) (B) were performed on each fraction to identify those 
nucleotides important for DNA binding (reduced or missing in bound). The antisense strand for 
each experiment is shown from 5’ to 3’ with the nucleotides identified indicated above the gels. 
(C) Quantitation of Pemm nucleotides exhibiting a reduction in the percentage bound versus free 
for each biochemical analysis presented from 5’ to 3’. Methylation protection (black bars), 
methylation interference (hatched bars), uracil interference (light gray bars), and missing thymine 
interference (white bars) are shown. The values are averages of two experiments. The broken line 
denotes 75% of wild-type binding. (D) Schematic diagram showing the locations of all 
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(8%), G10 (14%), and G19 (77%) were identified on the sense strand (Figure 7C), and 
G12 (39%) and A39 (57%) were identified on the antisense strand (Figure 7B, top gel, 
and C).  Methylation interference assays were performed to determine at which guanines 
and adenines would prior methylation prevent Mga binding (Figure 7B, bottom gel).  
Nucleotides G9 (11%), G10 (11%), G18 (75%), G19 (62%), G40 (21%), and G41 (16%) 
were identified on the sense strand (data not shown), and A11 (8%), G12 (23%), and A39 
(33%) were identified on the antisense strand (Figure 7B, bottom gel, and C).  A 
summary of all the biochemical results is provided using the Pemm1 sequence (Figure 
7D). 
In vivo analysis of Pemm1 binding site mutants.  
Luciferase assays were performed to study the effect on transcriptional activity of 
a Pemm1-luc reporter by directed mutagenesis of selected conserved nucleotides based on 
the alignment of the M1 and M6 Pemm and PscpA Mga binding site (Figure 6B).  In 
addition, mutations were introduced into all cytosine nucleotides on the sense strand (C3, 
C12, C23, C29, C38, and C42) as well as any nucleotides identified as important for 
binding in the biochemical assays above yet not already targeted. Pemm-luc plasmids 
containing each mutant promoter, a wild-type Pemm-luc plasmid, and a promoterless luc 
control plasmid were transformed into wild-type strain MGAS5005.  Samples were taken 
at mid-logarithmic phase (80 Klett units), a time of maximal Mga-regulated expression, 
in order to quantify activity.  The wild-type Pemm promoter was set at 100% relative 
luciferase activity, and the activity of each mutated promoter was calculated as a 
percentage of the activity of the wild-type (Figure 8A).  Strains with the C3A, G10A, 




Figure 8 Luciferase promoter reporter assays of Pemm site-directed mutations in 
vivo 
The 226-bp Pemm1 probe for the wild-type strain and mutant strains with each point mutation 
was cloned into the firefly luciferase reporter pKSM720 and transformed into M1T1 MGAS5005 
GAS for in vivo analysis. (A) Quantification of the relative luciferase activity (RLU) of each 
Pemm point mutation was compared to that of the wild-type and shown as percent luciferase 
activity. Mutants showing less than 75% wild-type activity (white), 75 to 100% of wild-type 
activity (dark gray), and greater than wild-type activity (light gray) are indicated. The broken line 
denotes 75% of wild-type luciferase activity. (B) Schematic diagram showing the locations of all 
nucleotides within the Pemm1 49-mer identified as important for Pemm activity (bold and 
underlined). The nucleotides leading to increased promoter activity (G9A and C38A) are shown 
as gray underlined letters with an asterisk. 
 
considered to have wild-type activity (Figure 8A, dark gray bars).  Strains with the single 
mutations T11C, C12A, G19A, C23A, C29A, A34C, A35C, G37A, T39C, G40A, C43A, 
T44C, and T45C and the double mutation C12/43A (C-to-A mutations at positions 12 and 
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bars).  Strains with two different mutations, G9A and C38A, had increased luciferase 
activity, which increased transcriptional activity to 445% and 241% of the wild-type, 
respectively (Figure 8A, light gray bars).  These two mutated plasmids were also 
transformed into the mga-inactivated KSM165L-5005 strain.  Luciferase assays with this 
strain showed that these mutations caused the same amount of activity as the wild-type   
Pemm promoter in the absence of Mga and that the increase in transcriptional activation 
with each Pemm1 mutant is Mga dependent (data not shown).  A summary of all the in 
vivo reporter results is provided using the Pemm1 sequence (Figure 8B). 
EMSA analysis of Mga binding to Pemm mutants 
 EMSA analysis was performed in order to determine the effect on Mga binding 
of the nucleotides identified by either the biochemical binding assays or luciferase 
reporter assays.  In each assay, 2.5 µM Mga1-His6 was incubated with either 0.1 nM 
concentration of the Pemm1 MBS 49-mer probe or a mutated probe at the ratio of protein 
to probe previously determined to be saturating with the probe (Figure 9A and data not 
shown).  All mutant Pemm1 probes were constructed so that guanines and cytosines were 
mutated to adenines, whereas the adenines and thymines were mutated to cytosine.  
Following EMSA, densitometry was performed to measure the amount of total probe 
bound, and each mutated probe was then compared to the wild-type to calculate the 
percentage shift (Figure 9B).  Since the EMSA was saturating for the wild-type, this was 
set at 100%. Mga shifted wild-type amounts (<75%) of the Pemm1 mutants A13C, 
G18A, C23A, A33C, G41A, T44C, and T45C MBS 49-mer probes (Figure 9B, dark gray 
bars).  Mga shifted significantly less (>75%) of the G9A, G10A, T11C, C12A, G19A, 




Figure 9 DNA-binding activity of Pemm site-directed mutations 
EMSA analysis of strains with Pemm1 49-mer point mutations compared to the wild-type 
strain was performed to identify nucleotides important for Mga binding. Each probe (0.1 nM) was 
incubated with 2.5 μM Mga1-His6 (except the C38A 49-mer was incubated with 1.25 μM Mga1-
His6). (A) Representative EMSA results for Pemm1 wild-type (WT), G18A, and T11C 49-mer 
probes with Mga1-His6 (2.5 μM) or without Mga1-His6 (0) are shown. The positions of free (F) 
and bound (B) bands are indicated to the right of the gel. (B) Quantification of EMSA results for 
each Pemm1 49-mer point mutant (shown below the bars) as determined by densitometry and 
shown as percent shifted by Mga1-His6 compared to wild-type Pemm1. Mutants that shift less 
than the wild-type (white), comparable to the wild-type (dark gray), and greater than the wild-
type (light gray) are indicated. The broken line denotes 80% and 120% of wild-type binding. (C) 
Schematic diagram showing the locations of all nucleotides within the Pemm1 49-mer identified 
as important for DNA binding (bold and underlined). The C38A mutation leading to increased 
binding is shown in gray italic underlined letters with an asterisk.  
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mutant C12/43A MBS 49-mers (Figure 9B, white bars).  The Pemm1 C38A MBS 49-mer 
was found to have a wild-type shift when incubated with 2.5 µM protein/0.1 nM probe 
(data not shown); however, when incubated with 1.25 µM protein/0.1 nM probe, Pemm1 
C38A MBS 49-mer bound 128% of the probe compared to the wild-type (Figure 9B, 
light gray bars).  A summary of all the DNA-binding results is provided using the Pemm 
sequence (Figure 9C). 
Conservation of critical Pemm1 nucleotides in other category A Mga-regulated 
promoters  
A goal of this study was to use our in-depth analysis of Pemm1 to determine 
whether these results could be used to predict important nucleotides in other category A 
binding sites.  To test this, directed mutations were subsequently made in PscpA (C5a 
peptidase gene promoter) and Psic (secreted inhibitor of complement gene promoter) 
M1T1 Mga binding sites.  Three conserved nucleotides were chosen for analysis, C12A, 
G40A, C43A, and a double mutation C12/43A, that had exhibited both binding and 
activation defects in Pemm, and were located at either end of the binding site.  Luciferase 
reporter assays using wild-type and mutant PscpA-luc and Psic-luc alleles were 
performed as described above (Figure 10A to C).  The C12A mutation showed widely 
variable impacts in the various promoters, with 12% of wild-type activity in Pemm1, yet 
16,265% of wild- type activity in PscpA and wild-type levels in Psic.  The G40A 
mutation had decreased luciferase expression in PscpA similar to Pemm, but dramatically 
increased expression (1,179% of wild-type) in Psic.  Only the C43A single mutation and 
the C12/43A double mutation resulted in a comparable decrease in promoter activity 
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Figure 10 Role of functional Pemm nucleotides conserved in PscpA and Psic 
Three nucleotides conserved in Pemm, PscpA, and Psic (C12, G40, and C43) and found to be 
important for both activity and DNA binding in Pemm1 were chosen for analysis. (A to F) Single 
mutations (C12A, G40A, and C43A) and the C12A C43A double mutation in Pemm (A), PscpA 
(B), and Psic (C) were assayed for promoter activity by luciferase reporter assay (A to C) and 
DNA binding by EMSA (D to F) for each promoter. Quantification of RLU is shown as percent 
luciferase activity compared to the respective wild-type promoter. Mutants showing less than 
75% wild-type activity (light gray bars), 75 to 100% of wild-type activity (dark gray bars), and 
greater than wild-type activity (white bars) are indicated. Quantification of EMSA Pemm (D), 
PscpA (E), and Psic (F) is shown as percent shifted by Mga1-His6 compared to the respective 
wild-type. Mutants that shift less than the wild-type (light gray bars), comparable to the wild-type 
(dark gray bars), and greater than the wild-type (white bars) are indicated. (G) Methylation 
Interference on the PscpA Antisense strand.  (H and I) Quantitation of methylation interference 
assays on the sense (H) and antisense (I) strands of PscpA. Nucleotides exhibiting a reduction in 
percentage bound versus free presented from 5’ to 3’. The values are averages of two independent 
experiments. The broken line in all panels denotes 75% of either wild-type binding or luciferase 
activity. 
 
performed on the same mutations introduced into a PscpA MBS 49-mer and a Psic MBS 
49-mer (Figure 10D to F).  The strain with the C12A mutation shifted less than the wild-
type did for all three binding sites, despite the fact that normal (Psic) and even increased 
(PscpA) expression was observed in the cognate luciferase reporter assays. The G40A 
mutation resulted in normal wild-type binding in PscpA that did not correlate with 
luciferase results.  However, the Psic G40A mutant showed 123% of wild-type binding 
that mirrored the increased Psic G40A luciferase expression.  Finally, the C43A and 
C12/43A probes had a decrease in the amount of protein shifted for all three promoters 
that correlated directly with reduced luciferase activity.  Overall, C43 appears to play a 
conserved role in both binding and transcriptional activation in all category A Mga-
regulated promoters tested.  In contrast, C12 and G40 impacted Mga activation and 
binding differently between the three. 
Given the observed variability in the importance of Pemm1 residues conserved in 
other category A promoters for Mga binding, we performed a methylation interference 




Figure 11 Summary of Pemm nucleotides important for Mga binding and activity 
(A) Schematic diagram summarizing nucleotides important for Mga-dependent activation (red), 
Mga binding (green), or both (blue) identified in this study. Based on these results, a proposed 
minimal Pemm1 Mga binding site of 35 bp from C9 to C43 is indicated by bar below and bold 
sequences, with nucleotides not essential for binding and activation in faded font. (B) 
Quantification of EMSA comparing Mga1-His6 binding to Pemm1 49-mer and Pemm1 G9C43 
probes. Data are presented as a percent shift of the total probe. 
 
the nucleotides A8 (64%), G9 (22%), G10 (24%), and A41 (28%) were identified as 
important for Mga1-His6 binding (Figure 10H), whereas on the antisense strand, A11 
(38%), G12 (51%), G42 (30%), and G43 (29%) were critical (Figure 10I). G9 and G10 
(sense) and A11 and G12 (antisense) were identified in both Pemm1 and PscpA, 
suggesting that they play comparable roles.  However, the identified A8 (sense) and G42 
(antisense) in PscpA are irrelevant thymines (T8 and T42) in Pemm1.  Nucleotides at 
position 41 were identified as important for binding in both Pemm1 (G41) and PscpA 
(A41) but were different residues. While G40 was important in Pemm1 (Figure 10D), it 
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result when mutated (Figure 10E).  Finally, G43 on the sense strand was identified in 
PscpA, but not Pemm; however, the cognate sense strand C43A mutation resulted in 
decreased binding in both promoters.  These data further support the conclusion that 
while Mga does utilize conserved residues for binding at different category A promoters,  
overall binding occurs in a promoter-specific context. 
Overall, we propose that the minimal nucleotides within Pemm1 critical for proper 
interaction with Mga should encompass the bases required for both binding and 
activation (Figure 11A, gray bar), resulting in a smaller 35-bp binding region from G9 to 
C43.  In support of this hypothesis, EMSA analyses comparing this minimal Pemm1 
G9C43 35mer probe to the larger Pemm1 49-mer probe using Mga1-His6 revealed that 
they had essentially identical binding profiles (Figure 11B).  EMSA analysis was then 
performed to determine if the PscpA and Psic possessed the same minimum binding site.  
Oligonucleotide probes containing PscpA G9 to C43 and Psic G9 to C43 were generated.  
The PscpA G9C43 34mer shifted 48.1% of the PscpA1 MBS 49mer (Figure 12A) while 
the Psic G9C43 34mer shifted 35.2% compared to the Psic1 MBS 49mer (Figure 12B) 
and therefore are not minimum binding sites.   
As the Pemm binding site indicated that Mga might bind as a dimer, the binding 
site was divided to investigate half-site binding.  Oligonucleotides probes containing 0.1 
nM Pemm 3-20, Pemm 28-47 and the Pemm1 MBS 49mer, and 0.05 nM each Pemm 3-20 
and Pemm 28-47 were incubated with 2.5 µM Mga1-His6.  After an overnight exposure 
no shift was detected for either half site alone or in combination (Figure 12C).   
Discussion 
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Figure 12 Category A Minimum binding sites 
EMSA analyses of the PscpA and Psic minimum binding site and the Pemm1 half sites.  0.1 nM 
of each oligonucleotide probed was incubated with 2.5 µM Mga1-His6.  Nucleotides in bold 
indicate the minimum binding site. (A) EMSA analysis of the PscpA1 G9C43 34mer versus the 
PscpA1 MBS 49mer probe.  (B) EMSA analysis of the Psic1 G9C43 34mer versus the Psic1 MBS 
49mer.  (C) EMSA analysis of the Pemm1 3-20 and Pemm1 28-47 half-sites. 
 
binding site established by DNase I footprinting (Figure 5) that contribute to 
either DNA binding, transcriptional activation, or both (Figure 11A, colored nucleotides). 
Some nucleotides (C23, T44, and T45) and their complementary antisense bases 
contribute only to Mga-dependent transcriptional activation (Figure 11A, red 
nucleotides). Nucleotides G10 and G18 (sense strand) and C10 and T13 (antisense 
strand) show a contribution to binding by at least one biochemical method yet have only 
minor effects on transcriptional activation (Figure 11A, green nucleotides). The 
nucleotides G9, T11, C12, G19, C29, A34, A35, G37, C38, T39, G40, and C43 (sense 
strand), along with their complementary bases (antisense strand), had effects on both 
binding and transcriptional activation (Figure 11A, blue nucleotides). Therefore, the most 
common phenotype reflected in this study showed mutations that both reduced binding 
and activity.  
The nucleotides identified within Pemm1 necessary for both binding and 
activation are biased toward guanines and cytosines (66.7%) compared to the overall 
G+C content (37.5%) found within the initial 45-bp binding site. Interestingly, most of 
the bases that are not required for Mga binding or activation are found as runs of 4 to 6 
adenines (sense strand) that could be functioning to orient Mga to the DNA, as spacer 
regions between the points of direct contact, or introducing curvature [117]. The 
methylation protection and interference assays (Figure 7) predominately identified 
guanine residues located within the major groove of the DNA helix as important for Mga 
 76 
 
binding. Specifically, direct interactions are suggested to occur in the major groove at G9, 
G10, G18, G19, G40, and G41 (sense strand) and G12 (antisense strand). The 
predominant DNA-binding domain of Mga (wHTH-4) is a winged helix-turn-helix 
domain that would be expected to use its recognition helix to contact nucleotides in the 
major groove [72,79]. Furthermore, the charged residues within the Mga recognition 
helix are lysine (positions 5 and 9) and arginine (position 6), which have been shown in 
other wHTH proteins to form hydrogen bonds primarily with guanines at N7 or O6 in the 
major groove [79]. This corresponds with our guanine methylation assays, since they 
target N7 in the major groove. Some minor groove interactions were identified at A11 
and A39 on the antisense strand; however, these can result from DNA interactions with 
the C-terminal β-strand “wing” of the wHTH domain [113,116]. Nucleotides G18 and 
G19 are subject to hypercleavage by DNase I footprinting upon Mga binding (Fig. 2.1C, 
Pemm1, asterisks) and may indicate a location of DNA bending. It is possible that 
methylation of G18 and G19 may actually prevent this flexibility and indirectly lead to 
the observed reduction in Mga binding and activation. Interestingly, the methylation 
interference assay performed on PscpA did not show a potential bend, which may suggest 
that the flexibility of the DNA affects Mga’s ability to activate transcription. 
Most of the critical nucleotides in Pemm are found clustered at the 5’ and 3’ ends 
of the binding site with a few dispersed between the ends (Figure 11A). Combined with 
the large size of the DNase I-protected region (45 bp), this suggests that Mga might 
interact with DNA as a dimer despite the lack of any apparent dyad symmetry. Recently, 
we were able to show that Mga can form dimers in solution and that this self-interaction 
occurs in vivo [73]. Interestingly, although the dimerization of the protein is necessary for 
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transcriptional activation, it does not change the affinity with which Mga interacts with 
DNA promoter targets. A newly available crystal structure for the Enterococcus faecalis 
Mga-like regulator EF_3013 (Protein Data Bank [PDB] accession no. 3SQN) showed that 
this ortholog also formed a homodimer in the absence of bound DNA and possessed an 
amino-terminal wHTH DNA-binding domain in each monomer. Using the PyMol 
molecular visualization system (www.pymol.org), the wHTH recognition helices in each 
dimer were estimated to be approximately 95 Å to 100 Å apart (data not shown), 
corresponding to about 30 nucleotides (3.4 Å x 30 = 102 Å). Although this is slightly 
smaller than the 35 bp predicted for the minimal Mga binding site (Figure 11A), it is 
based on an orthologous protein, and it does support the hypothesis that Mga and related 
regulators might interact with target DNA at two distinct sites within the binding region. 
Further studies will be necessary to confirm the stoichiometry of Mga molecules in this 
interaction but initial studies suggest that Mga cannot bind independently to these 
potential “half sites” in Pemm1.   
As discussed above, the majority of mutations (24/34) demonstrated both reduced 
Mga binding in vitro and reduced activation in vivo (Figure 8, 2.5, and 2.7A). This 
supports a model where less Mga bound to a promoter leads to less transcriptional 
activation of that promoter. Even when the mutation led to an increase in Mga binding to 
Pemm (C38 mutant), the resulting Pemm-luc activity was also increased over that of the 
wild-type. However, the G9 mutant presented with decreased Mga binding yet showed an 
increase in Mga-dependent transcriptional activation (Figure 8 and 2.5). It is possible that 
while Mga has less affinity for this mutation, it may still be positioned to interact with 
RNA polymerase, and the lower binding affinity may enhance promoter clearance, 
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leading to an increase in activity. Regardless, this suggests that the exact role of G9 in 
Mga binding and activation is more complex and will require further investigation.  
Interestingly, there does not always appear to be a direct correlation between the 
amount of DNA bound versus the amount of transcriptional activation. For example, the 
binding site with the C12A mutation shifted 6.03% and had 11.2% of wild-type RLU, 
while the binding site with the C23A mutation shifted 59.65% and had 2.62% of wild-
type RLU. The location of the mutation could potentially change the orientation of one 
dimer to another, affecting how Mga interacts with RNAP and influences transcription. In 
this case, the effect on transcription would be cumulative with the effect on binding. The 
T44C and T45C mutations both decreased transcription levels in vivo without altering 
Mga binding (Figure 8 and 2.5), which was predicted, as both residues are part of the -35 
hexamer recognized by RNA polymerase. Since these nucleotides are also outside the 35-
bp minimal Mga binding site (Figure 11A), it suggests that they are protected from 
DNase I digestion but do not contribute to direct protein-DNA contacts. The C23A 
mutation also showed a decrease in transcription but no effect on binding ability. As with 
the G9 mutation discussed above, future studies will focus on how much and where Mga 
binds DNA contributes to transcriptional activation. Combination mutants of the up 
transcriptional mutations G9A and C38A with a strong down mutation such as C12A or 
C23A could also be used to dissect how different mutations combine to affect both 
binding and transcriptional activity and whether one mutation can compensate for 
another. 
The M1T1 Pemm1 binding site was chosen for analysis as a possible paradigm for 
how Mga binds to DNA at other similar Mga-regulated promoters. To test this 
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possibility, we made directed mutations in the category A binding sites for PscpA and 
Psic using conserved nucleotides found to be essential for Mga-Pemm1 interactions 
(Figure 10). Interestingly, the phenotypes varied considerably between PscpA, Psic, and 
Pemm for both Mga binding in vitro and promoter activation in vivo. A C43A mutation 
and a C12/43A double mutation had the same effect at each of the three category A 
promoters, suggesting that Mga may interact at this nucleotide in a conserved manner at 
each target. However, this was not the case for the other two conserved nucleotides. A 
C12A mutation resulted in a decrease in binding at all three promoters, but in vivo 
activity varied considerably (Figure 10). A G40A mutation had the greatest variation 
between promoters with wild-type binding and reduced activation in PscpA compared to 
increased binding and activation in Psic. Methylation interference assays performed on 
the PscpA binding site further demonstrate that Mga interactions with its promoters are 
only partially conserved. Of the 7 nucleotides identified in PscpA, 3 were unique to this 
promoter. Interestingly, PscpA has an inverted trinucleotide repeat of GGT. This pattern 
is only partially conserved in Pemm1; the repeat is present at the 5’ end on the binding 
site, but the sequence differs at the 3’end.  
A true minimum-binding site will contain the entire sequence necessary for DNA 
binding and have the same shift as wild-type.  EMSA analysis found that the Pemm1 
G9C43 35mer did contain all sequence necessary for a wild-type shift, but the Psic 
G9C34 34mer and the PscpA G9C43 34mer did not. The methylation interference assay 
of PscpA indicated that A8 was important for binding, which is not encompassed by the 
Pemm minimum site.  This nucleotide is also present in Psic.  Due to variation in the 
binding sequence, the PscpA and Psic G9C43 is only 34 bp and including the A8 would 
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make these sites the same size as the Pemm G9C43 35mer.  This further indicates that 
even within promoters of the same category, Mga interacts with each binding site in a 
unique manner.   
It can be said that all of the conserved Pemm1 nucleotides did have some 
importance for Mga interactions. However, these results show that Pemm1 serves only as 
a general model for identifying important Mga contacts in other category A promoters. 
As Mga appears to interact differently with each of its promoters, detailed analysis of 




Interaction of Mga with RNA Polymerase 
Introduction 
Bacterial transcription factors that bind DNA commonly enhance transcription by 
directly stabilizing or recruiting RNA polymerase to the promoter by protein-protein 
interactions.  Most of these can be simply categorized as Class I or Class II transcription 
factors, although other interactions may occur.   Class I proteins interaction with the α-
CTD (C terminal domain); the classic example is CRP, cyclic AMP receptor protein, at 
the lac promoter [95].  Class II transcription factors stabilize interactions through protein-
protein interactions with domain 4 of σ factor, and includes the transcription factors PhoB 
and AraC [97].  These factors may act independently or in concert, and some factors do 
not interact with the holoenzyme itself.  
The Category A Mga binding site is centered at -54 from the start of transcription 
and overlapping the -35 hexamer [78], which suggests that Mga is positioned to interact 
directly with RNA polymerase to activate transcription. If Mga acts as a class I 
transcription factor, the α-CTD will be necessary to stabilize its binding at these promoter 
and obtain Mga-dependent transcriptional activation[96]. Alternatively, Mga may 
function as a class II transcription factor, and domain 4 of σ factor would be necessary 
for the same result.  The following studies present preliminary evidence that Mga does 
not interact solely with either the α-CTD or domain 4 of σ factor, which suggests that at 
the Category A promoters, Mga may interact with jointly with the α-CTD and σ domain4, 




Bacterial 2 Hybrid Assay for Protein-Protein Interactions 
In order to study protein-protein interactions in vivo, a bacterial two-hybrid 
system was used.  In this system the two catalytic subunits of the Bordetella pertussis 
adenylate cyclase, T18 and T25, are fused to the proteins of interest [118].  These 
plasmids are then co-transformed into an E.coli strain lacking adenylate cyclase (cya).  If 
the T18 and T25 are brought into close contact through protein-protein interactions, 
cAMP is made, which activates CRP, and thus the lac and mal operons.  E. coli that can 
now use lactose or maltose can be identified by a color change of white to blue or from 
white to pink.   
A comparison of the Δcya E. coli strains DHM1 and BTH101 on LB-X-gal-IPTG 
and MacConkey Maltose plates showed that the BTH101 strain on MacConkey Maltose-
IPTG gave the most consistent phenotype.  On the MacConkey Maltose plates, positive 
colonies were characterized by a deep magenta color, and the media remained red.  
Negative colonies were clear or yellow, and the surrounding media turned a yellowish 
color due to a pH increase that accompanies the utilization of peptones for energy.   To 
assay for protein-protein interactions, equal amounts of the plasmids pT18N-link/pT25N-
link, pT18N-Mga/pT25N-Mga, pT18N-his6-α/pT25N-Mga and pT18N-his6-σ/pT25N-
Mga were transformed into BTH101, plated on MacConkey Maltose-IPTG to obtain 
countable colonies and placed at 30°C.  Colonies were considered positive for protein-
protein interactions if they turned magenta while the negative controls remained yellow, 
over 3-5 days. Mga-Mga colonies displayed a strong magenta color within 24 hours of 




Figure 13 Bacterial 2-Hybrid Assays 
(A) pT18N-link/pT25N-link, pT18N-Mga/ pT25N-Mga, pT15N-his6-α/pT25N-Mga and pT18N-
His6-σ/pT25N-Mga in the strain BTH101 on MacConkey Maltose media grown at 30°C for ~ 4 
days.  Negative colonies are pale pink to yellow on a yellow background while positive colonies 
appear as magenta on a re background.  (B) pT25N-Mga/pT18N-Mga, pT25N-link/pT18C-link, 
pT18N-α/pT25N-Mga in the strain DHM1 plated on A+B minimal media at 30 °C.  (C) Western 
blot showing the full-length Mga-T18 an Mga-25 protein expressed in BTH101 at ~52 hours 
growth in LB at 30°C, with the Mga1-His6 protein for a size comparison.  (D) Expression of 
pT18N-His6-α and pT18N-His6-σ grown in ZYP-5052 for ~52 hours at 30°C.  1, 2 and 3 are the 
soluble fraction of T18-His6-α, T18-His6-σ and Mga1-His6 grown under the same conditions, 4, 5 
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expected as Mga is known to dimerize (Figure 13A) [73].  In this assay the Mga-α and 
Mga-σ colonies turned yellow, or were negative for protein-protein interactions. 
While initial studies found a weak positive interaction between Mga and α when 
transformed into DHM1, grown to OD600 of 1.6 in LB at 37°C, spotted on A+B minimal 
media and placed at 30°C overnight, this result could not be replicated (Figure 13B).  The 
assay was also performed after swapping the location of the tag, but these results were 
also negative.  The δ subunit was tested for interactions, but remained again the result 
was negative. 
Western blots were performed to determine if full-length, soluble proteins were 
expressed in the two-hybrid assay. LB-IPTG-X-gal was inoculated with pT18N-
link/pT25N-link or pT18N-Mga/pT25N-Mga, and grown at 30°C.  Samples were take 
every ~12 hours for ~52 hours.  When probed with α-Mga1 antibody, a doublet 
corresponding to Mga-T18 and Mga-T25 was detected faintly at ~24 hours and showed 
an intense band at ~52 hours (Figure 13C).  Antibodies against the T18 and T25 domains 
of adenylate cyclase were tested but these antibodies had a strong cross-reaction in 
DHM1, BTH101 and C41 E. coli backgrounds.  pT18N-His6-α and His6-σ were then 
constructed.  As the α-His antibody also had cross reaction to BTH101, pT18N-His6-α 
and pT18N-His6-σ were transformed into C41[DE3] and grown in ZYP-5052 at 30°C and 
assessed for protein production and solubility.  Full-length proteins were detected in the 
whole cell lysate, but only His6-α was detected in the soluble fraction (Figure 13D).  
While the α subunit could be available to interact with Mga during the assay, the negative 
result for Mga-σ factor was due to an artifact of the assay, and was inconclusive. 
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Creation of strains for in vivo protein-protein interaction studies 
To study protein-protein interactions between Mga and σ factor in vivo in GAS, a 
replicating plasmid expressing a N terminal His6-σ or a His6-σ-Δ4 under the control of 
PrpsL (pKSM284 and pKSM285) was transformed into the M4 GA40634 GAS strain.  
Each strain was grown until mid-logarithmic phase and the lysate was passed over a 
NiNTA agarose column to verify that each protein was expressed in GAS (Figure 14A). 
To study the interaction between Mga and α, the His6-α and His6-α-ΔCTD were 
also cloned into a replicating plasmid under PrpsL.  Transformations of >250 µg of 
plasmid failed to produce colonies.  The plasmid pMSP3535-H3, which contains a nisin 
inducible promoter was then used to determine if controlling the expression of the protein 
would overcome the problem of transformation.  However, this plasmid was also 
untransformable. 
 In order to overcome this limitation the suicide plasmid pCIV2, which is 
kanamycin resistant but cannot replicate in GAS, was used.  ~1 kb of identical upstream 
DNA was PCR SOEed to His6-α-ΔCTD under the expression of the artificial promoter 
Pami, which created the plasmid pKSM281.  After transformation, homologous 
recombination allows for a strain with either a His6-α and α-ΔCTD or a His6-α-ΔCTD 
and the wild-type α.  This strategy was used to maintain a full-length copy of α in the 
genome.  The presence of the plasmid and the 5’ junction with gDNA was detected by 
colony PCR.  Due to cross reaction with the α-His antibody, Western blotting was 
inconclusive.  To determine if the N-terminal His tag was an available target and which 
variant of α was his tagged, a GA40634.pKSM281 strain was grown to mid-logarithmic 




Figure 14 Creation of Mutant RNA Polymerases 
(A) Coomassie gel depicting His6-σ purified from GAS 1. Pellet 2. Eluent. 3. Wash 1. 4. Wash 2. 
5. Fractions or His6-σ-Δ4 6. Pellet 7. Eluent 8. Wash 1 9. Wash 2 and 10. Fractions. (B) Western 
blot for RNAP purified from 1. GA40634.pKSM295 (α-His6) or 2. GA40634.pKSM295 (α-
ΔCTD-His6).  In vitro transcription using the Pemm 232 template of the RNAPs purified from 
GA40634.pKSM295 and GA40634.pKSM294.  (C) Coomassie blue staining of RNAP containing 
1. α-His6, or 2. α-ΔCTD-His6 after denaturing and refolding with a >20 fold molar excess of the 
His tagged subunits.   
 
 were detected in the lysate by Coomassie staining, but were lost in the eluted fraction, 
suggesting that the His-tag was buried within the core (Data not shown). 
An accessible C-terminal α-His6 and α-ΔCTD-His6 were then cloned into pCIV2 
under the control of Pami and transformed into M4 GA40634, creating the strains 
A. 
B. 















GA40634.pKSM295 and GA40634.pKSM294.  Colony PCR detected the plasmid and 
the 5’ junction.  Active RNAP was successfully purified by over NiNTA agarose from 
each (Figure 14B) and His-tagged proteins of ~35 and 27 kDa could be detected by 
Wester blotting.  
Creation of Mutant RNAP for in vitro transcription 
Mutant RNAPs were created to determine if Mga interacts with domain 4 of σ or 
the CTD of α.  Core RNAP were purified from the strain JRS4-PolHis [98] while each 
His-tagged α and σ were purified from E. coli.  Before each assay, the core was incubated 
with a σ factor.  In order to integrate the α constructs, core RNAP was denatured with 6 
M GuaHCl, then spiked with a ~20 fold molar excess of either His6-α or His6-α-ΔCTD, 
then these new subunits were used as the nucleus of core formation.  Excess α was 
removed by ultrafiltration and the polymerases were assessed by Coomassie staining and 
Western blot (Figure 14C). 
In vitro Co-affinity Purification 
In vitro co-affinity purification assays were performed to study protein-protein 
interactions with an individual subunits or the intact holoenzyme, either in solution, or 
while bound to the promoter.   10 µL of Mga4-CBP was incubated with 10 µL of 20 µM 
Mga1-His6, His6-α, His6-α-ΔCTD, His6-σ or His6-σ-Δ4, and purified with NiNTA 
agarose.  The eluent, wash and purified fractions were run for Western blotting and then 
probed with both α-His and α-CBP.  The His-tagged proteins were present in the initial 
and purified fractions.  Mga4-CBP was found in the initial fraction of all samples, but 





Figure 15 In vitro Co-affinity Purification of Mga with RNAP 
(A) Western blot probing for Mga4-CBP co-purified with Mga1-His6 1. Initial Fraction 2. 
Purified Fraction, with His6-α 3. Initial Fraction 4. Purified Fraction, with His6-α-ΔCTD 5. Initial 
Fraction, 6. Purified Fraction. with His6-σ 7. Final Fraction 8. Purified Fraction, with His6-σ-Δ4 9 
Initial Fraction, 10 Purified Fraction.  (B) Western blot probing for Mga4-CBP co-purified with 
1. Mga1-His6, and 2. RNAP wild-type holoenzyme in solution. (C) Western blot probing for 
Mga4-CBP co purified with 1. Mga1-His6 bound to Pemm 232 2. RNAP bound to Pemm 232 and 
3. RNAP bound to MBS +10 PrpsL.  D. Western blot probing for Mga4-CBP co-purified with 1. 
Mga1-His6, 2. RNAP wild-type holoenzyme 3. RNAP with His6-σ-Δ4 4. RNAP with His6-α 5. 
RNAP with His6-α-ΔCTD 6. His-MBP and 7. with NiNTA agarose solely.   
 
 
Mga4-CBP was then incubated with the holoenzyme either in solution or in the presence 
of a Mga binding site.  When incubated in solution, Mga4-CBP co-purified with the 
holoenzyme (Figure 15B).  Mga4-CBP was detected when incubated with the 



















holoenzyme and either the Pemm 232 or the MBS +10 PrpsL 1201 template, indicating 
that it can co-purify when with a MBS (Figure 15C). 
Mga4-CBP was then incubated in solution with the wild-type RNAP-σ, RNAP-
His6-σ-Δ4, RNAP-His6-α, RNAP-His6-α-ΔCTD, and Mga1-His6.   Mga4-CBP was also 
incubated with His-MBP and without any His-tagged protein to serve as controls for non-
specific interactions.  Mga4-CBP was detected in all starting fractions.  Mga4-CBP co-
purified with Mga and each holoenzyme, but no Mga4-CBP was detected co-purifying 
with His-MBP or through non-specific interactions with the NiNTA agarose (Figure 1D). 
In vitro Transcription of Mutant RNAP 
In vitro transcription assays were performed to determine if the deletion mutants 
of α or σ resulted in a loss of Mga-dependent transcriptional activation.  The PrpsL +30 
1201 PCR product and the Pemm 232 PCR product served as the control and Mga-
dependent promoter templates, respectively.  When wild-type holoenzyme was incubated 
with PrpsL, a band of ~ 257 bp was detected (Figure 16A).  The addition of 1.25 µM 
Mga1-His6 had no effect on this reaction.  Wild-type holoenzyme incubated with the 
Pemm 232 transcript produced a band of ~232 bp, showing basal levels of transcription.  
When the Pemm 232 template was incubated 1.25 µM Mga1-His6, a band of ~232 bp had 
a strong increase in intensity compared to the basal level of transcription of the Pemm 
promoter in the absence of Mga.  
To determine if Mga interacts as a Class II transcription factor, RNAP core was 
incubated with either His6-σ or His6-σ-Δ4 to generate holoenzymes. Three times as much 
His6-σ-Δ4 than His6-σ needed to be added to core RNAP to activate transcription and 




Figure 16 In vitro Transcription with mutant RNA polymerases 
(A) In vitro transcription with 1.25 µM Mga1-His6 on the PrpsL +30 1201 or the Pemm 232 
templates using wild-type holoenzyme.  (B) Transcription assay using 1.25 µM Mga1-His6 on the 
PrpsL +30 1201 or Pemm 232 template using wild-type core and either His6-σ or His6-σ-Δ4.  (C) 
Transcription assay using 1.25 or 2.5 µM Mga1-His6 on the PrpsL +30 1201 or Pemm 232 
template with either the refolded RNAP His6-α or the RNAP His6-α-ΔCTD with wild-type σ 
factor. 
 
reaction was also adjusted to decrease the concentration of HEPES from 50 to 10 mM.  
These conditions were then used for both His6-σ and His6-σ-Δ4 holoenzymes.  RNAP-
His6-σ had no Mga-dependent transcription on the PrpsL +30 1201 template, but showed 
a strong increase in transcript when Mga1-His6 was added to the Pemm 232 template.  
The RNAP-His6-σ-Δ4 holoenzyme also had an increase in of the 232 bp transcript when 
Mga1-His6 was added to the Pemm 232 template, but no Mga-dependent transcription 
was observed on the PrpsL +30 1201 template (Figure 16B).     
RNAP WT 
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When in vitro transcription was performed using the RNAP-His6-α and RNAP-
His6-α-ΔCTD, no transcript was detected from the PrpsL +30 1201 templates.  However, 
when incubated with Pemm 232, each transcript showed an increase in the intensity upon 
the addition of Mga1-His6 over basal levels of Pemm transcription (Figure 16C).  
Discussion 
 These studies provide preliminary evidence that Mga does not activate 
transcription by functioning solely as a Class I or Class II transcription factor.  The 
bacterial two-hybrid system was unable to detect protein-protein interactions between 
Mga and the α subunit.  However RNAP is a 3-dimensional, multisubunit protein that 
interacts with DNA, and therefore studying the Mga-α interaction outside of this context 
may miss these interactions.  The protein may also not be properly folded.  The bacterial 
two-hybrid assay also was unable to detect an interaction with σ factor.  While the T18-
His6-σ protein was produced, it does not appear to be in the soluble fraction.  Therefore 
protein-protein interactions may be missed if E. coli places this protein in inclusion 
bodies where it cannot interact with its binding partner.  Overall the two-hybrid system is 
an insufficient tool for studying interactions of these protein complexes. 
 Mga was able to activate transcription from Pemm when domain 4 of σ factor or 
the CTD of α was removed, indicating that these domains are not the sole point of 
interaction for Mga to activate transcription.  However, Mga does appear to co-purify 
with the holoenzyme in vitro, suggesting that the protein-protein contacts are present.  
Interestingly, these interactions action can be detected in solution, in the absence of 
DNA, which may suggest that Mga recruits the polymerase to the promoter.  Mga is 
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suspected to bind to DNA as a dimer; it is possible that one Mga monomer contacts the α-
CTD and the other Mga monomer contacts domain 4, and that either of these protein-
protein contacts is sufficient to activate transcription in vitro.  To determine if Mga 
simultaneously interacts with these domains, in vitro transcription and co-affinity 
purification with the RNAP double mutant and Δ139-Mga will be performed.  The RNAP 
double mutant should have no Mga-dependent transcription or should not co-purify with 
the Mga4-CBP protein if Mga contacts both domains.   
The amino acids involved in these contacts would be identified by first narrowing 
the region of interaction in each domain, combined with alanine scanning mutagenesis.   
Amino acids will also be targeted based on known interactions with other transcription 
factors.  If Mga makes protein-protein contacts elsewhere in the holoenzyme, identifying 
the amino acid contact points will be more difficult.  Directed mutations will be made 
based on other known interactions.  These mutations will be assessed for their ability to 
activate transcription and co-purify with Mga in vitro.  The His6-σ and His6-σ-Δ4 proteins 
will be purified from GAS and will be assessed for activity by in vitro transcription.  Co-
affinity purification in vivo will then be performed to confirm the biological relevance of 




Interaction of Mga with other Promoters and 
Regulatory Elements 
Introduction 
This studies discusses preliminary work done to better understand how Mga 
functions as a whole within GAS.  Studies have so far focused on identifying the Mga 
binding sites [76–78,114], identifying the key binding domains [79,119], more recently 
studying how the domains of the protein contribute to its regulation [73], and how Mga 
interacts with just one of its binding sites [120].  These studies look at various aspects of 
Mga binding, multimerization and activation in isolation, but ultimately the goal is to fit 
this work, along with previous studies into a broad understanding of Mga’s function both 
at the promoter and cell-wide.   
One aspect of these studies is to better understand the role of each domain within 
the protein.  Mga contains two DNA binding domains, HTH-3 and wHTH-4. Directed 
mutations of each of these domains observed that the wHTH-4 is the essential DNA-
binding domain and that HTH-3 plays a role in Pmga binding [79], but the role of HTH-3 
overall is not known.  The EIIBGAT domain at the C terminus is responsible for Mga 
dimerization [73].  Though the Δ139Mga EIIB truncation binds DNA with the same 
affinity as wild-type, it does not activate transcription in vivo.  Mga contains two PRD 
domains and the histidines H204/H270 of PRD1 are phosphorylated in vitro by the PTS 
(Hondorp, et al, in review).  While PTS phosphorylation in vitro and decrease in 
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expression of Mga-regulated genes had been observed in vivo with phosphomimetic 
mutants, this has not been directly linked. 
When the known Mga-binding sites from all three categories of Mga-regulated 
promoters (Pemm6, PscpA, PsclA, Pmga1, and Pmga2, Pemm1, PscpA, and Psic) [76,77] 
were aligned using ClustalW, only 13.4% sequence identity was observed [120].   
However after dissecting the Pemm1 binding site, it appears that Mga interacts with each 
binding site in a distinct manner.     
Previous microarray studies found that the Mga regulon is composed of ~10% of 
the GAS genome.  Interestingly, as Mga had been previously known as only a 
transcriptional activator, in M1 SF370 103 genes and in M4 GA40634 118 genes were 
repressed.  Initial studies scanned the mannose (ptsA-D) operon, glucose (ptsG), maltose 
(malE-G) and iron uptake (siuADBG) for the consensus Mga binding site, but none were 
identified [72].  However the EMSA analysis found no binding to any of these promoters, 
which suggests that, the Mga-regulation occurs indirectly.  The Mga consensus sequence 
is weak, a consensus of Pemm6 and PscpA6 did not identify the Mga binding site in 
Pmga6 [76] indicating that Mga binding sites may easily be overlooked.   Initial ChAP, 
chromosome affinity purification, studies were performed to better understand the full 
binding profile for Mga, and how it controls its regulon.       
Results  
Dimerization of Mga4-His6 and Δ139Mga4-His6 in solution 
Previous gel filtration experiments found that Mga4-His6 forms oligomers in 
solution with increasing amounts of NaCl, while the Δ139Mga4-His6 protein remains 
monomeric [73].  To verify this oligomerization, sedimentation equilibrium by analytical 
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ultracentrifugation (AUC) experiments were performed on Mga4-His6 and Δ139Mga4-
His6 in 50 mM HEPES/Citrate pH 7.5 with of 100 mM NaCl.  Mga4-His6 was prepared at 
7.5, 20 and 30 µM and centrifuged at 14, 16, 18, 20 and 22 Krpm (Figure 17A).  Analysis 
of the data indicates an average molecular weight of 89.9 kDa, (confidence interval 83.5-
96.3 kDa), significantly larger than the value of 63.2 kDa predicted.  When fit to a 
monomer-dimer model, the equilibrium dissociation constant for dimerization  (Kdim) was 
found to be 9.41 µM (confidence interval 5.99-14.5 µM)[73]. Analysis of the data using 
 
Figure 17 Dimerization of Mga4-His6 and Δ139Mga4-His6 
Sedimentation equilibrium of Mga4-His6 and Δ139Mga4-His6 in 100 mM NaCl, 50 mM 
HEPES/Citrate, pH 7.5 [74]. (A) 7.5 (circle) 20 (square) and 30 (triangle) µM Mga4-His6 spun at 
16 Krpm.  Fifteen data sets were fit to a monomer-dimer model (solid lines) resulting in the 
residuals depicted (B). (C) 7.5 µM of Δ139Mga4-His6 centrifuged at 18 (square) 20 (inverted 
triangle) and 22 (circle) Krpm.  Six data sets were fit to a model for a single homogenous species 




































monomer-trimer or monomer-tetramer models indicated no improvement in the fit based 
on the magnitude of the square root of the variance of the fit and the residuals of the fit 
(data not shown).  Δ139Mga4-His6 was prepared at 7.5 and 30 µM and centrifuged at 18, 
20 and 22 Krpm (Figure 17C).  For the Δ139Mga4-His6 protein the best fit of the data 
indicated a monomeric species in the presence of 100 mM NaCl with a molecular weight 
of 50.7 kDa, which matches the predicted weight of 47.2 kDa [73].   Interestingly, the 
AUC experiments performed with Mga4-His6 in the absence of 100 mNaCl indicated a 
Kdim of 6.13 µM, (confidence intervals 3.48-10.7 µM) presence of 100 mM NaCl (data 
not shown), suggesting that in this system salt did not have a significant effect.   
PTS Phosphorylation of Mga leads to inactivation in vitro 
Previously we found that Mga was phosphorylated in vitro via the PTS, and in 
vivo that the Mga phosphomimetic mutant has a decrease in the inactivation of Mga-
regulated genes (Hondorp, in review).  In order to directly link phosphorylation of the 
protein to the downregulation of its activity, first the PTS system was reconstituted in 
vitro and used to phosphorylate Mga.  As expected, when EI, Hpr and Mga were 
incubated in the presence of PEP, a band that corresponded to P~Mga was detected 
(Figure 18A).   
To link this phosphorylation to down-regulation of Mga-dependent transcription, 
the phosphorylation reaction was performed with template DNA, but in the presence or 
absence of PEP.  Then the in vitro transcription was performed as described previously.  
In the absence of PEP, a strong increase in emm transcript was observed when Mga was 
incubated with Pemm compared to the Mga minus lane, while no difference was seen in 
the rpsL transcript levels.  When PEP was added to the reaction, the rpsL transcript again  
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showed no difference in the presence or absence of Mga in the reaction.  However, at the 
Pemm promoter, in the presence of PEP and the components of the PTS system, no Mga-
dependent transcription was observed (Figure 18B).  This was observed for both Mga4-
His6 and Mga1 His6. 
Figure 18 Effect of in vitro phosphorylation of Mga on transcription 
(A) The reconstitution of the PTS phosphorelay in vitro (Hondorp, 2012, in review).  In the 
presence of PEP, EI phosphorylates Hpr, which passes the phosphate to the PRDs of Mga.  (B) In 
vitro transcription assay performed with the phosphorylated Mga1-His6 leads to the 
downregulation of transcription.    
 
Purification of Mga by TAP tagging 
To enhance the purity of Mga for x-ray crystallography, a TAP, tandem affinity 
purification, tagged protein was created.  Previous work found that Mga from an M4 
GAS strain gave better yield during protein purification than the Mga from a M1 GAS 
strain, and so the M4 Mga (Mga4) protein was used [73].  Mga4, was first cloned into 
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pCAL-C to introduce a C-terminal, thrombine cleavable CBP, calmodulin binding 
protein, tag.  This Mga4-CBP was then cloned into pET21a to add a C-terminal 6x His 
tag (Figure 19).  Mga1, Δ29Mga4, which has a size difference but no change in activity, 
and Δ139Mga4 CBP-His6, the dimerization mutant, proteins were also created.  The wild-
type Mga4-CBP-His6 was then grown in C41[DE3] in ZYP-5052 for ~ 60 hours as 
previously described [73].  The protein was purified first over the calmodulin column, 
followed by NiNTA agarose, as well as the reverse (Figure 21B).  Between the 
calmodulin and NiNTA columns, the protein was initially dialyzed overnight against 4 L 
NiNTA lysis buffer.  At this point Mga remained bound to NiNTA agarose.
 
Figure 19 Schematic of TAP tagged Mga 
(A) Full-length Mga with both a CBP and His6 tag at the C terminal end of the protein for tandem 
affinity purification.  The red arrow indicates the thrombin cleavage cite.  (B) Red lines indicate 
the location of the Δ29 and Δ139 truncations.  Δ29 removes the disordered region at the C-
terminus or the protein.  Δ139 removes the EIIB dimerization domain.   
 
Mga4-CBP-His6 was then dialyzed against 1 L NiNTA lysis buffer, with four 
buffer exchanges in order to remove the EGTA from the CaCl2 Elution buffer.  This 
allowed Mga to be eluted from the NiNTA column.  When passed over the NiNTA 
column, the affinity of Mga4-CBP-His6 for the NiNTA agarose was reduced compared to 
Mga4-His6, all protein eluted into 70 mM imidazole wash, as opposed to the 250 mM 
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imidazole elution buffer.  Proteins were dialyzed into 50 mM HEPES/Citrate, pH 7.5, and 
concentrated to ~500 µL.  For each direction of purification, multiple bands were 
detected along with the expected 65 kDa band, so that Mga4-CBP-His6 was 
approximately half the protein present (Figure 21B). 
 
Figure 20 Schematic of HTH mutations 
(A) Mga1-HTH3-His6 contains point mutations within the recognition helix of HTH-3 in order to 
study the binding ability of wHTH-4. (B) Mga1-HTH4-His6 contains point mutations within the 
recognition helix of wHTH-4 on order to study the binding ability of HTH-3.  (C) Mga1-HTH34-
His6 has a mutation binding domain and does not bind to DNA.    
 
Purification of Mga1-HTH4-His6  
To study the contribution of HTH-3 and wHTH-4, the essential binding domain, 
to DNA-protein interactions mutant proteins were created for expression in E. coli.  The 
Mga1-HTH3-His6 protein contains a mutation in the recognition helix of HTH3, Mga1-
HTH4-His6 contains a mutation in the recognition helix of HTH4 and the Mga1-HTH34-
His6 contains both mutations (Figure 20).  Expression of each protein was monitored 
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across growth in ZYP-5052 for ~56 hours at 37°C.  Western blots of the soluble fraction 
showed that Mga1-HTH4-His6 and Mga1-HTH34-His6 were expressed as the wild-type 
protein, but Mga1-HTH3-His6 was insoluble, even when grown at RT (Figure 21A).  The 
Mga1-HTH4-His6 protein was subsequently purified in the same manner as Mga1-His6. 
 
Figure 21 Purification of Mga1-HTH4-His6 and TAP Tagged Mga 
(A) Western blot probing with α-His for Mga1-HTH4-His6 in the soluble fraction across growth 
found that the protein expressed similarly to wild-type.  (B) Coomassie gel of the final purified 
and concentrated Mga4-CBP-His6 after purification from the CBP column to the NiNTA column, 
or from NiNTA to the CBP column shows the predicted 65 KDa band, as well as several other 
bands of near equal intensity.   
 
Category B Binding Sites 
In order to study Mga interactions at a category B binding site, luciferase assays 
were performed to characterize the transcriptional activity of PsclA.  The M1 PsclA 
binding site was cloned to drive luciferase expression on a plasmid and transformed into 
MGAS5005.  Samples of the PsclA-luc and promoterless luc plasmids were taken in  
α-His 












Figure 22 DNA-binding and Transcriptional Activation of Category B Promoters 
(A) Luciferase assay of PsclA-luc shows low levels of activity across exponential growth in the 
strain MGAS5005 The dashed line represents growth, the blue line represents luciferase activity.  
(B) The PsclA promoter.  The predicted MBS is underlined in dark blue [78], the actual MBS is 
extended by the light blue nucleotides.  The -35, -10 and +1 transcription start are highlighted in 
bold.  (C) DNaseI footprint on the sense strand of PsclA protects the nucleotides from -201 to -
154 relative to the start of transcription.  (D).  In vitro transcription assay for Mga-dependent 
transcription when the Pemm MBS is placed either 10 or 15 bp upstream of the PrpsL -35 
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triplicate every ~15 Klett over exponential growth.  PsclA-luc showed low levels of 
expression across growth, ~ 1-2 x 102 relative luciferase units (RLU) (Figure 22A).   
 The PsclA MBS site had been determined by sequence alignments and then 
confirmed by EMSA analysis and in vitro transcription but was not directly footprinted 
[78].  The PsclA site was predicted to be 44 bp and encompass the nucleotides -153 to -
197 relative to the +1 transcription start site (Figure 22B).  To determine the PsclA 
binding site DNase I footprints were performed.  In this assay a footprint of 59 bp was 
detected that protected the region from nucleotides -201 to -154 (Figure 22C).   
Both Category B and C promoters activate transcription from a distal binding site.  
In order to understand the mechanism of activation at a distance an in vitro template was 
constructed were the Pemm MBS was placed either 10 or 15 bp upstream from the PrpsL 
-35 hexamer to create the templates MBS +10 PrpsL 1201 and MBS +15 PrpsL 1201.  
The Pemm MBS was used as it is the produces the strongest Mga-dependent 
transcriptional activation, and because the exact binding site has been defined, while 
PsclA has very low levels of activity and where Mga binds to DNA is not as clear.  In 
vitro transcription assays performed with each of these templates did not have an increase 
in PrpsL transcript levels upon the addition of Mga1-His6 to the reaction (Figure 22D).   
Category C Binding Sites 
EMSA analysis was performed to determine if Mga1-His6 interacted with Pmga in the 
same manner as MBP-Mga6, which is the M6 strain Mga protein originally used for 
DNA-binding studies [76].  Increasing amounts of each protein was incubated with ~2.5 




Figure 23 EMSA comparing Mga1-His6 to MBP-Mga6 at Pmga 
~2.5 ng of the Pmga2315 probe was incubated with 2, 3 and 3 µM Mga1-His6 or 8.3, 10.45 and 
16.6 µg/µL of MBP-Mga6.  Two distinct bands were present when Pmga was incubated with 
Mga1-His6 while only 1 band was observed with MBP-Mga6. 
described.  While MBP-Mga6 shifted a single band, at each concentration, the Mga1-His6 
protein shifted the probe as a doublet (Figure 23).   
Comparison of DRACALA to EMSA and Filter-binding 
DRACALA, differential radial capillary action of ligand assay, is a method for 
assessing protein-DNA binding in which bound ligand remains stuck on a nitrocellulose 
membrane while unbound ligand can move away by capillary action [111].  Densitometry 
can then be used to measure free versus unbound ligand, and subsequently obtain Kd 
values.  DRACALA was performed to compare the Kd calculated by this method to the 
previously published Kd that was determined for Mga by filter-binding [73].   Mga4-His6 
was incubated with 0.1 nM Parp MBS 49mer and Mga1-His6 was incubated with 0.1 nM 
of Pemm1 MBS 49mer.   The binding reaction was performed as in the EMSA analyses, 
using 0.01, 0.1, 0.5, 1, 5, 10 and 20 µM of either Mga-His6 protein.  5 µL of each reaction 











Figure 24 Mga-DNA binding by DRACALA 
(A) DRACALA of Mga4-His6 with the Parp MBS 49mer calculated a Kd of 286 nM.  (B) 
DRACALA of Mga1-His6 with the Pemm MBS 49mer calculated a Kd of 396 nM.  DRACALA 
values are ~10 fold greater than those obtained by filter-binding.  (C) EMSA comparing the DNA 
binding ability of the HTH-3 to wild-type.  0.1 nM Pemm1 MBS 49mer was incubated with 2.5 
and 5 µM of Mga1-His6 or 5 µM of Mga1-HTH4-His6.  (D) DRACALA of Mga1-HTH4-His6 
protein.  0.01, 0.1, 0.5, 1, 5, and 10 µM Mga1-HTH4-His6 was incubated with either 0.1 nM of 
the Pemm1 MBS 49mer or the Pemm1 Random 49mer.  The Mga1-HTH4-His6 protein 
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densitometry was performed to determine the bound versus free probe.  The Kd for 
Mga4-His6 binding to Parp was 286 nM, while the previously determined Kd was ~30-50 
nM (Figure 24A).  The Kd for Mga1-His6 binding to Pemm was 396 nM while previously 
a Kd of ~50-65 nM was determined (Figure 24B).  Each measurement by DRACALA 
was ~10 fold greater than previously found.   
To study the contribution of the HTH-3 to DNA binding the Mga1-HTH4-His6 
protein was tested for DNA binding activity by EMSA and DRACALA.  For EMSA, 0.1 
nM of the Pemm1 MBS 49mer was incubated with 2.5 and 5 µM of Mga1-His6 and 5 µM 
of Mga1-HTH4-His6 (Figure 24C).  For DRACALA, 0.01, 0.1, 0.5, 1, 5 and 10 µM 
Mga1-HTH4-His6 was incubated as for the EMSA with either 0.1 nM the Pemm1 MBS 
49mer or the Pemm1 Random 49mer.  As described previously, the protein with only 
HTH-3 was unable to bind DNA in the EMSA [121], but did show some binding activity  
in the DRACALA assay (Figure 24D).  
Validation of the Chromosome Affinity Purification 
To identify the genome wide binding profile of Mga, ChAP assays were 
performed.  The GAS strains KSM547 (pLZ12-Spc) (mga-/mga-) and KSM547 
(pKSM808) (mga-/mga+) were grown to mid-logarithmic phase (Klett 75-80).  
Following crosslinking with 1% formaldehyde, cells were lysed.  The DNA was sheared 
by both a sonication using the Covaris system and then the Mga was purified over 
NiNTA agarose.  Crosslinks were reversed overnight and the DNA was purified.  The 
affinity purification was assessed by collecting samples after cell lysis, and after the 
protein was eluted from the NiNTA agarose.  Western blots for these samples were 
probed with a α-his antibody.  A His-tagged protein of ~62 kDa, corresponding to Mga, 
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was detected in the whole cell lysis and final elution of the strain containing pKSM808 
(Figure 25A).  No proteins were detected in the mga- strains.   
The DNA was analyzed by qRT-PCR for enrichment of Mga binding sites in the 
Mga + strain over the Mga- strain.  gyrA was used as an internal control in the reaction.  
Primers for Parp and Pmrp, two directly Mga-regulated genes were chosen as a positive 
control.  On average of 3 replicates, Parp was enriched 3.32 fold +/- 0.19, and Pmrp was 
enriched 7.87 +/- 0.97 (Figure 25B).  PrpsL, a non-Mga regulated gene, and PmalR, a 
Mga-regulated gene that does not bind to Mga, were used to determine if promoter DNA 
was being enriched over genomic DNA.  Neither promoter was significantly enriched.  
As the purified DNA was successfully enriched for MBSs, it was sent for library 
formation and sequencing.       
DNA was first submitted for quality analysis by Bioanalyzer and was found to be 
~40 bp in size (Figure 25C), which is insufficient to separate unused linkers during the 
formation of the sequencing library.  gDNA was extracted from samples directly before 
crosslinking, after crosslinking and after overnight incubation at 65°C and assessed on a 
1% agarose gel.  The gDNA was degraded during the crosslinking step, leading to 
overshearing of the DNA fragments for library preparation.  Due to this degradation, 
sequencing libraries could not be generated from the enriched DNA.   
Discussion 
Prelimary studies were performed to study further interactions of Mga at the 
promoter, from the view of the DNA and the Mga protein.  Dimerization is a necessary 
attribute of Mga’s role as a transcriptional activator.  Sedimentation equilibrium was 




Figure 25 Validation of ChAP-Seq DNA 
(A) Western blot for the presence of Mga after cell lysis (S) and after purification by NiNTA 
agarose (AP) detects a band in the Mga + strain but not the Mga- strain.  (B) qPCR data showing 
a significant enrichment of DNA containing the MBS at Parp and Pmrp over the Mga- strain 
relative to gyrA.  (C) High Sensitivity DNA Assay found that the DNA fragments in ChAP 
sample DNA are ~40 bp in size.  
 
dimerization coefficient of each and assess the effect of salt concentration on the 
dimerization.  Interestingly, while the previous gel filtration experiments found that salt 
concentration effected the formation of dimers, this effect was not seen by AUC.  Future 
studies will be needed to fully understand the mechanism of dimerization.  These 
experiments also set up for future sedimentation equilibrium experiments to determine if 
Mga binds DNA as a dimer.   
The in vitro phosphorylation-transcription assay demonstrates the first direct link 
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gene regulation, supporting the hypothesis that Mga down-regulates its genes in response 
to the carbon status of the cell through the PTS.  Further assays using the Mga 
H204A/H270A protein will be performed to demonstrate that this effect is specific to the 
phosphorylated histidines of Mga’s PRDs.  This Mga A/A protein should be insensitive 
to phosphorylation.  Ideally this phosphorylation would also be detected within a GAS 
cell.  Interestingly, while only a small portion of Mga appears to phosphorylated in vitro 
by the PTS system, Mga-dependent transcription was completely abrogated.  This 
suggests that the bulk of the protein may be misfolded or aggregated, and only a fraction 
of Mga is actually active.   
A Mga-CBP-His6 protein was created in order to enhance the purity of the protein 
for X-ray crystallography by tandem affinity purification.  Initial purifications found that 
Mga was not the predominated band in in the final fraction when purified in either 
direction.  Much of the protein also appears to be lost during purification.  The increased 
purity of the Mga-His6 protein is partly due to increased washes combined with 
increasing amounts of imidazole to remove impurities [73].  However, the Mga-CBP-
His6 protein elutes at a much lower imidazole concentration. The CBP tag also introduced 
a thrombin cleavage site.  If the CBP-His6 tag can be successfully removed, than further 
optimizing the purification would be highly beneficial to crystallizing the protein.   
Mutations were created in the HTH-3 and wHTH-4 to study the contribution of 
each domain to DNA-binding in isolation.  Unfortunately the M1 Mga HTH-3 mutant 
protein was insoluble in E. coli.  As the M4 strain Mga protein is somewhat less finicky, 
future studies may focus on the M4 version or alternatively the HTH-3 mutant may be 
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purified from GAS.  The wHTH-4 protein was expressed similarly to the wild-type 
Mga1-His6 protein, and so it was purified and tested for DNA binding. 
While the majority of work so far has focused on Category A promoters, and 
Pemm specifically, understanding how Mga interacts with Category B and C promoters 
was also an important goal.  The Pmga promoter had previously been characterized for 
expression across growth [57], but no Category B promoters had been tested.  A PsclA-
luc plasmid was constructed and monitored for expression.  PsclA was found to have very 
low luciferase activity across growth, comparable to what was seen for PscpA [120].  The 
Category B promoters PsclA and Psof-sfbX were both identified by sequence alignments 
and confirmed by EMSA and in vitro transcription.  This study performed the first 
DNaseI footprints on the PsclA promoter.  Surprisingly the footprint protected a region of 
59 bp, as opposed to the predicted 44, which resembles the Pmga binding sites.  As PsclA 
is centered -173 bp upstream from the start of transcription, the additional protected 
region may be a result of DNA bending to interact with the downstream promoter.  This 
may also be the explanation for the large size of the two Pmga MBSs.  Footprints will be 
performed on other Category B promoters to confirm this phenotype. 
A template that placed the Pemm MBS binding site 10 and 15 bp upstream of the 
PrpsL -35 hexamer was created to shift the binding site 1 and 1.5 helical turns away from 
the promoter.  At each promoter this adjustment was sufficient to disrupt Mga’s ability to 
activate transcription.  Future studies will be done to determine how far from the -35 the 
binding site can be moved before Mga-dependent transcription is disrupted.  MBSs at 
Category B promoters will also be investigated to determine how the position of the 
binding site affects transcription.  Mga may activate transcription at the Category B 
 110 
 
promoters through a different mechanism than at the Category A promoters, so the RNAP 
mutants will also be assessed at these promoters.   
To investigate the Category C promoter, EMSA using Pmga2315, which contains 
both MBSs was performed.  While the MBP-Mga6 protein shifted in a single band, the 
Mga1-His6 protein shifted as a doublet.  Each Mga protein has an identical wHTH-4, 
which is the essential binding helix, and an identical HTH-3, that acts as an accessory at 
Pmga [79] so this could be an artifact of the large size of the MBP tag.  The Mga-His6 
protein will be used in future studies that would include DNaseI footprinting, and 
competition assays with probes containing either or both Pmga MBS site. 
DRACALA assays were performed using the Mga4-His6 protein with the Parp 
MBS 49mer and the Mga1-His6 protein with the Pemm MBS 49mer to compare the Kd 
from this technique to the previously published values obtained by filter-binding.  For 
each protein/probe combination the Kd determined by DRACALA was approximately 10 
fold larger than that determined by the filter-binding technique.  The reason for this 
difference has yet to be determined.  Mga appears to readily precipitate onto the 
nitrocellulose membrane during filter binding assays, making it difficult to obtain clear 
measurements.  While the DRACALA method has its limitations, it offers the advantage 
of being a quick and straightforward method of assessing many binding sites.   
 As previously seen, the wHTH-4 mutant had no DNA-binding activity when 
tested by EMSA [79], however binding activity was detected by DRACALA.  EMSA 
extends the DNA binding assay over time and so with weak binding, this interaction may 
be lost.  The DRACALA assay is much quicker, and appears to be more sensitive.   
 111 
 
Future studies with the HTH mutants or weak binding sites should be performed with 
DRACALA in order to not overlook weak or transient interactions.   
These initial studies demonstrate that the ChAP technique can successfully enrich 
for DNA containing Mga binding sites.  This technique could also be applied to other 
GAS transcription factors.  However, at this time the DNA is too small to be successfully 
incorporated into the sequencing libraries.  This degradation may be due to the many 
DNases present or a variation in strain used and further studies will be needed to 
overcome this problem.  If the experiment finds new targets for DNA-binding, these 
sequences will be first compared against genes of the known Mga-regulon in both the 
GA40634 strain used and in the clinically relevant MGAS5005 strain.  DRACALA will 
be used to test probes containing these sequences for DNA-binding activity.  Probes that 
bind to Mga will then be aligned with known Mga binding sites.  Further binding studies 
will also be performed to compare the contribution of Mga’s two DNA binding domains 






 The Group A streptococcus is an obligate human pathogen that causes a wide 
range of diseases within diverse niches of the human body.  Mga, the multigene regulator 
of GAS, is a key global transcription factor that regulates many of the virulence genes 
necessary for infection.  While Mga’s broad function as the activator of virulence genes 
such as emm, scpA and sclA is known, the specifics of these interactions have not been 
well understood.  Overall these studies have focused on the mechanism by which Mga 
functions at the promoter and together this data has allowed us to build a model of Mga at 
the promoter. 
Model of Mga interactions at the promoter 
Dimerization 
The key components that allow Mga to activate transcription are DNA-binding, 
dimerization, protein-protein contacts with RNA polymerase and PTS phosphorylation.  
DNA-binding and dimerization are tightly linked (Figure 26).  The distribution of 
nucleotides within the Pemm1 binding site, in particular the GGTC and GCTG motifs 
support a model in which two Mga proteins are bound [120].  The lack of apparent half-
site binding (this study) and the cooperativity observed in the binding curve [73] also 
support the idea that Mga DNA binds as a dimer.  That Mga does form multimers in vivo 
and dimers in solution [73] has also been shown and is further supported by the crystal 
structure of the E. faecalis Mga homolog EF3013 (Protein Data Bank [PDB] accession 




Figure 26 Model of Mga Binding to the Pemm MBS 
Mga forms a dimer in solution through its EIIB domain.  The arrangement of the domains is 
based on the E. faecalis Mga homolog EF3013.  The wHTH4 forms specific contacts with GGTC 
at the 5’ end and with the GCTG at the 3’ end.  The 3’ dimer also makes contacts with C29 and 
C43.  As the distance between the wHTHs is ~100 A or 30 bp, a bend in Pemm at G18 and G19 
fits the binding site to the protein.  
 
this is slightly smaller than the Pemm1 minimum MBS, the differences between Mga and 
this homolog, and DNA-bending can further fit a Mga dimer onto DNA. 
To demonstrate the validity of this model, definitively showing the dimerization 
of Mga at a MBS will the most important future experiment.  In order to do so, 
sedimentation equilibrium studies will be performed, first using Mga with Pemm, and 
later using Mga with a binding site from each category.  SAXS, small angle X-ray 
scattering, is another technique that can be used to study this interaction.  The current 
effort to crystallize Mga within the presence of DNA will also shed light on this 
interaction.  Δ139Mga, which binds to DNA with a similar Kd as wild-type but does not 
dimerize will be another key component to understand Mga-DNA interactions.  DNaseI 
footprints will also be performed to determine if this protein binds monomerically. 
TGGCAAAAGCTAAAAAAGCTGGTCTTTACC!ACCGTTTTCGATTTTTTCGACCAGAAATGG!
9 43 
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While overall Mga binding sites have low sequence identity we propose that Mga 
does make specific contacts with DNA using wHTH-4.  In the Pemm1 binding site the 
specific contacts are with 5’ GGTC and 3’ GCTG.  The 3’ dimer makes additional 
contacts with C29 and C43. Similar motifs are found in the other binding sites that 
suggest that Mga recognizes a small specific sequence.  PscpA and Psic have a 5’ GGTC 
motif, as does Pmga2.  PsclA and Pmga1 each have a 1 nucleotide change: to AGTC for 
PsclA and and GTTC Pmga1.  PscpA, Psic, PsclA and Pmga1 also have a 3’ GGTC motif 
that is inverted and on the opposite strand.  The distance and orientation of these motifs 
likely plays an important role in affinity and activity of each binding site.   Each half-site 
may also vary in affinity for a Mga monomer, so that while Mga binds as dimer, some 
breathing occurs between the interactions.  One hypothesis is that the variation of the 
known Mga binding sites is allows for fine control of the genes expressed.  This 
hypothesis is illustrated by comparing Pemm, PscpA and Psic.  The luciferase assays 
found that Pemm is highly expressed, PscpA is lowly expressed and Psic falls in between.  
These finding are quite interesting in that PscpA and Psic are extremely similar in 
sequence, but have more than ~10 fold difference in expression.   Pemm and Psic also 
shown similar DNA-binding abilities, but again Pemm expression is more than 10 fold 
greater than Psic.   
As these studies have shown that predictions using the Pemm MBS as model do 
not necessarily predict the function of nucleotides in other binding site, each site will 
need to be screened individually.  To rapidly screen the binding sites, biochemical 
interference assays will be used.  Methylation interference and protection assays will be 
most informative, in particular to look for the GGT motif.  Directed mutagenesis will be 
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performed to understand the roles of DNA-bending, spacing and orientatation of the 




Figure 27 Protein-protein contacts with RNA Polymerase 
We predict that the Mga dimer forms protein-protein contacts with RNAP through the α-CTD and 
domain-4 of σ concurrently, either in solution where Mga recruits RNAP to the promoter, or 
when an already bound Mga stabilizes the polymerase at the promoter.  These protein-protein 
contacts allow RNAP to more quickly find the promoter and stabilize it through the formation of 
the elongation conformation. 
Interactions with RNA Polymerase 
Protein-protein contacts between Mga and the holoenzyme are another essential 
component for Mga-dependent transcriptional activation.  While Mga does interact with 
the holoenzyme in solution, neither the α-CTD nor the domain 4 of σ factor are the sole 
point of contact (this study).  However at bacterial promoters multiple transcription 
factors may be present to interact with RNAP [95].  As Mga likely binds as a dimer and 
this dimer is necessary for activation, we propose a model were the Mga dimer forms 
protein-protein contacts with RNAP through the α-CTD and domain-4 of σ concurrently.  
These interactions occur in solution where Mga recruits RNAP to the promoter, or an 
TGGCAAAAGCTAAAAAAGCTGGTCTTTACC!ACCGTTTTCGATTTTTTCGACCAGAAATGG!
9 43 
Pemm1 minimal Mga binding site 
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already bound Mga stabilizes the polymerase at the promoter (Figure 27).  These protein-
protein contacts allow RNAP to both more quickly find the promoter and then stabilize it 
through the formation of the elongation conformation.  Most point mutation had a simple 
connection between DNA-binding affinity and transcriptional activation: less binding, 
less activity, more binding, more activity.  These are simple to place in the model, as 
more/less Mga binding leads to more/less RNAP recruitment leads to more/less 
transcription.  However mutations were identified with less binding and more activation 
(Pemm1 G9A, PscpA C12A), wild type binding with a decrease activity (Pemm1 C23A, 
PscpA) and mutations with a decrease in binding but no change in activity (Pemm1 
G10A, Pemm1 G18A, PscpA C12A).  The G9A mutation decreases binding but increases 
transcription possibly through increasing promoter clearance.  The orientation and 
spacing of the Mga dimer may explain the phenotype of these other mutations.  Pemm 
contains a strong DNA bend at A17, G18 and G19 that is not present in PscpA, while the 
GGT motif at the 3’ end of PscpA is shifted 3’ from the CGT that appears to be important 
in Pemm.  If Mga is binding as dimer, than these difference in the space between the 
“half-sites” both linearly along the DNA and in 3-dimensional space could have 
important implications for making the optimal contacts with RNAP.  Future studies of 
these interactions will include DNaseI footprinting of Mga with RNAP polymerase with 
the mutants from both the protein and DNA standpoint.  The Δ139 Mga mutant is of 
particular interest in observing how Mga makes contacts with RNAP; DNaseI footprint, 
methylation interference assays as well as in vitro co-affinity purification assays will be 
performed to understand how activation occurs.   
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PTS Regulation of Mga Activity 
The PTS phosphorylation of Mga is the last component that allows Mga to 
activate transcription identified so far.  This phosphorylation results in the loss of Mga-
dependent transcriptin in vitro and specifically this phosphorylation disrupts dimerization 
as shown by co-IP studies using a Mga phosphomimetic (Hondorp, 2012, in review).  In 
EF3013, the phosphorylated histidines are not present.  However the PRD-1 of each 
monomer, which contains the phosphorylation site, are separated and do not form a dimer 
 
Figure 28 Effect of PTS phosphorylation on Mga dimerization 
The PTS phosphorylation of Mga disrupts dimerization, and transcriptional activation, but not 
DNA binding (Hondorp, 2012, in review).  We predict that the PRD-1 phosphorylation changes 
the structure of the protein so that the EIIB domains no longer dimerize.  The phosphorylated 
protein still binds to DNA, but as a monomer instead of a dimer.  This also disrupts protein-
protein interactions with RNA polymerase, which turns off Mga-dependent transcription.   
         
interface.  Our model therefore proposed that this phosphorylation changes the structure 
of the protein so that the EIIB domains no longer interact.  As a result Mga may bind 
DNA as a monomer and the protein-protein interactions with RNAP are disrupted.   
In the future, the in vitro phosphorylation-transcriptions experiment will be 
























phosphorylated have been mutated to alanines, and therefore this protein should not be 
down-regulated by the PTS system.  The in vitro phosphorylation of Mga will also be 
used to confirm the loss of dimerization phenotype by co-affinity purification.  Changes 
to DNA binding will also be studied by DNaseI footprinting.  Changes to protein-protein 
interactions with RNAP will be studied by co-affinity purification as well as DNaseI 
footprinting with Mga~P.   
Mga’s role as a regulator within GAS 
Another important goal of these studies is refine Mga’s role as a regulator within 
a GAS cell.  Genome-wide binding profiling by ChAP-Seq will create a complete picture 
of where Mga binds in the genome, and could help answer the question of how it 
regulates ~10% of the GAS genome.  Identifying under what conditions Mga is 
phosphorylated and dephosphorylated in vivo would also help explain how this regulation 
occurs.   
While the wHTH-4 is the essential DNA-binding domain, HTH-3 may still play 
an important role.  Future studies will look at the contribution to binding of each DNA-
binding domain at both known MBSs and any further identified MBSs.     
The spacing between the binding site and the promoter could another component 
of how Mga differentially regulates gene expression.  Transcription activation will be 
studied at a distance will be studied by changing both the distance between a MBS. with 
particular attention to the orientation along the DNA helix, and the promoter, and the 




While these studies have narrowly focused on the function of Mga as a 
transcriptional activator, Mga belongs to a larger family of PRD containing   
transcriptional regulators.  Phyre2 analysis of RivR, another virulence regulator within 
GAS, also detects PRDs within its structure.  Many other streptococcal species contain 
Mga orthologues, which include DmgB (dmgB) or MgrC, in S. dysgalactiae and MgrA 
(mgrA) in S. pneumoniae.  Outside of the streptococci, the virulence regulator AtxA of 
Bacillus anthracis contains PRD domains, and can also dimerizes through its C-terminal 
EIIB domain [122]. Understanding how Mga functions will aid in understanding this 




Table 1: E. coli Strains 
E. coli Strains Description Reference 
DH5α (hsdr17 reca1 gyra enda1 
rela1) 
[123] 
C41[DE3] F- ompt hsdsb(rb - mb - ) 






δlacχ74 reca1 arad139 
δ(ara-leu) 7697 galu galk 
rpsl (strr) enda1 nupg λ-) 
Stratagene 
DHM1 F-, cya-854, reca1, enda1, 
gyra96 (nal r), thi1, 
hsdr17, spot1, rfbd1, 
glnv44(as) 
Gift, D. Kearns 
BTH101 F-, cya-99, arad139, 
gale15, galk16, rpsl1 (str 
r), hsdr2, mcra1, mcrb1 




Table 2: GAS strains used in these studies 
GAS Strains Description Reference 




GA40634 emm4 Georgia Emerging 
Infections Program 
(GaEIP) 
KSM547 emm4 mga::pKSM547 KnR [72] 
JRS4-PolHis str rpoC::pPolHisPyo spR 
knR 
[98] 
GA40634.pKSM294 pKSM294 KnR This Study 




Table 3: Table of Plasmids 
Plasmid Name Description Reference 
pCal-C Expression vector C-terminal CBP tag  Stragagene 
pCR-Blunt-
II-TOPO 
pUC ori f1 ori KnR Ampr LacZα Invitrogen 
pCIV2 GAS suicide vector, Ω KnR Cassette [125] 
pET21a Expression Vector C terminal 6x His tag  Novagen 
pMSP3535-H3 Nisin Inducible promoter, GAS replicating 
Plasmid 
[126] 
pProEX-htb Expression Vector N-terminal 6x His tag  Sigma(Genosys) 
pT18N-link   C-terminal T18 expressing two-hybrid vector 
with linker 
Gift, D. Kearns 
pT18C-link N-terminal T18 expressing two-hybrid vector 
with linker 
Gift, D. Kearns 
pT25N-link C terminal T25 expressing two-hybrid vector 
with linker 
Gift, D. Kearns 
pJRS525 GAS replicating vector SpR [127] 
pLZ12-Spc GAS replicating vector SpR [128] 
pVL847 Expression vector N terminal 10x His-MBP [129] 
pMga1-His M1 Mga-his under PT7 promoter in pET21a for 
purification of c-terminal tagged protein in E. 
coli 
[73] 
pKSM720 SpR promoterless luciferase plasmid [57] 
pKSM210 Pemm1-luciferase reporter plasmid in pKSM720 
backbone 
[120] 
pKSM211 PscpA1-luciferase reporter plasmid inpKSM720 
backbone 
[120] 
pKSM212 Pemm1-luciferase reporter with the C43A 
mutation 
[120] 
pKSM213 Pemm1-luciferase reporter with the A35C 
mutation 
[120] 
pKSM214 Pemm1-luciferase reporter with the G40A 
mutation 
[120] 
pKSM215 Pemm1-luciferase reporter with the G37A 
mutation 
[120] 
pKSM216 Pemm1-luciferase reporter with the C38A 
mutation 
[120] 
pKSM217 Pemm1-luciferase reporter with the T44C 
mutation 
[120] 
pKSM218 Pemm1-luciferase reporter with the T45C 
mutation 
[120] 
pKSM219 Pemm1-luciferase reporter with the C12A 
mutation 
[120] 
pKSM220 Pemm1-luciferase reporter with the C23A 
mutation 
[120] 
pKSM221 Pemm1-luciferase reporter with the C29A 
mutation 
[120] 
Plasmid Name Description Reference 
pKSM222 Pemm1-luciferase reporter with the T11C 
mutation 
[120] 
pKSM223 rpoD in pT18C-link This Study 
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Name Description Reference 
pKSM224 rpoA in pT18C-link This Study 
pKSM225 rpoD in pT18N-link This Study 
pKSM226 Mga in pT25N-link This Study 
pKSM227 Mga in pT18N-link This Study 
pKSM228 rpoA in pT18N-link This Study 
pKSM229 rpoA in pT25N-link This Study 
pKSM230 rpoD in pT25N-link This Study 
pKSM231 M1 Sf370 PsclA in pKSM720 This Study 
pKSM232 Pemm1-luciferase reporter with the C3A 
mutation 
[120] 
pKSM233 rpoE in pT18N-link This Study 
pKSM234 α in pProEX-htb This Study 
pKSM235 α-ΔCTD in pProEX-htb This Study 
pKSM236 Mga1-Δ139 in pT25N-link This Study 
pKSM237 rpoE in pT18C-link This Study 
pKSM238 M1 Sf370 PsclA minus MBS1 This Study 
pKSM239 M1 PscpA delta attenuator in pKSM720 This Study 
pKSM240 Pemm1-luciferase reporter with the G9A 
mutation 
[120] 
pKSM241 Pemm1-luciferase reporter with the G10A 
mutation 
[120] 
pKSM242 Pemm1-luciferase reporter with the T39C 
mutation 
[120] 
pKSM243 PscpA1-luciferase reporter with the C12A 
mutation 
[120] 
pKSM244 Pemm1-luciferase reporter with the C12/43A 
mutation 
[120] 
pKSM245 Psic1-luciferase reporter plasmid in pKSM720 
backbone 
[120] 
pKSM246 σ in pProEX-htb This Study 
pKSM247 His6-α-ΔCTD in pKSM683 This Study 
pKSM683 pKSM201-PrpsL This Study 
pKSM248 His6-α in pKSM683 This Study 
pKSM249 Mga1 HTH3/4 in pET21a This Study 
pKSM250 Mga1 HTH-4 in pET21a This Study 
pKSM251 His6-α-ΔCTD in pMSP3535-H3 This Study 
pKSM252 His6-α in pMSP3535-H3 This Study 
pKSM253 pKSM874 modified to M1Mga HTH3 This Study 
pKSM254 pKSM874 modified to M1 HTH3/4 This Study 
pKSM255 pKSM874 modified to M1 HTH4 This Study 
pKSM256 PscpA1-luciferase reporter with the C43A 
mutation 
[120] 
pKSM257 PscpA1-luciferase reporter with the C12/43A 
mutation 
[120] 
pKSM258 Pemm1-luciferase reporter with the G41A 
mutation 
[120] 
pKSM259 Pemm1-luciferase reporter with the A13C 
mutation 
[120] 
pKSM260 Pemm1-luciferase reporter with the G18A 
mutation 
[120] 





Name Description Reference 
pKSM262 Pemm1-luciferase reporter with the A33C 
mutation 
[120] 
pKSM263 Pemm1-luciferase reporter with the A34C 
mutation 
[120] 
pKSM264 C terminus of M1 Mga in pET21a This Study 
pKSM265 N180 of M1 Mga in pET21a This Study 
pKSM266 Pmga-mga1-HTH4 in pJRS525 This Study 
pKSM267 Pmga-mga1-HTH3 in pJRS525 This Study 
pKSM268 Pmga-mga1-HTH3/4 in pJRS525 This Study 
pKSM269 M1 RofA in pET21a This Study 
pKSM270 M1 RivR in pET21a This Study 
pKSM271 Psic1-luciferase reporter with the G40A 
mutation 
[120] 
pKSM272 Psic1-luciferase reporter with the C12A 
mutation 
[120] 
pKSM273 Psic1-luciferase reporter with the C43A 
mutation 
[120] 
pKSM274 Psic1-luciferase reporter with the C12/43A 
mutation 
[120] 
pKSM275 PspcA1-luciferase reporter with the G40A 
mutation 
[120] 
pKSM276 M4 RALP3 in pET21a (adam) This Study 
pKSM277 His6-α in pT18N-link This Study 
pKSM278 His6-σ in pT18N-link This Study 
pKSM279 σ-Δdomain4 in pProEX-htb This Study 
pKSM280 M4 Mga E413A in pKSM808 (adam) This Study 
pKSM281 His6-α suicide in pCIV2 This Study 
pKSM282 rpoA-Δ1/3CTD in pProEX-htb This Study 
pKSM283 rpoA-Δ2/3CTD in pProEX-htb This Study 
pKSM284 His6-σ in pKSM683 This Study 
pKSM285 His6-σ-Δdomain4 in pKSM683 This Study 
pKSM286 His-MBP-RofA1 in pVL847 This Study 
pKSM287 His-MBP-RivR1 in pVL847 This Study 
pKSM288 Mga1 in pCal-C This Study 
pKSM289 Mga4 in pCal-C This Study 
pKSM290 Promoter upstream α-Pami-his6-α-ΔCTD in 
pCIV2 
This Study 
pKSM291 α-ΔCTD in pET21a This Study 
pKSM292 α in pET21a This Study 
pKSM293 Promoter upstream α -Pami-his6-α-Δ1/3CTD in 
pCIV2 
This Study 
pKSM294 Pami-α-ΔCTD-his6-downstream in pCIV2 This Study 
pKSM295 Pami-α-his6-downstream in pCIV2 This Study 
pKSM296 α-Δ1/3CTD in pET21a This Study 
pKSM297 α-Δ2/3CTD in pET21a This Study 
pKSM298 Mga4-CBP in pET21a This Study 
pKSM299 Mga4Δ29 in pCal-C This Study 
pKSM415 PrpsL in pBluescript This Study 
pKSM420 Psof in pBluescript This Study 
pKSM550 Mga4Δ139 in pCal-C This Study 
pKSM551 Mga4Δ139-CBP in pET21a This Study 
pKSM552 Mga4Δ29-CBP in pET21a This Study 
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Plasmid Name Description Reference 
pKSM553 αNTD-σdomain4 in pProEX-htb This Study 
pKSM683 PrpsL in pKSM201 This Study 
pKSM801 Mga4 in pET21a This Study 
pKSM808 Pmga-mga4-his6 in pLZ12-Spc This Study 
pKSM802 Mga4Δ29 in pET21a This Study 
pKSM874 WT Mga1-his6 under PrpsL with native GAS 
RBS 
This Study 
TOPO-Pemm Pemm1 in pCR-Blunt-II-TOPO [120] 
TOPO-Pemm C3A Pemm1 with the C3A mutation in pCR-Blunt-II-
TOPO 
[120] 
TOPO-Pemm G9A Pemm1 with the G9A mutation in pCR-Blunt-II-
TOPO 
[120] 
TOPO-Pemm G10A Pemm1 with the G10A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm T11C Pemm1 with the T11C mutation in pCR-Blunt-
II-TOPO [120] 
TOPO-Pemm C12A Pemm1 with the C12A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm A13C Pemm1 with the A13C mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm G18A Pemm1 with the G18A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm G19A Pemm1 with the G19A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm C23A Pemm1 with the C23A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm C29A Pemm1 with the C29A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm A33C Pemm1 with the A33C mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm A34C Pemm1 with the A33C mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm A35C Pemm1 with the A35C mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm G37A Pemm1 with the G37A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm C38A Pemm1 with the C38A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm T39C Pemm1 with the T39C mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm G40A Pemm1 with the G40A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm G41A Pemm1 with the G41A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm C43A Pemm1 with the C43A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-Pemm T44C Pemm1 with the T44C mutation in pCR-Blunt-
II-TOPO 
[120] 










Name Description Reference 
TOPO-PscpA PscpA1 in pCR-Blunt-II-TOPO [120] 
TOPO-PscpA C12A PscpA1 with the C12A mutation in pCR-Blunt-
II-TOPO 
[120] 
TOPO-PscpA G40A PscpA1 with the G40A mutation in pCR-Blunt-
II-TOPO 
[120] 





PscpA1 with the C12/43A mutation in pCR-
Blunt-II-TOPO 
[120] 




Table 4: Table of Primers 
Target Name Sequence 5’-3’ Reference 
GA40634 M4 RpoA outside L ATTACATTCGTATTTTAGTAGGTGACCG This Study 
 M4 RpoA outside R TTCCCGCTAGGAAAAATCCT This Study 





 Downstream RpoA R GAAAACCATAATCGCCTTATTCTCAG This Study 
 Downstream RpoA 
XmaI 
tttCCCGGGTTAAACTAATTCAATAATTGC This Study 
Mga1 Mga1 CBP BglII tttAGATCTAGTTGTGGAGGG This Study 
 Mga1 CBP NcoI tttCCATGGATGTATGTAAGT This Study 
 Mga XhoI gCTCGAGTGTCTAAGTTGTGGAGGG  
 T25N Mga HindIII AAGCTTAATGTATGTAAGTAAGTTGTTT This Study 
 T25N Mga R GGATCCTTAGTTGTGGAGGG This Study 










 M1 C Mga NdeI cccCATATGATGAACTGTGAGCGGCTAC This Study 
 Mga1 NdeI gggggCATATGTATGTATGTAAGTAAGTTG [73] 
 MgaN180 XhoI gggggCTCGAGCTTTAAGTTTAGG [73] 
Mga4 Mga4 CBP BglII tttAGATCTTGATGATGTTGCTTG This Study 
 Mga4 CBP NcoI tttCCATGGATGAAGTTAATGC This Study 
 Mga4CBP pET NdeI tttCATATGATGCATGTAAGTAAATTG This Study 
 Mga4CBP pET XhoI tttCTCGAGAAGTGCCCCG This Study 
 Mga4 139 CBP NcoI tttCCATGGATGCATGTAAGTA This Study 
 Mga4 139 CBP BglII tttAGATCTTTCCCAGGTAATAAAGAAACA
ATA 
This Study 
 Mga4 29 CBP BglII tttAGATCTTTCGAGGTTT This Study 
Pami Pami in vitro L GTACACAAGGGATATCTGCAGAATT This Study 
 Pami in vitro R AAAATACAGGTTTTCGGTCGTTGG This Study 
 Pami Sew L TCATAGCCGAATAGC This Study 
Pami Pami Sew R CCAACCATTATATCAC This Study 
 Pami Sew Inside L GGATATCTGCAGAATTCG This Study 
 Pami Sew Inside 
XbaI 
tttTCTAGAGGATATCTGCAGAATTCGCC This Study 
PaphA3 PaphA3 +30 in vitro 
L 
ACTATGTTATACGCCAACTTTCAA This Study 





pCal-C pCALC-L CCTGCCACCATACCCACG This Study 
 pCALC-R CCCGTTTAGAGGCCCCA This Study 
pCIV2 pCIV2 Seq A GGATCCCCTGCGGTGT This Study 
 pCIV2 Seq B CATTAGGCACCCCAGGC This Study 
Pemm M1 SF370 Pemm L GGATCCTCCACAACTTAGACAGC [120] 
 M1 SF370 Pemm R CTCGAGCGTGTTATTTTTAGCCA [120] 
 M1 Pemm Luc L gggGGATCCTCCACAACTTAGACAGC [120] 
 M1 Pemm Luc R gggCTCGAGCGTGTTATTTTTAGCCA [120] 
 M1 FPR Pemm L CCCAGTCACGACGTTGTAAAA [120] 
 M1 FPR Pemm R CCCTCATTTTCAGGGTTTAACTCTAA [120] 
 Pemm 35 In vitro CATTAATAGCATTTAGGTCAAAAA This Study 
Target Name Sequence 5’3’ Reference 
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 Pemm in vitro SOE L TAAACCTATTCATTGTTTTAAAAATATCT
C 
This Study 
 Pemm in vitro SOE R GGTAAAGACCAGCTTTTTTAGCTTTT This Study 
 Pemm in vitro 232 R CTCCAGCGGTTCCATCCTCT This Study 
 M1 Pemm in vitro 
132  R 
AATTCGAGCTCCCATCTGAA This Study 
 M1 Pemm in vitro 
164 R 
ATTTTACCAACAGTACCGGAATG This Study 
 M1 Pemm in vitro 
114 R 
AACTCTCCTGCATCCTGCA This Study 
pKSM72
0 
720 conf L ACGACGTTGTAAAACGACGGC [120] 
 720 conf R AGCCTTATGCAGTTGCTCTCC [120] 
Pmga Oyl15 CAGTCACGATCACGCAAT [77] 
 Oyr 25 AATTGACTGAAGTATGATAGAAT [77] 
pProEX-
htb 
pProL GTGAGCGGATAACAATTT [55] 
Target Name Sequence 5’-3’ Reference 
pProEX-
htb 
pProR AAAATCTTCTCTCATCCG [55] 
PscpA M1 FPL PscpA L AGTCCGTAATACGACTCACTTAAGGCCT [120] 
 M1 FPL PscpA R GCAAACAGGGGTTATTTGCATATGATAC
A 
[120] 
 M1 FPR PscpA L 
New 
TAACGCCAGGGTTTTCCCAG [120] 
 M1 FPR PscpA R 
New 
CTTGCTTTTGTCATAATGATTAAATGT [120] 
 M1 PscpA Bam L gcGGATCCTATGTCTAAAAGAATGAG [120] 
 M1 PscpA Xho R gcCTCGAGGATGAGAGACTTTGTCTT [120] 
Psic M1 Psic Luc BglII L cacAGATCTCAGCAGTTGTAAAACGCAAA
G 
[120] 
 M1 Psic Luc XhoI L gggCTCGAGTAGTATTCTCTCCTTAATAAA
TT 
[120] 
 M1 FP Psic L CGCAAAGAAGAAAACTAAGCTATC [120] 
 M1 FP Psic R TGCAGGAATTCCTCGAGTAGTAT [120] 
PsclA PsclA FPL L GAAGATCTAACAAACAAGTAAAG This Study 
 PsclA FPL R ACTCTTTTGTGGAGATCAGA This Study 
 PsclA FPR L AGGGCTACTTTGGCACTTGC This Study 
 PsclA FPR R CGGCCAGTCCGTAATACGACT This Study 
 PsclA BglII cccAGATCTAACAAACAAGTAAAGAAGAA
ACCTA 
This Study 
 PsclA w/o MBS 
BglII 
cccAGATCTAAGAAAGGATCCGGATG This Study 
 PsclA XhoI cccCTCGAGTGGTAGCTAGACCTGATTATT
TATA 
This Study 
Psof Psof L3 TTTGGTCTCAGACGGCGCCA [78] 
PrpsL PrpsL +30 in vitro L CATAAGCAATTGCATCAAAGG This Study 
 PrpsL 35 in vitro TTCTATTTGACATGAAGTGCCG This Study 





Target Name Sequence 5’-3’ Reference 
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 PrpsL In vitro 1201 
R 
AACAGCTATGACCATGATTACGCCAA This Study 
RivR M1 RivR NdeI gttCATATGTTGGATTATTAT This Study 
 M1 RivR XhoI gttCTCGAGAGAAGGAACT This Study 
 RivR1 HisMBP XhoI cccCTCGAGTTAAGAAGGAACTCTCCAAA
GTTCTTCTAAACGTTT 
This Study 
RofA M1 RofA NdeI gttCATATGTTGATAGAAAAATACTTGGAA
T 
This Study 
 M1 RofA XhoI tttCTCGAGTGTTAATTGCTTGGTTAAATCA
GCTTGGAATTT 
This Study 
 M1 RofA HisMBP 
XhoI R 
cccCTCGAGTTATGTTAATTGCTT This Study 
RpoA T18C rpoA BamHI L cccGGATCCATGATTGAGTTTGAAAA This Study 
 T18C rpoA EcoRI R cccGAATTCTTATTTATCGTTTTTTAGTCCG
AGAC 
This Study 
 T18N rpoA L cccAAGCTTTATGATTGAGTTTG This Study 
 T18N rpoA R cccGGATCCATTTTATCGTTTTT This Study 





 T18N his rpoA 
HindIII 
cccAAGCTTTCATCACCATCACCA This Study 
 RpoA his Tag L cccGGATCCATGATTGAGTTTGAAAAACCA
ATAATAA 
This Study 
 RpoA His Tag R cccTCTAGATTATTTATCGTTTTTTAGTCCG
AGACC 
This Study 
 RpoACTD His Tag R cccTCTAGATTAATCGTTCACTTTTTCAGTT
TCTTTC 
This Study 
 rpoA pet21a HindIII tttAAGCTTTTTATCGTTTTTTAGTCCGAGA
CCTAA 
This Study 
 RpoA pet21a NdeI tttCATATGATGATTGAGTTTGAAAAACCAA
TAATAA 
This Study 





 RpoACTD Sew 
Overlap L 
TAATGGTTGCGGTCCGTATAATCTGT This Study 
 RpoACTD Sew 2R ATTAATCGTTCACTTTTTCAGTTTCTTT This Study 
 RpoA Upstream Sew 
2L 
ATGAAGGTAAGACCATCGGTTAA This Study 
 RpoA Upstream 
Overlap Sew R 
GCAGATATCCCTTGTGTACTATTTGT This Study 
 RpoANTD R ATCGTTCACTTTTTCAGTTTCTTT This Study 
 RpoA Pet Overlap L GATATAATGGTTGGTTTAACTTTAAGAAG
GAGA 
This Study 
 RpoA Pet R TCAGTGGTGGTGGTGGTGGT This Study 
 RpoA Trunc1 
HindIII 
tttAAGCTTAAGATTACGGACTTTCATCA This Study 





 RpoA Trunc2 XmaI2 tttCCCGGGTTAACGTTTTAAACAGTTAT This Study 
Target Name Sequence 5’-3’ Reference 
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 RpoAhis Trunc1 
XmaI 
tttCCCGGGTTAAAGATTACG This Study 
RpoD T18C-rpoD-L cccGGATCCATGACAAAACAA This Study 
 T18C-rpoD R cccGAATTCTTAGTCCTCTATAAAGTCT This Study 
 T18N rpoD HindIII cccAAGCTTTATGACAAAACAAAAAGAAA
TAACAAC 
This Study 
 T18N rpoD BamHI cccGGATCCATGTCCTCTATAAAGTCTCTT
AATTGTT 
This Study 
 T18N his rpoD 
EcoRI 
cccGAATTCGAGTCCTCTATAAA This Study 
 Sigma his BamHI tttGGATCCATGACAAAACAAAAAGAAATA
ACAACT 
This Study 
 Sigma His XbaI cttTCTAGATTAGTCCTCTATAAAGTCTC This Study 
 Sigma hisdelta4 
+stop XhoI 
tttCTCGAGTTAAAGAACAACACGCGTCGT This Study 
 RpoA-RpoD4 
Overlap 
GTGAACGATCGTGAGCAATTG This Study 
 RpoDhis RBS EcoRI tttGAATTCAGGAAACAGACCATG This Study 
 RpoDd4his RBS 
XbaI 
tttTCTAGAGTTAAAGAACAACACGCGT This Study 
 RpoDhis RBS XbaI tttTCTAGATTAGTCCTCTATAAAGTCTCT This Study 
rpoE T18N rpoE HindIII cccAAGCTTAATGGTAGAGAATGATAAAAT
AAGGAGAACTG 
This Study 
 T18N rpoE BamHI cccGGATCCTGGAGAACTGGTTCTTCATCT
TCTTCATCTTCTT 
This Study 
 T18C rpoE BamhI cccGGATCCATGGTAGAGAATGATAAAAT This Study 
 T18C rpoE EcoRI cccGAATTCTTAGAGAACTGGTTCTTCA This Study 
pVL847 pVL847 Seq L GAAGTCTTACGAGGAAGAGTTGG This Study 
 pLV847 Seq R GCCCTTTCGTCTTCAAGAATT This Study 
Table 5 Primers 





Table 6: Table of Mutagenic Oligonucleotides 
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pKSM245 Psic1 C12A 
SDM L 
AATGAGGTTAAGGAGAGGTAACAAACTAAACAACTC [120] 
 Psic1 C12A 
SDM R 
GAGTTGTTTAGTTTGTTACCTCTCCTTAACCTCATT [120] 
Target Name Sequence 5’-3’ Reference 
 14 
 












































Table 7: Table of qPCR Primers 
Target Name Sequence 5’-3’ Reference 
gyrA M4 gyrA RT-L AGTGTCATTGTGGCAAGAGC [72] 
 M4 gyrA RT-R CACACCGAGTTCATTCATCC [72] 
Parp M4 Parp qPCR L GGAAGCCCCTTCCTCTTTT This Study 
 M4 Parp qPCR R GCGGTAAAAGGTAAAGACCAG This Study 
PmalR M4 PmalR qPCR L AACCTGATCCACATCCCACT This Study 
 M4 PmalR qPCR R AGCTTGAAATCATGGCAAAAA This Study 
Pmrp M4 Pmrp qPCR L TAGGATTTCAGACGTCATGGT This Study 
 M4 Pmrp qPCR R AGCCAAAAGGTAAAGGTCAGT This Study 
PrpsL M4 PrpsL qPCR L GCAATTGCATCAAAGGAAAAA This Study 
 M4 PrpsL qPCR R GCAACAATTGTCAGCACGTC This Study 




Table 8: Table of Binding Oligonucleotides 
Name Sequence 5’-3’ Reference 












Pemm1 3-20 CATTTAGGTCAAAAAGGT 
GTAAATCCAGTTTTTCCA 
This Study 
Pemm1 28-47 GCTAAAAAAGCTGGTCTTTA 
CGATTTTTTCGACCAGAAAT 
This Study 










































































































































Psic1 MBS 49mer GTAAGGAGAGGTCACAAACTAAACAACTCTTAAAAAGCTGACCTTTACT 
CATTCCTCTCCAGTGTTTGATTTGTTGAGAATTTTTCGACTGGAAATGA 
[120] 
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